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1.1 Abbreviations
AaDG2 alveolar-arterial difference in partial pressure of oxygen
ACT 2 activated clotting time
AR autoregulation
CBF cerebral blood flow
CBFV cerebral blood flow velocity
CBV cerebral blood volume
CDH congenital diaphragmatic hernia
cHHb concentration of deoxyhemoglobin
CI confidence interval
cG2Hb concentration of oxyhemoglobin
CPR cardiopulmonary resuscitation
CT computed tomography
ctHb concentration of total hemoglobin
CV coefficient of variation
DIC disseminated intravascular coagulation
ECLS extracorporeal life support
ECMG extracorporeal membrane oxygenation
EDV end diastolic flow velocity
ELSG extracorporeal life support organisation
FiG2 fraction of inspired oxygen
HbD hemoglobine oxygenation index
HFG high frequency oscillation
HR heart rate
ICH intracranial hemorrhage
iNG inhaled nitric oxide
IVA intravascular volume administration
MAP mean arterial pressure
MAS meconium aspiration syndrome
MRI magnetic resonance imaging




paCG2 arterial partial pressure of carbon dioxide
paG2 arterial partial pressure of oxygen
patm atmospheric pressure
pH2G vapour pressure
PEEP positive end expiratory pressure
PI pulsatility index
PIP peak inspiratory pressure
PPHN persistent pulmonary hypertension of the newborn
PSV peak systolic flow velocity
Qcar blood flow in the left carotic artery
RDS respiratory distress syndrome
RIJV right internal jugular vein
saG2 arterial oxygen saturation
SD 2 standard deviation
TAM time averaged mean flow velocity
va-ECMG veno-arterial extracorporeal membrane oxygenation
vv-ECMG veno-venous extracorporeal membrane oxygenation
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1.2 Background -  risk factors for the brain
Historical perspectives
From a historical point of view, extracorporeal membrane oxygenation (ECMO) is not even such 
an old treatment modality for neonates suffering from severe respiratory failure. Although sev­
eral forms of extra corporeal life support (ECLS) are possible, like temporary cardiac support in 
infants with poor cardiac output after cardiac surgery, this thesis will concentrate on ECLS in 
newborns with severe, but potentially reversible, respiratory failure, often complicated by pul­
monary hypertension. Right from its introduction in neonatology, ECMO became a rescue, life- 
saving, therapy in newborns who were considered to have a high mortality risk when treated 
with conventional methods only. It was in such a manner, that Bartlett and colleagues treated the 
first newborn, called Esperanze (hope) by the nursing staff, with ECMO for severe respiratory fail­
ure due to meconium aspiration syndrome (MAS) in 1976 (1). Several years later, in 1982, Bartlett 
presented the results of 45 newborns treated with ECMO (2). In these newborns, ECMO was used 
as a rescue therapy after maximal conventional therapy had failed in severely ill neonates with an 
estimated mortality risk of 90%. Treatment with ECMO resulted in an over 50% survival. Studies 
with a more randomized character were indicated to determine the usefulness of ECMO. Again, 
Bartlett et al, presented a study in which ECMO and conventional therapy were compared by us­
ing the so called "randomized play the winner" method. In this method the chance of randomly 
assigning an infant to one treatment or the other is influenced by the outcome of treatment of 
each patient in the study. If one treatment is more successful, more patients are assigned to that 
treatment (3). Finally 1 patient was treated by conventional therapy and died, 11 consecutive 
patients were treated with ECMO and survived. Results were considered as supportive for using 
ECMO. In another study of O'Rourke et al (4), neonates were prospectively randomized to ECMO 
or conventional ventilator management, but with an adapted design, in which randomisation 
continued until 4 deaths occurred in either treatment group. At that point, randomization would 
cease and all subsequent patients would be enrolled in the group with less than four deaths. En­
rolment would continue until the fourth death occurred in that group or the number of survivors 
was significantly larger than the number of survivors in the arm that had been discontinued first. 
The survival in the ECMO group was 97% compared to 60% in the conventional group. Although 
there were concerns about the quality, especially the randomization methods, of the studies 
so far, in the following period, interest in ECMO was growing, resulting in the institution of the 
Extracorporeal Life Support Organization (ELSO) and a National Institute of Health consensus to 
continue the use of ECMO. The ELSO counts 109 members from 17 countries nowadays. From 
ELSO data a survival rate of 83% in 3500 newborns suffering from respiratory failure (estimated 
mortality 80%) was demonstrated (5). An important additive study came from the UK collabora­
tive ECMO group in 1996. Till today this has been the only large randomized trial on survival of 
newborns treated with ECMO (6). Newborns with severe respiratory failure were randomised to 
either ECMO treatment in one of the five ECMO centres or conservative treatment at the partici-
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pating centres. The conclusion was that survival until discharge in all diagnoses groups of new­
borns with severe respiratory failure was better in the ECMO group, compared to the convention­
al treatment group. Cost-effectiveness was also evaluated and it was concluded that ECMO was 
likely to be as cost-effective as other life-extending technologies (7). In 2008 a Cochrane Review, 
an update of an earlier review in 2003, was performed (8), including the studies mentioned be­
fore and one more study by Bifano et al (9). The Cochrane group concluded that the use of ECMO 
in newborns with severe, but potentially reversible, respiratory insufficiency resulted in signifi­
cantly improved survival, without an increased risk of severe disability in survivors. Although the 
risk of death was significantly reduced, the effect of ECMO was less in newborns suffering from 
congenital diaphragmatic hernia (CDH). That this group of infants might be a special group is 
confirmed by the fact that in terms of death or disability, the advantage of ECMO treatment over 
conventional treatment in CDH patients had disappeared at 4 years of follow-up in the UK Trial 
(10). The authors of the Cochrane review group advised further studies to optimize optimal time 
of the initiation of ECMO and to determine which infants will benefit most. In general, the results 
of follow-up studies might play a role in the decision to use ECMO. Further on these long-term 
outcomes will be discussed. As mentioned before, ECMO has always been considered to be a 
rescue therapy in newborns. This persisted while other techniques were introduced to treat neo­
nates with severe respiratory failure, complicated by pulmonary hypertension, like surfactant, 
high frequency oscillation (HFO) ventilation and inhaled nitric oxide (iNO).
Neonatal ECMO criteria in severe respiratory failure
In table 1 selection criteria and (relative) contra-indications for the initiation of ECMO are given 
as used at the department of Neonatology of the Radboud University Nijmegen Medical Centre, 
Nijmegen, The Netherlands. Criteria fit closely to those described by the ELSO (11). These criteria 
concern newborn patients with severe respiratory failure, often complicated by pulmonary hy­
pertension. Criteria for ECMO in patients with cardiac failure are not further described here. His­
torically, developed inclusion criteria are aimed to initiate ECMO in newborns with an estimated 
mortality of 80% with maximal conservative therapy. Exclusion criteria are mainly based on the 
fact that, when present, they increase the risk for ECMO related complications, especially (intra­
cranial) hemorrhage. However with modern developments in intensive care treatment, like sur­
factant, HFO ventilation and the use of iNO, predicted mortality without ECMO is probably less 
than 80%. With the criteria used in the UK trial mentioned before (6), the control group had, de­
pending on underlying disease a mortality rate of 43% (MAS) to 100% (CDH). On the other hand, 
to avoid a delay in the use of ECMO because of an inadequate response to prior iNO treatment 
and other techniques like HFO ventilation, it has been suggested to adapt the current ECMO 
criteria and to lower the threshold for the initiation of ECMO in patients suffering from severe 
hypoxic respiratory failure, who are already treated with iNO and HFO ventilation (12,13).
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Table 1. Inclusion criteria for neonatal ECMO at the department of Neonatology of the 
Radboud University Nijmegen Medical Centre
1 AaDO2 > 600 mmHg (80 kPa) for more than 8 hours
2 AaDO2 > 605 mmHg (80.6 kPa) for more than 4 hours with peak inspiratory pressure 
> 38 mbar or mean airway pressure > 22 mbar
3 Acute deterioration for at least 2 hours with pH < 7.15 and paO2 < 40 mmHg (5.3 kPa)
4 No clinical improvement on maximal conventional therapy for 3 hours with paO2 
< 40 mmHg (5.3 kPa)
5 Signs of barotrauma (at least 4): lung emphysema, pneumothorax or 
pneumomediastinum, pneumopericardium, pneumoperitoneum, subcutaneous 
emphysema, air leak >24 hours, mean airway pressure > 15 mbar
6 OI > 40 for 3 to 5 hours
7 In patients with CDH, at least once a documented paO2 > 80 mmHg (10.6 kPa)
(Relative) contra-indications
1 Gestational age < 34 weeks or birth weight < 2000 grams
2 Underlying lung disease or cause of respiratory insufficiency, that is not expected to be 
reversible within 10-14 days
3 Mechanical ventilation > 10 days
4 Chromosomal or other congenital or acquired abnormalities incompatible with life, 
including severe asphyxia
5 Intraventricular or cerebral parenchymal haemorrhage > grade II
6 Coagulopathy or bleeding complication for which heparin administration is 
contra-indicated
AaDO2 = Alveolar-arterial difference in pa rtia l oxygen pressure, AaDO2 = (patm - pH2O) x  FiO2 -  (paO2 
+ paCO2), where patm  = atmospheric pressure (mmHg), pH2O = vapour pressure (being 47 mmHg at 
37°C), paO2 = arterial pa rtia l pressure o f oxygen (mmHg), paCO2 = arteria l pa rtia l pressure o f carbon 
dioxide (mmHg), FiO2 = fraction o f inspired oxygen, OI = Oxygenation Index = (MAP x  FiO2 x  100)/paO2, 
where MAP = mean airway pressure in mbar
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One study of Schumacher et al showed a shorter length of hospitalization and better cost-effec­
tiveness when infants were randomized to lower threshold criteria (Oxygenation Index >25 but 
<40 instead of an oxygenation index > 40). Outcome at 1 year of age seemed to be better in the 
group with the lower criteria (14). A more recent study of Radhakrishnan et al suggested to use 
"relaxed" entry criteria for ECMO in newborns suffering from meconium aspiration syndrome 
(15). From the ELSO database we know that newborns with MAS have the best prognosis com­
pared to other neonates treated with ECMO.
ECMO and technical aspect
Neonatal ECMO is a form of extracorporeal life support (ECLS) in which lung function of the new­
born with severe, but potentially reversible, respiratory failure is temporary supported by an 
external circuit with an artificial oxygenator. As ECMO is considered to be a rescue therapy, it is 
only initiated in those newborns with high mortality rates despite treatment with maximal con-
Figure 1. overview of the veno-arterial ECMO circuit.
(printed with permission from CNMC ECMO Training Manual, Short BL, Mikesell G, and Muir R, (eds), 2004)
ventional therapy. Figure 1. shows the va-ECMO circuit. During ECMO venous blood is passively 
drained from the right atrium through the venous cannula of the ECMO circuit, which is inserted 
into the right internal jugular vein (RIJV). Blood then passes the bladderbox, a device that will 
control the venous drainage from the right atrium. When the venous drainage from the right
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atrium is inadequate, the bladderbox will be less filled by blood and some collapse of the blad- 
derbox will occur, resulting in release of a switch which will slow down and finally interrupt the 
ECMO pump. After the bladderbox, the blood is actively pumped by the ECMO pump at a regu­
lated variable ECMO flow rate through a membrane oxygenator. In the membrane oxygenator, a 
gas mixture of air, oxygen and carbon dioxide passes in the opposite direction to the blood flow. 
Here the blood is oxygenated and the partial carbon dioxide pressure is regulated. Before the 
oxygenated blood is returned to the patient, it is rewarmed by a heat exchanger. In case of veno­
arterial ECMO, the blood will be returned to the aortic arch through an arterial cannula, inserted 
in the right common carotid artery. If veno-venous ECMO is used, the blood will return through 
the same venous cannula (in this case a double lumen cannula) into the right atrium, as is shown 
in figure 2. As the artificial external oxygenator will take care of the lung function, the lungs 
will be able to "rest and recover" at low intensity of artificial ventilation. Since the ECMO system 
is made of artificial materials that will have continuous contact with the patient's blood, clot 
formation has to be avoided by heparinization of the patient. The (partial) bypass is continued 
until lung function recovers, after which the ECMO flow rate of the pump is decreased and finally 
stopped. At the end of the ECMO treatment, after decanunulation, mechanical ventilation is still 
required, but at much lower intensity and with less oxygen than before the initiation of the ECMO 
treatment. ECMO in general therefore has two positive effects. Firstly, it prevents newborns from 
dying due to persistent severe hypoxia. Secondly, it prevents the lungs from being damaged due 
to intense artificial ventilation and high inspiratory oxygen fraction.
Figure 2. The double lumen 
venous cannula used in 
veno-venous ECMO.
(printed with permission from CNMC ECMO 
Training Manual, Short BL, Mikesell G, and Muir R, 
(eds), 2004)
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Neonatal ECMO and outcome.
Cerebral injury, intracranial hemorrhage (ICH) as well as ischemia belong to the most devastating 
complications of ECMO. Imaging studies revealed hemorrhagic or ischemic intracranial abnormal­
ities in 10% up to as high as 52% of the neonates (16-18). Although ECMO has increased survival 
rates, the occurrence of hemorrhagic and ischemic cerebral lesions, resulting in future neurological 
and neurodevelopmental dysfunction are of major concern (19,20). Next to this, most of non­
survivors of ECMO treatment do not die from respiratory problems, but as a result of ICH (ELSO 
data). An important study, describing the relation between severity of neonatal brain injury as de­
tected by ultrasound and CT-scan related to ECMO and neuropsychological and neurobehavioral 
outcome at age 5 years was performed by Glass et al in 1997 (21). Disability was found from 10% 
in children with no radiologic brain abnormalities up to 57% in those with severe radiologic brain 
abnormalities. In the control group, newborns without ECMO and without hospital admission, 
disability was detected in 2% of cases. Although limited, some studies concern the more short­
term outcome of newborns treated with ECMO, like feeding problems, growth and persistent 
pulmonary problems (22-24). For the purpose of this thesis, however, this introduction will con­
centrate on long-term neurodevelopmental and neuropsychological outcome. Most long-term 
follow-up studies show mild to major neurological impairment in 15 up to 25% of ECMO survivors. 
Impairment involves different kinds of neurological development, cognitive development, IQ and 
neuromotordevelopment. More subtle signs of neurological involvement occur at higher rates in 
ECMO survivors. Learning problems at school age appear to be as high as 50% and ECMO parents 
reported behavioral problems more often compared to normal controls (10,20-23,25-28). A Dutch 
follow-up study found the veno-arterial ECMO population to be highly at risk for developmental 
problems, most prominently in the motor domain as compared to normal reference populations 
(29). Assessment in 149 survivors over a 7 years period (1993-2000) showed normal development 
in all fields in 49%, severe disability in 13% and impaired motor development combined with cog­
nitive and/or behavioral problems in 9%. Outcome differed between primary diagnosis with CDH 
showing lowest normal outcome in all domains, 37.5% versus 52.6% in the MAS group.
In all long-term follow-up studies the selection of the control group is very important, especially 
as neonates treated with ECMO are generally severely ill and suffered from episodes of hypoxia 
and/or hemodynamic instability. Although several authors use near-ECMO patients as a control 
group, the most reliable control group can probably be found in the follow-up studies of the UK 
collaborative randomized trial of neonatal extracorporeal membrane oxygenation (6,30-32). In 
their studies, the UK ECMO trial group found an improved survival at 1, 4 and 7 years of age in 
ECMO treated newborns compared to those treated with conventional therapy. Even though 1 
in every 4 patients treated with ECMO showed signs of impairment, there seemed to be a favor­
able outcome at 4 and 7 years of age in those newborns treated with ECMO. Finally it might be 
important to mention that in an additional study, ECMO showed to be cost-effective compared 
to conventional treatment based on the 7 years results in the UK (33).
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Neonatal ECMO and risk factors for the brain
The studies described above make clear that ECMO is an effective therapy to increase survival 
in newborns with severe respiratory failure, but that the morbidity like intracranial injury, ICH 
as well as ischemia, are very important complications that determine long term outcome. From 
this point of view a continuous effort for recognizing the risk factors for intracranial injury in an 
attempt to further improve outcome is absolutely justified. The origin of cerebral injury in ECMO 
treated newborns is probably a combination of factors, including pre-ECMO, patient and disease 
related factors as well as factors related to the ECMO treatment itself and a combination of both 
(19,34). Literature concerning these risk factors can be divided in two categories. The first cat­
egory contains those studies looking for risk factors, like primary diagnosis, in patients who did 
develop cerebral lesions, with or without a control group. Studies of the second category focus 
more indirectly on possible risk factors in patients and on technical aspects and consequences 
of ECMO, like the changes in pulsatility of the cerebral blood flow pattern. Several of the studies 
of the first category are important to mention; Hardart et al (35,36) determined gestational age, 
postconceptional age, acidosis, sepsis, coagulopathy and treatment with epinephrine as inde­
pendent pre-ECMO factors associated with ICH in neonates who were treated with ECMO. Dela 
Cruz et al (37) demonstrated that an elevated activated clotting time (ACT) and low platelet 
counts requiring transfusion were statistically associated with an increase in the development of 
ICH. Especially the relation between ACT and ICH might reflect the role of anticoagulation, which 
is necessary to perform during ECMO. Hirthler et al (38) reviewed that instability of ACT and 
platelet count are early predictors of ICH. In general the equilibrium between anticoagulation 
and clotting complications is difficult to manage. Clotting complications and especially dissemi­
nated intravascular coagulation (DIC) might result in embolization of (micro) clots to different 
organs. Finally lactate before ECMO treatment was found to be a useful marker for the develop­
ment of ICH during ECMO (39). Major ischemic lesions seem to be related to longer ECMO treat­
ment and more conservative use of heparin (40,41). Since randomized controlled studies can­
not be performed due to ethical considerations, the second category of studies contains mainly 
observational aspects and concerns in patients treated with ECMO. One interesting aspect both 
influenced by patient factors like severity of illness and hypoxia as well as by the ECMO treatment 
itself is the disturbance of cerebral autoregulation (AR). In normal, healthy situations cerebral AR 
maintains the cerebral blood flow over a wide range of cerebral perfusion pressures with a contra 
regulation response occurring with a delay of 2 seconds after sudden changes in blood pressure. 
It has been shown, however, that AR is disturbed in severely ill term infants (42-45). Additional 
studies in newborn lambs showed that prolonged hypoxia and/or the ECMO treatment itself will 
significantly disturb the cerebral AR (46-49). As a result of this disturbed AR, the capillary vascula­
ture of the brain might be at increased risk in case of systemic blood pressure changes. This could 
be an additional risk for ischemic complications due to hypoperfusion as well as hemorrhagic 
complications due to hyperperfusion.
Right from the start of ECMO treatment, cannulation of the right common carotid artery and in­
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ternal jugular vein became a concern. Some authors describe predominance of cerebral lesions 
in especially the right hemisphere of the brain, while in other studies this predominance, pos­
sibly related to ligation of the right common carotid artery and right internal jugular vein, could 
not be confirmed (49-56). Theoretically, in the presence of an intact circle of Willis, ischemia of 
the right cerebral hemisphere will never occur. However, incompleteness of the circle of Willis 
has been found in 0.6% of normal brains, which is a possible risk factor for ischemic lesions of the 
right hemisphere (57). Reassuring data concerning the cannulation came from two studies. First 
Short el al showed that 4 hours of hypoxia in lambs before cannulation caused a 100% increase 
in CBF, with maintenance of oxygen transport to the brain and cerebral oxygen metabolism. 
These parameters were not altered by cannulation of the right common carotid artery and/or the 
right internal jugular vein (58). A second study, by Klein et al. found no statistically significant or 
persistent differences on MRI performed directly after ligation between rats in which either the 
jugular vein and/or the carotid artery where ligated compared to control rats (59). Less reassur­
ing studies, considering the cannulation procedure occurred as well. Liem et al found alterations 
in cerebral oxygenation after carotid artery ligation in human newborns, possibly reflecting an 
increased O2 extraction due to increased transit time of the blood resulting from the diversion of 
arterial blood supply from the left common carotid artery to the right hemisphere. After jugular 
vein ligation, no changes were found. At 60 minutes after the initiation of ECMO there was a 
significant increase in cerebral blood flow velocity and cerebral blood volume (60). In a consecutive 
study van Heijst et al confirmed these data. They measured changes in the right and left cerebral 
hemisphere separately, but found no right - left differences (61). These findings combine well 
with the results of the studies of Raju et al and Matsumoto et al, who both demonstrated a tem­
porary decrease in CBFV after ligation of the right common carotid artery (62,63). Finally Hunter 
et al. performed a study in which the CBF of lambs was measured by laser Doppler flowmetry 
during va- as well as vv-ECMO. Ligation of the right common carotid artery resulted in temporary 
(1 minute) decrease in CBF to the right cerebral cortex (64). It can at least be concluded that there 
are some concerns about possible negative effects for the brain related to the ligation of the right 
common carotid artery. Besides this, there is a lack of knowledge about life-long consequences 
of permanent ligation of the right common carotid artery. All these concerns mentioned, stimu­
lated the development of vv-ECMO, using a double-lumen cannula, inserted in the right atrium 
of the patient. Even though, for the purpose of this thesis, attention is directed mainly on va- 
ECMO it has to be mentioned that vv-ECMO might have its own risks for the brain. There is espe­
cially fear for venous congestion due to obstruction caused by the thicker double lumen venous 
cannula. This is supported by three, somewhat older, studies. Two of them described a high 
frequency of ICH in the posterior fossa of the brain (65,66). The third study found a high incidence 
of subarachnoid space enlargement at the interhemispheric fissure and frontal, temporal and 
parietal convexity (68%) and ventricular enlargement (35%) in patients treated with vv-ECMO. In 
this same study ICH occurred in 7 out of 31 (22%) patient, all neonates (67). However, a possible 
positive effect of vv-ECMO compared to va-ECMO might be the maintenance of pulsatile arterial
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flow to the brain. Once va-ECMO is initiated, Taylor et al found the systolic phase broadened and 
diastolic flow velocities markedly increased, as measured by Doppler imaging of the pericallosal 
portion of an anterior cerebral artery (68). This resulted in a decrease of the pulsatility index [PI, 
in which PI = ( systolic CBF velocity - diastolic CBF velocity) / systolic CBF velocity] most clearly 
at higher ECMO flow rates. There was also an increase in true CBF expressed by the area under 
the velocity curve. Although clinical relevance and importance of these findings remain unclear, 
as is the fact for many observational studies, this loss of arterial pulsatility might be additionally 
harmful for the vulnerable brain (19). One of the underlying mechanisms might be the increased 
disturbance of cerebral AR in va-ECMO compared to vv-ECMO in studies by Ingyinn et al. Vascu­
lar reactivity to acetylcholine was measured in middle cerebral arteries from lambs exposed to 
ECMO (69,70). There are still conflicting data about the influence of non-pulsatile flow on cere­
bral perfusion (71,72). However, in recent literature there is some evidence for more benefit of 
pulsatile circulation on cerebral blood flow and increased vital organ flow (73,74). A concern for 
va-ECMO as well as for vv-ECMO could be the extensive contact of blood with the plasticizers 
containing tubings of the ECMO system, which might result in exposure of the brain to potential 
toxic agents (75,76).
Other ECMO related factors might further influence the occurrence of complications in the vul­
nerable brain. A good example is the use of the veno-arterial bridge (va-bridge) between the 
arterial and venous side of the ECMO system. Historically this va-bridge was filled with blood 
and opened and closed several times per hour to avoid clotting in it. Studies of Liem et al and 
van Heijst et al showed significant changes in cerebral oxygenation and hemodynamics related 
to the use of the va-bridge that can be avoided if the va-bridge does not have to be opened 
intermittently by filling it with normal saline instead of blood and connecting it with stop cocks 
to the venous and arterial cannula (77,78). Other aspects of the ECMO treatment, like bladderbox 
alarms and different kinds of pumps seem all to be interesting to be further studied in their pos­
sible relation to cerebral complications.
Conclusion
ECMO has proven to be an effective and life-saving therapy with increased survival and possibly 
a favorable outcome compared to newborns with severe but reversible respiratory failue treated 
conventionally. However, cerebral hemorrhage and ischemia are important complications result­
ing in long-term neurological and neurodevelopmental sequelae. More research is necessary to 
gain more knowledge of pathophysiological mechanisms underlying these complications. When 
this mechanism has been recognized, improved ECMO treatment strategies can be developed in 
order to reduce these cerebral complications. This thesis will try to contribute to further improve­
ment of this knowledge.
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1.3 Outline of the thesis
This thesis describes the results of several studies, all concerning possible risk factors for cerebral 
hemorrhage and/or ischemia during va-ECMO. In general these factors can be patient as well as 
ECMO therapy specifically related. The studies presented can be considered to be part of a con­
tinuous search to improve the ECMO outcome.
Besides an introduction focusing on the relation between ECMO and outcome and cerebral 
complications, chapter 1 gives a short introduction in near infrared spectrophotometry. This 
technique might be less known by several readers and was used in two of the studies presented.
In chapter 2 the possible relation between prior iNO use and the occurrence of (cerebral) hemor­
rhagic complications, disseminated intravascular coagulation and clotting complications during 
consecutive ECMO treatment were studied.
Chapter 3 describes disturbances of the cerebral circulation caused by repetitively opening and 
closure of the veno-arterial bridge, a connecting tube between the venous and arterial side of 
the ECMO system. CBFV measurements were performed by echo-Doppler in the pericallosal ar­
tery and the relation between the observed changes in CBFV and ECMO flow rate was studied.
Chapter 4 contains three studies focusing on a possible relation between bladderbox alarms 
and consecutive intravascular volume administration and the effects on cerebral oxygenation 
and hemodynamics and the occurrence of cerebral complications. In the first study, the relation 
between the frequency and amount of intravascular volume administration and the occurrence 
of ICH during va-ECMO is described. The second, consecutive study in lambs, was developed to 
determine the changes in cerebral oxygenation and hemodynamics caused by simulated blad­
derbox alarms during va-ECMO. The third study describes the effects of intravascular volume 
administration on cerebral oxygenation and hemodynamics in human newborns treated with 
va-ECMO.
In chapter 5 the main findings of the studies of this thesis are described in a general discussion 
and thoughts about future perspectives and proposals for studies and the place of ECMO in the 
treatment of severe neonatal respiratory failure, mostly complicated by persistent pulmonary 
hypertension, are shared with the readers.
Finally a summary, together with a Dutch version, is presented in chapter 6.
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1.4 Introduction in near infrared spectrophotometry
In two of the studies presented in this thesis, near infrared spectrophotometry (NIRS) is used as a 
tool for measurement of changes in cerebral oxygenation and hemodynamics in events related 
to ECMO. Although this technique is widely used in medical research it might be less known 
compared to several other techniques used. For this reason a short introduction is presented in 
this section.
Since Jobsis was the first to use NIRS in humans in 1977 (1), it became a frequently used noninva­
sive and safe technique to study tissue oxygenation and hemodynamics. In our research group, 
NIRS has been used extensively to study changes in cerebral oxygenation and hemodynamics in 
term as well as preterm neonates. These studies concern ECMO-related topics as well as a variety 
of other situations (2,3,4).
Background o f NIRS
NIRS is based on the principle of oxygenation-dependent changes in the absorption by chro- 
mophores of near infrared light passing through relatively transparant tissue like the brain. Al­
though not the only chromophore, the most important oxygen-dependent chromophore in the 
brain is hemoglobin. Total hemoglobin (tHb) in the brain consists of oxyhemoglobine (O2Hb) and 
deoxyhemoglobine (HHb). Both forms of Hb have different absorption spectra in the near infra­
red region (1,5,6). In homogenous and non-scattering tissue, the concentration of a chromophore 
can be determined from light absorption at specific wavelengths using the Lambert-Beer law;
OD(A) = £(X)*c*d
In this formula OD is the light absorption in optical densities, A is the used wavelength, £ is the 
extinction coefficient of the chromophore (l.mmol-1.cm-1) for the used wavelength, c is the con­
centration of the chromophore (mmol.l-1) and d is the optical pathlength (cm), representing the 
distance between the point where near infrared light enters and leaves the tissue, usually the 
distance between the transmitting and receiving optode. In this thesis, Hb is the only chromo­
phore used. The extinction coefficients of O2Hb and HHb are obtained in vitro with hemoglobin 
solutions (5,6).
There are two important restrictions for the use of the Lambert-Beer law in brain tissue. Since 
brain tissue is non-homogenous, anisotropic and also containing other chromophores, photon 
loss will occur due to scattering and absorption by oxygen-independent chromophores in the 
brain, skull or skin. Besides this, scattering will lengthen the pathlenghts of photons. However, 
with some modification, the Lambert-Beer law can be used;
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OD(A) = £(A)*c*d*B+OD(A)R
In this modified formula B is the multiplication factor for the increase in optical path length 
caused by scattering and considered to be constant and wavelength independent (7,8). OD(A)R 
reflects the loss of photons caused by scattering and absorption by oxygen-independent chro­
mophores. Although the absolute value of OD(A)R is unknown, it is assumed to be a constant pa­
rameter in the same patient as long as positions of the transmitter and receiver are not changed. 
By measuring OD changes at three different wavelengths, changes in concentration of O2Hb 
(AcO2Hb) and HHb (AcHHb) can be obtained. These changes can be expressed in |jmol.100g-1 
brain tissue.
Application o f NIRS in this thesis.
We studied changes in cO2Hb and cHHb by using continuous wave NIRS (Oxymon, Artinis, the 
Netherlands). Three wavelengths of near infrared light (905, 850 and 767 nm) were transmitted 
through the brain with a three-brance fiberoptic bundle and the transmitter placed in the mid­
line of the skull. Two separate receiving optodes were placed on the left and right parietotempo­
ral region of the skull. This enabled us to study AcO2Hb and AcHHb separately for the right and 
left hemisphere of the brain, which might be especially interesting in studies concerning extra­
corporeal membrane oxygenation as the right carotid artery and/or jugular vene are cannulated. 
Although several important NIRS variables can be derived using continuous wave NIRS, we used 
changes in hemoglobin oxygenation index (AHbD) and changes in cerebral blood volume (ACBV) 
to study changes in cerebral oxygenation and hemodynamics.
Changes in hemoglobin oxygenation index (AHbD)
AHbD is defined as the difference between AcO2Hb and AcHHb (AHbD = AcO2Hb - AcHHb) and 
expressed in ^mol.100g-1. It represents changes in global cerebral oxygenation and its use is pref­
erable above isolated changes in cHHb and cO2Hb as AHbD is not influenced by simultaneous 
changes in AcO2Hb and AcHHb caused by changes in CBV. It provides a continuous and direct 
measure for global cerebral oxygenation. Changes in HbD can be explained by changes in ce­
rebral oxygen consumption or by changes in cerebral oxygen delivery. The latter is mainly de­
termined by cerebral blood flow (CBF), arterial oxygen saturation (saO2) and blood hemoglobin 
concentration (cHb). In general, AHbD like used in our studies, is strongly correlated with CBF 
over a wide range of intracranial pressures (9,10). CBF is determined by cerebral perfusion pres­
sure (CPP) and cerebral vascular resistance (CVR). CPP is the difference between mean arterial 
blood pressure (MAP) and cerebral venous pressure, which can be replaced by the intracranial 
pressure (ICP). The most important limitation of AHbD is the lack of reference values below which 
cerebral oxygenation or CBF is compromised and potentially harmful to the brain. Reference 
values might also depend on the clinical situation. Baseline variability of HbD has been reported 
to be from -0.12 to +0.13 |jmol.100g-1 brain (11). In the same study a decrease in HbD of > 0.3
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|jmol.100g-1 reflects the effect of reducing saO2 by approximately 12%. Another comparison can 
be found in relation to other physiologic parameters. During hypercapnia in piglets on ECMO 
after hypoxia, a mean AcO2Hb of 0.16 |jmol.100g-1.kPa-1 occurred (12). AcO2Hb is one of the main 
factors for calculating AHbD.
Changes in cerebral blood volume (ACBV)
If blood hemoglobin concentration (cHb) is stable, ACBV, expressed in ml.100g-1 can be calcu­
lated using the following formula:
ACBV = (4*ActHb) * (R*cHb)-1
In this formula ActHb is the sum of AcHHb and AcO2Hb (expressed in |jmol.100g-1), R is the cere­
bral arterial hematocrit ratio which is stated to be 0.69 (13), and 4 is a correction factor, since ctHb 
is expressed in mmol.100g-1 as a tetraheme molecule. cHb is expressed in mmol.l-1 as monoheme 
molecule.
Cerebral vasodilatation or vasoconstriction as well as changes in CBF might result in changes in 
CBV. The most important limitation in using ACBV is the lack of reference values below or above 
which ACBV might cause or reflect harm to the brain. Some reference might be found in two 
studies by Wyatt et al. In the first study, changes in CBV, calculated in relation to changes in paCO2 
in term infants, were 0.51 mL.100g-1.kPa-1 (13). In a second study mean CBV was demonstrated to 
be 2.2 ± 0.40 mL.100g-1 in normal infants and 3.00 ± 1.04 mL.100g-1 in infants with brain injury 
(15). Additional data come from animal studies in which changes in CBV have been compared 
with usual physiological parameters like changes in paCO2 and mean blood pressure. During 
hypercapnia in normoxemic piglets on ECMO, a mean increase of CBV of 0.03 mL.100g-1.kPa-1 
occurred. In piglets after hypoxemia this increase was 0.10 mL.100g-1.kPa-1 (12). In another study 
an increase in CBV of 0.07 mL.100g-1.mmHg-1 has been shown in relation to changes in mean 
blood pressure in newborn lambs (16). Finally the value of CBV in lambs has been found to be 2.5 
mL.100g-1 of brain tissue (17).
Conclusion
Despite its limitation, NIRS is a valuable tool for investigation of changes in cerebral hemody­
namics in newborns during ECMO treatment. This can improve our knowledge about the cere­
bral hemodynamic response to many events during ECMO.
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Chapter 2
iNO before the start of ECMO and complications of the brain
2.1 Abnormalities of coagulation related to the use of inhaled nitric oxide before extracorpo­
real membrane oxygenation
2.2 The effect of inhaled nitric oxide on the course of extracorporeal membrane oxygenation 
and the occurrence of hemorrhagic complications
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Chapter 2.1
Abnormalities of coagulation related to the use of iNO prior to extracorporeal membrane 
oxygenation
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Abstract
Objective. Evaluation of the influence of previous inhaled nitric oxide (iNO) treatment on the 
occurrence of clotting complications and disseminated intravascular coagulation during extra 
corporeal membrane oxygenation (ECMO).
Design: Retrospective study in newborns treated with veno-arterial ECMO during a 5-yr period. 
Setting: Neonatal intensive care unit of a university medical center
Patients: A total of 59 Newborns with severe respiratory insufficiency treated with veno-arterial 
ECMO.
Interventions: Patients received iNO before ECMO (iNO group) or not (control group). 
Measurements and main results: There were no differences between the groups for patient 
characteristics and medication use before ECMO, except for norepinephrine. After correction for 
diagnosis and duration of ECMO, significantly more clotting complications and DIC as individual 
variables were seen in the iNO group. For the combination of clotting complications and dissemi­
nated intravascular coagulation there was a significantly higher prevalence in the iNO group. 
Conclusions: In our population we found a remarkable relationship between clotting complica­
tions or a disseminated intravascular coagulation and iNO use prior to ECMO treatment, which 
needs further prospective research before conclusions can be drawn.
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Introduction
Veno-arterial extracorporeal membrane oxygenation (ECMO) is a rescue therapy for neonates 
with severe respiratory failure (1). One of the major causes for complications of ECMO is the 
disturbance in normal coagulation, resulting in an increased risk of disseminated intravascular 
coagulation (DIC) and clotting complications in the ECMO system (2,3). Because persistent pul­
monary hypertension is one of the most important indications for ECMO in newborns, inhaled 
nitric oxide (iNO) is usually part of the treatment before the start of ECMO (4). Although used for 
its specificity as a pulmonary vasodilator, iNO has systemic effects as well (5). There are sugges­
tions in literature that iNO might be involved in the initiation of the coagulation cascade (6-13). 
The aim of this study is to evaluate the influence of previous iNO treatment on the occurrence of 
clotting complications and DIC during the ECMO treatment.
Materials and methods
In a retrospective study of a 5-yr period, 85 patients treated with ECMO in our hospital were analyzed. 
The project was approved by the institutional review board. Patients with congenital diaphragmatic 
hernia were excluded (n=26) because in our center iNO is not part of the standard treatment protocol 
in congenital diaphragmatic hernia (14). In addition, patients with congenital diaphragmatic hernia 
on ECMO receive tranexamic acid, an anti-fibrinolytic drug, during the operation. Finally 59 patients 
were included, of which 25 patients received iNO treatment before ECMO (the iNO-group) and 34 pa­
tients started with ECMO without previous iNO treatment (control group). The control group consists 
of patients from the time prior to the introduction of iNO at our institution and from the time that 
there was limited availability of iNO. No more patients were included from the time when iNO was 
fully available. Through the study period selection criteria to start iNO were based on an oxygenation 
index of > 25 while on assisted ventilation. Patients were treated with 20 ppm NO. The iNO group and 
the control group were compared for gestational age, birth weight, lowest arterial oxygen saturation 
(saO2), lowest arterial partial pressure of oxygen (paO2), maximum alveolo-arterial difference in partial 
pressure of oxygen (AaDO2) before ECMO, ventilator settings, postnatal age at the initiation of ECMO, 
duration of ECMO, worst pH before ECMO and Apgar scores at 1 and 5 minutes using a student f-test. 
Primary diagnoses were compared using Fisher exact test. The independence between sex and iNO 
in this study was analyzed using a chi-square test.
All patients received a heparin-loading dose of 150 units/kg at the initiation of ECMO. After this, hepa- 
rinization was checked every hour by measuring the activated clotting time aiming for values be­
tween 200 and 220 secs (Hemochron, ITC Europe, Italy). iNO was stopped immediately after the initia­
tion of ECMO. We studied differences in the occurrence of clotting complications or DIC between the 
iNO group and the control group. Clotting complications were defined as cerebral infarction on ul­
trasound, computed tomographic scan or magnetic resonance image or clot formation in the ECMO- 
system by visual inspection. The diagnosis of DIC was based on laboratory results performed on a 
daily basis with D-dimer concentration of > 10.000 units/L in combination with decreasing fibrinogen 
levels to values of < 1500 mg/L. We performed a linear logistic regression analysis (Statistical Analysis
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System, SAS Institute, Cary, NC) to look for significant relations with iNO treatment before ECMO. For 
clotting complications and DIC, iNO treatment and primary diagnosis were included in the regression 
models. Other factors included were gestational age, birth weight, postnatal age at start of ECMO and 
pre-ECMO medication. Patient characteristics are presented as mean ± SD. Odds ratios for complica­
tions are presented with a 95% confidence interval; p values of <.05 were considered significant.
Results






Pre-ECMO Parameter Mean SD Mean SD P
Gestational age (weeks) 39 2 39 3 0.69
Birth weight (gram) 3422 586 3392 626 0.86
Lowest saO2 (%) 64 22 63 21 0.85
Lowest paO2 (mmHg) 42 17 35 11 0.11
Maximum AaDO2 (mmHg) 636 21 644 14 0.12
PIP (cm H2O) 36.8 1.8 37.5 2.6 0.45
MAP (cm H2O) 19.6 2.1 19. 2.5 0.74
PEEP (cm H2O) 5.0 1.2 4.6 1.2 0.25
Duration of ECMO (hours) 173 52 155 74 0.27
Postnatal age at start ECMO (hours) 59 68 53 63 0.70
Worst pH 7.31 0.16 7.26 0.16 0.29
Apgar 1 minute 5.4 3.1 5.8 2.8 0.63
Apgar 5 minutes 6.3 2.4 6.9 2.2 0.30
Gender (male/female) 13/12 25/9 0.05
Primary diagnosisa Number (%) Number (%)
MAS 19 (76) 19 (56) 0.17
Sepsis 4 (16) 8 (24) 0.53
Pneumonia 2 (8) 7 (21) 0.28
RDS 2 (8) 2 (6) 1.00
Primary PPHN 2 (8) 5 (15) 0.69
Total number of primary diagnosis 29 41
a Several patients had more than one prim ary diagnosis. iNO group = group treated w ith inhaled nitric 
oxide, saO2 = arterial oxygen saturation, paO2 = arterial pa rtia l pressure o f oxygen, AaDO2 = alveolo- 
arterial difference in pa rtia l pressure o f oxygen, PIP = positive inspiratory pressure before ECMO, MAP 
= mean airway pressure before ECMO, PEEP = positive end-expiratory pressure before ECMO. ECMO 
= extracorporeal membrane oxygenation, MAS = meconium aspiration syndrome, RDS = respiratory 
distress syndrome. PPHN = persistent pu lm onary hypertension o f the newborn.
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No significant differences were found for pre-ECMO characteristics between groups (table 1). 
More than one primary diagnosis was found in several patients. In the iNO group, two patients 
were diagnosed with the combination of sepsis and pneumonia, one patient with meconium 
aspiration syndrome and sepsis, and one patient with respiratory distress syndrome and sepsis. 
There was no significant difference in pre-ECMO medication between the two groups except 
for the use of norepinephrine (four patients in the iNO group vs. no patient in the control group 
[Fisher's exact test, p=0.03]). Mean OI at or near the time iNO was initiated was 38 ± 9.
Table 2. Occurrence of clotting complications and DIC during extra corporeal membrane oxy­
genation in the inhaled nitric oxide group and control group
iNO Control Regression analysis
group group Corrected
(n=25) (n= 34) Not corrected For diagnosis For diagnosis and 
duration of ECMO
complication No.(%) No.(%) OR (95% CI) p OR (95% CI) OR (95% CI)
Clotting 10 (40) 6 (18) 3.1 (1.0-10.8) 0.056 3.4 (2.1-22.6)a 3.4 (1.0-11.8)a
DIC 10 (40) 6 (18) 3.1 (1.0-10.8) 0.056 4.5 (1.3-19.6)a 4.3 (1.2-17.4)a
Clotting 
and/or DIC 17 (68) 9 (26) 5.9 (2.0-19.3) 0.001 6.4 (2.1-22.6)a 5.9 (1.7-20.4)a
Odd's ratios (OR) are presented w ith a 95% confidence interval (CI) for each complication before and 
after correction for diagnosis and diagnosis as well as duration o f extracorporeal membrane oxygen­
ation (ECMO). iNO group = group treated w ith inhaled nitric  oxide, DIC = disseminated intravascular 
coagu lation.a Statistically significant (p<0.05) after correction for diagnosis or a fter correction for d i­
agnosis and ECMO run-time.
The occurrence of clotting complications or DIC during ECMO is shown in table 2. A p value just 
above the defined level of significance was observed for the relationship between previous iNO 
use and clotting complications and DIC. This became statistically significant (odds ratio, 3.4 [95% 
confidence interval, 2.1-22.6] and 4.5 [1.3-19.6]) after correction for diagnosis and duration of 
ECMO. For the combination of clotting complications or DIC a statistically significant relation­
ship with previous iNO was found, which persisted after correction for diagnosis and duration of 
ECMO (odds ratio, 5.6 [95% confidence interval, 1.7-20.4]).
Discussion
iNO effectively reduces the number of ECMO treatments, but does not reduce mortality in term 
infants with hypoxic respiratory failure (15). Clotting complications and DIC are major problems
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for patients receiving ECMO. Because of the potential effects on the coagulation cascade, the use 
of iNO in this population has been of our concern (6-13).
In this retrospective study we found a remarkable relationship between the occurrence of clot­
ting complications or DIC and the use of iNO prior to ECMO. After correction for diagnosis and 
duration of ECMO, both clotting complications and DIC were significantly more present in the 
iNO group than in the control group. When combined, clotting complications or DIC occurred 
significantly more often in the iNO group than in the control group. The fact that the differ­
ence in clotting complications and DIC between the iNO group and control group increased 
after correction for diagnosis might be explained by the fact that there were more patients with 
sepsis in the control group. Because sepsis, even without ECMO, is related to the occurrence of 
clotting complications and DIC, these complications might already be present in these patients. 
Pre-treatment with iNO of newborns in need of ECMO therapy seems to have an effect on the 
coagulation cascade in this study. It is hard to explain this from the known effects of iNO. Based 
on literature hypothetical explanations might be found in vascular and tissue damage, apoptosis, 
an increase in free radicals and increased expression of factors initiating the coagulation cascade, 
like tissue factor. In term infants prolonged, 24 to 48 hours, exposure to iNO is associated with an 
increase in markers of oxidative injury in serum samples (6). Kobayashi et al. found a relationship 
between long-term inhalation of NO and activation of the clotting system by increasing the lung 
expression of tissue factor (7). It is known that free radicals and apoptosis are likely to play a role 
in the expression of tissue factor and increased thrombin generation on the surface of mono­
cytes, macrophages and endothelial cells (8-11). Finally NO can influence coagulation parameters 
in vitro via nitrosylation of thiol groups (12,13). The clinical relevance of these mechanisms re­
mains unclear. It is speculative whether there might be a cumulative effect in the initiation of the 
coagulation cascade by the combination of iNO and a consecutive ECMO treatment.
We recognize the limitations of a retrospective study design in which patients are not random­
ized and findings could be influenced by many factors. However, we are not aware of any study 
focusing on the possible negative effects of iNO treatment before ECMO. Because iNO has been 
accepted as standard therapy for newborns with severe respiratory insufficiency with pulmo­
nary hypertension, prospective studies are hard to perform because of medical as well as ethical 
considerations. Due to the limited capacity of iNO treatment in our hospital during the study 
period, the start of iNO depended on its availability. If more patients with an iNO indication were 
presented at the same time with limited availability of iNO the choice to use iNO in which patient 
was at the discretion of the treating physician and bias related to myriad factors cannot be ruled 
out. Although the two groups were not completely homogeneous for diagnosis, especially sepsis 
and MAS, this was not statistically significant. To correct for the possible influence of primary 
diagnosis on complications we did however perform a logistic regression analysis. Treatment in 
both groups was equal except for the use of norepinephrine, which was significantly more used 
in the iNO group. It is unclear whether this was related to the use of iNO. Finally the control group 
had a higher percentage of males than the iNO group. Although this was just above of the level
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of significance, any influence on the findings cannot be excluded.
If our results would be confirmed by prospective studies it is of great interest to further inves­
tigate the possible mechanisms of iNO on the coagulation system. Major clot formation in the 
circuit can be detected by circuit inspection, but small clots can escape into the circulation of the 
patient and cause (small) infarctions. Disturbance in other organ functions can also be involved 
in DIC. We should be aware of this potential risk of using iNO in newborns with respiratory failure 
qualifying for ECMO treatment.
Conclusions
In this retrospective study we found a remarkable relationship between clotting complications 
and/or DIC and iNO use prior to ECMO treatment. A prospective, randomized study is indicated, 
which should also investigate the mechanisms of possible adverse effects of iNO on the coagula­
tion system before and during ECMO, before strong conclusions can be made.
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Abstract
This study evaluated the relation between prior inhaled nitric oxide (iNO) and the time to ini­
tiation and duration of treatment with veno-arterial extracorporeal membrane oxygenation 
(ECMO) and the occurrence of hemorrhagic complications.
A retrospective study was conducted in 59 human newborns treated for respiratory insufficiency 
with ECMO over a 5-years period. Patients received iNO before ECMO (iNO group) or not (control 
group). Both groups were compared for patient characteristics, postnatal age at the initiation of 
ECMO, duration of ECMO treatment and hemorrhagic complications.
There were no significant differences between the iNO group and the control group for patient 
characteristics and medication use before the ECMO treatment, except for norepinephrine. There 
was no significant difference for postnatal age at the initiation of ECMO and mean duration of 
ECMO treatment. We found no statistically significant difference in hemorrhagic complications 
between both groups. This persisted after correction for diagnosis and ECMO run-time in linear 
logistic regression analysis.
Inhaled nitric oxide before ECMO did not result in a significant delay in the initiation of ECMO or 
longer duration of the ECMO treatment. There was no significant relationship between the use of 
prior iNO and the occurrence of hemorrhagic complications during the ECMO treatment.
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Introduction
Since Bartlett et a!) first used neonatal veno-arterial extracorporeal membrane oxygenation 
(ECMO) in 1975, ECMO became an effective rescue therapy for newborns suffering from severe, 
but potentially reversible respiratory insufficiency. Without ECMO there is a high mortality in this 
patient group.2,3 The occurrence of hemorrhagic and ischemic cerebral lesions, resulting in neu­
rological and neurodevelopmental dysfunction are major complications of ECMO treatment.4-6 
One of the causes for these devastating complications is the disturbance of normal coagulation 
resulting in an increased risk for clotting complications and hemorrhagic complications, the lat­
ter occurring in up to 20% of cases.7
Because persistent pulmonary hypertension is one of the most important indications for ECMO 
treatment in newborns, the application of inhaled nitric oxide (iNO) is usually part of the con­
ventional treatment before the start of ECMO.8 The use of iNO to treat pulmonary hypertension 
might result in a delayed initiation of ECMO since a certain time is required to evaluate the effect 
of iNO. Due to a possible longer pre-ECMO treatment period, lung recovery might be prolonged, 
resulting in an increased duration of ECMO treatment, which consequently might result in more 
complications. Although used for its specificity as a pulmonary vasodilator, iNO has systemic, 
extra pulmonary effects as well.9,10 iNO is known to have an effect on platelet function in vitro. 
The relevance in vivo is unclear, especially as NO in the blood is reported to have a short half life 
time and will bind to proteins like hemoglobin and albumin.11,12 However, iNO in the systemic 
circulation might diffuse to circulating platelets and inhibit adhesion and aggregation.13,14 Next 
to this, elevated levels of NO metabolites, nitrite and nitrate, may result in prolonged reactivation 
into bioactive NO, especially in case of acidosis and hypoxemia,15,16 conditions occurring often in 
pre ECMO patients. Furthermore, the production of toxic free radicals by iNO with consecutive 
vascular and tissue damage may play a role.17,18 It is unknown whether this might result in an in­
creased vulnerability for hemorrhagic complications when iNO treatment is followed by ECMO 
for which the patient needs to be heparinized. In an earlier publication of our group in the same 
population, we found a remarkable and statistically significant relation between the use of iNO 
before veno-arterial ECMO and clotting complications or disseminated intravascular coagulation 
(DIC).19 The aim of this study is to evaluate the relation between the use of iNO before ECMO 
and the time to initiation and duration of treatment with ECMO. Furthermore, the occurrence of 
hemorrhagic complications in relation to iNO treatment was studied.
Materials and methods
In a retrospective study over a 5-year period, all newborn patients treated with veno-arterial 
ECMO for severe, but potentially reversible, pulmonary insufficiency and pulmonary hyperten­
sion in our hospital (n=85) were analyzed. The study was approved by the institutional review 
board. Patients with congenital diaphragmatic hernia were excluded (n=26) because, in our cen­
ter, iNO is not part of the standard treatment protocol in congenital diaphragmatic hernia.20 In 
addition, patients with congenital diaphragmatic hernia treated with ECMO receive tranexamic
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acid, an anti-fibrinolytic drug, during and 24 hours after surgery.21 Finally, 59 patients were in­
cluded in our study, of which 25 patients received iNO treatment before ECMO (iNO-group) and 
34 patients started with ECMO without prior iNO treatment (control group). The control group 
consists of patients from the time before the introduction of iNO at our institution and from the 
time that there was limited availability of iNO. No more patients were included from the time 
when iNO was fully available. During the study period, selection criteria to start iNO were based 
on an oxygenation index of > 25 although on assisted ventilation. Patients in the iNO group were 
treated with 20 ppm NO. All patients received a heparin-loading dose of 150 U/kg at the initiation 
of ECMO. After this, heparinisation was checked every hour by measuring the activated clotting 
time aiming for values between 200 and 220 seconds (Hemochron, ITC Europe, Italy). Inhaled 
nitric oxide was stopped shortly after the initiation of ECMO. During the course of ECMO, platelet 
transfusions were given to maintain a platelet count greater than 80.000/mm3. Erythrocyte trans­
fusions were given to maintain a hemoglobin level > 8.0 mmol/l and a hematocrit value > 0.40 
L/L. Hemoglobin level and platelet count were determined every 4 hours.
The iNO group and the control group were compared for gestational age, birth weight, low­
est arterial oxygen saturation (saO2), lowest arterial partial pressure of oxygen (paO2), maximum 
alveolo-arterial difference in partial pressure of oxygen (AaDO2) before ECMO, ventilator settings 
before ECMO (peak inspiratory pressure, mean airway pressure, positive end-expiratory pres­
sure), worst pH before ECMO, postnatal age at the start of ECMO, duration of ECMO and Apgar 
scores at 1 and 5 minutes using student t-tests. Primary diagnoses were compared using Fisher's 
exact test. The independency between gender and iNO and different medications and iNO in this 
study was analyzed using a Chi-square test.
We studied differences in the occurrence of hemorrhagic complications between the iNO- and 
control group, which were defined as intracranial hemorrhage as assessed by daily ultrasound 
during the ECMO treatment or computed tomographic scan or magnetic resonance image di­
rectly after the ECMO treatment, cannulation site hemorrhage, gastrointestinal hemorrhage or 
pulmonary hemorrhage. We performed linear logistic-regression analysis (Statistical Analysis 
System, SAS Institute, Cary, NC) to study the relation between iNO treatment before veno-arterial 
ECMO and hemorrhagic complications. Inhaled nitric oxide treatment or not, duration of ECMO 
and diagnosis were included in the regression models. Other factors included were gestational 
age, birth weight, postnatal age at start of ECMO and pre-ECMO medication. Patient characteris­
tics are presented as mean ± SD. Odds ratios for hemorrhagic complications are presented with 
a 95% confidence interval; p values of <0.05 were considered significant.
Veno-Arterial Extracorporeal Membrane Oxygenation in Relation to the Brain | 47
Results






Pre-ECMO Mean SD Mean SD P
Parameter
Gestational age (weeks) 39 2 39 3 0.69
Birth weight (gram) 3422 586 3392 626 0.86
Lowest saO2 (%) 64 22 63 21 0.85
Lowest paO2 (mmHg) 42 17 35 11 0.11
Maximum AaDO2 (mmHg) 636 21 644 14 0.12
PIP (cm H2O) 36.8 1 .8 37.5 2.6 0.45
MAP (cm H2O) 19.6 2.1 19.5 2.5 0.74
PEEP (cm H2O) 5.0 1.2 4.6 1.2 0.25
Duration of ECMO (hours) 173 52 155 74 0.27
Postnatal age at start ECMO (hours) 59 68 53 63 0.70
Worst pH 7.31 0.16 7.26 0.16 0.29
Apgar 1 minute 5.4 3.1 5.8 2.8 0.63
Apgar 5 minutes 6.3 2.4 6.9 2.2 0.30
Gender (male/female) 13/12 25/9 0.05
Primary diagnosisa Number (%) Number (%)
MAS 19 (76) 19 (56) 0.17
Sepsis 4 (16) 8 (24) 0.53
Pneumonia 2 (8) 7 (21) 0.28
RDS 2 (8) 2 (6) 1.00
Primary PPHN 2 (8) 5 (15) 0.69
Total number of primary diagnosis 29 41
a Several patients had more than one prim ary diagnosis. iNO group = group treated w ith inhaled nitric 
oxide, saO2 = arterial oxygen saturation, paO2 = arterial pa rtia l pressure o f oxygen, AaDO2 = alveolo- 
arterial difference in pa rtia l pressure o f oxygen, PIP = positive inspiratory pressure before ECMO, MAP 
= mean airway pressure before ECMO, PEEP = positive end expiratory pressure before ECMO. ECMO 
= extracorporeal membrane oxygenation, MAS = meconium aspiration syndrome, RDS = respiratory 
distress syndrome. PPHN = persistent pu lm onary hypertension o f the newborn.
No significant differences were found for pre-ECMO characteristics between the iNO group and 
the control group (Table 1). More than one primary diagnosis was found in several patients. In 
the iNO group there were two patients diagnosed with the combination of sepsis and pneumo-
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nia, one patient with meconium aspiration syndrome and sepsis and one patient with respiratory 
distress syndrome and sepsis. Mean oxygenation index at or near the start of iNO treatment was 
38 ± 9. There was no statistically significant difference in pre-ECMO medication between the iNO 
group and the control group except for the use of norepinephrine (4 patients in the iNO group 
versus no patient in the control group, p = 0.03). The postnatal age at the start of ECMO in the iNO 
group was 59 ± 68 hours versus 53 ± 63 hours in the control group (p = 0.70). Mean duration of 
ECMO in the iNO group was 173 ± 52 hours versus 155 ± 74 hours in the control group (p = 0.27). 
Regression analysis showed a statistically significant relationship between the postnatal age at 
the start of ECMO and the duration of ECMO (p = 0.003). There was an average 0.41 hour increase 
in duration of ECMO for every hour of postnatal age at the initiation of ECMO. In our study, how­
ever, the difference in postnatal age between the iNO group and control group at the start of 
ECMO was not related to a clinically relevant prolonged mean total duration of ECMO (2.9 hours).
Table 2. Occurrence of hemorrhagic complications during extra corporeal membrane oxygen­










For diagnosis For diagnosis and 
duration of ECMO
complication No.(%) No.(%) OR (95% CI) P OR (95% CI) OR (95% CI)
Hemorrhage 5 (20) 6 (18) 1.2 (0.3-4.4) 0.819 1.7 (0.4- 7.7) 3.2 (0.5-22.1)
Odd's ratios (OR) are presented w ith a 95% confidence interval (CI) before and after correction for 
diagnosis and for diagnosis and duration o f ECMO
The occurrence of hemorrhagic complications during ECMO is shown in Table 2. There was no 
statistically significant difference in hemorrhagic complications between the iNO group and the 
control group (p = 0.82). This did not change after correction for diagnosis and duration of ECMO. 
Hemorrhagic complications in the iNO group consisted of four patients with cerebral hemor­
rhage and one patient with pulmonary hemorrhage. In the control group, there were three pa­
tients with a cerebral hemorrhage, two with a gastro-intestinal hemorrhage and one with a pul­
monary hemorrhage.
Discussion
Inhaled nitric oxide is effective in reducing the number of ECMO treatments, but does not re­
duce mortality in term infants with hypoxic respiratory failure who do not have a diaphragmatic 
hernia.2223 ECMO related complications might be related to later initiation of ECMO and a pro­
longated duration of the ECMO treatment. To avoid a delay in the use of ECMO because of an 
inadequate response to prior iNO treatment and other techniques like high frequency oscilla-
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tion (HFO), it has been suggested to adapt the current ECMO criteria and to lower the threshold 
for the initiation of ECMO in patients suffering from severe hypoxic respiratory failure, who are 
already treated with iNO and HFO.3,24 Although there is a statistically significant relationship be­
tween the postnatal age at the start of ECMO and the duration of ECMO, in this study, the use 
of iNO did not result in a significant increase in the postnatal age at the start of ECMO nor in the 
duration of ECMO.
In earlier research, using a similar study in this population, we found a remarkable relation be­
tween iNO use and clotting complications or DIC.19 In this current study we focused on hemor­
rhagic complications, but did not find a statistically significant difference in the occurrence of 
hemorrhagic complications between the iNO group and control group. Because of the effect 
iNO is supposed to have on platelet aggregation and bleeding time,1214-25-26-27 this is an important 
finding. This is especially true in its relation to the use of ECMO in which bleeding is one of the 
most devastating complications. The effect of NO, added to the sweep gas, on the coagulation 
system has also been used in ECMO research to increase biocompatibility of the extracorporeal 
circulation system and to reduce clotting formation on the oxygenator surface.2829 Although 
not in combination with ECMO as a possible additive risk factor, a Cochrane review did not find 
evidence of an effect of iNO on intraventricular hemorrhage in preterm infants.30 A recent study, 
however, showed a significant association between increased nitrates and nitrites with hypox­
ic ischemic encephalopathy and possibly increased blood-brain barrier.18 Finally there is one 
study in piglets, that does not support the hypothesis that iNO increases the risk of bleeding in 
humans.31 Again this was not in combination with ECMO treatment.
Of all hemorrhagic complications, there were four cases of intracranial hemorrhage in the iNO 
group and three in the control group. As these intracranial hemorrhages were not predominantly 
located at one site of the brain, numbers are by far too small to make any conclusion about a 
possible relation between cannula position, of which depth of location was always checked by 
x-ray, and the occurrence of intracranial hemorrhage. Whether other treatment strategies like 
maintaining lower ACT levels would result in a decrease of hemorrhagic complications cannot 
be concluded from this study.
We recognize the limitations of a retrospective study design in which patients are not random­
ized and findings could be influenced by many factors. However, to our knowledge, this is the 
first study concerning the relation between prior iNO treatment and the occurrence of hemor­
rhagic complications, one of the most important complications of ECMO. Because iNO has been 
accepted as standard therapy for newborns with severe respiratory insufficiency with pulmonary 
hypertension, prospective studies are nowadays hard to perform because of medical and ethical 
considerations. Retrospective studies like ours might indicate whether there is a need for a 
prospective study or not. Due to the limited capacity of iNO treatment in our hospital during the 
study period, the start of iNO depended on its availability. If more patients with an iNO indica­
tion were presented at the same time with limited availability of iNO the choice to use iNO in 
which patient was at the discretion of the attending physician and bias related to myriad factors
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cannot be ruled out. Even though primary diagnosis was not significantly different between the 
two groups we performed a logistic-regression analysis to correct for any possible influence of 
primary diagnosis on the outcome. Treatment in both groups was equal, except for the use of 
norepinephrine. It is unclear whether this was related to the use of iNO.
Conclusion
Based on this retrospective study, we demonstrated that the use of iNO in severe respiratory 
insufficiency and pulmonary hypertension does not necessarily result in a delay in the initiation 
of ECMO or in an increase in the duration of ECMO treatment in our population. Additionally, we 
conclude that the use of iNO prior to veno-arterial ECMO treatment does not result in an increase 
of hemorrhagic complications, one of the most devastating complications.
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Abstract
P urpose: To describe the effects on cerebral blood flow  ve loc ity  (CBFV) o f in te rm itte n t opening 
o f the venoarterial bridge (VA bridge) during venoarterial extracorporeal membrane oxygen­
ation (VA-ECMO).
S tudy  design: Prospective study in 22 newborns during VA-ECMO. CBFV was measured in the 
pericallosal artery by Doppler-u ltrasound. Changes in peak systolic flow  ve loc ity  (PSV), end dia­
stolic flow  ve loc ity  (EDV) and tim e averaged mean flow  ve loc ity  (TAM) on day 1, 2, 3, and 5 and at 
low  ECMO-flow (50-150 m l/m in) were analyzed (mean percentage ± standard deviation (t-tests, 
p<0.05)). Changes >25% were considered relevant. The relationship between changes in CBFV 
and ECMO-flow rate (Pearson corre lation, p<0.01) was studied.
Results: Opening o f the VA bridge resulted in statistically significant and relevant decreases in 
PSV (35 ± 18%), EDV (93 ± 15%) and TAM (68 ± 13%), persisting during the consecutive days of 
treatm ent. Smaller changes in CBFV at low ECMO flow  were statistically significant and mostly 
relevant, PSV (15 ± 7%), EDV (76 ± 21%) and TAM (40 ± 12%). Changes in CBFV were positive ly cor­
related to  the ECMO-flow.
C onc lus ion : Use o f the VA bridge results in significant and relevant, ECMO flow  dependent, 
changes in CBFV, persisting during the treatm ent. The VA bridge should be used in such a way as 
to  a llow  regular unclam ping to be om itted
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Introduction
The first newborn was successfully treated w ith  veno-arterial extracorporeal m embrane oxygen­
ation (VA-ECMO) by Bartle tt and colleagues in 1976 (1). Since then, ECMO has become a rescue 
therapy fo r more than 22.000 neonates w ith  severe respiratory failure, o f which abou t 15.000 
patients were treated w ith  VA-ECMO, w ith  an overall survival rate o f 80% (2). A lthough ECMO has 
increased survival rates, the occurrence o f hem orrhagic and ischemic cerebral lesions, resulting 
in fu ture neurological and neurodevelopm ental dysfunction are major com plications (3,4). Imag­
ing studies revealed hem orrhagic or ischemic intracranial abnorm alities in 10% up to  as high as 
52% o f the patients (5,6,7).
The occurrence of complications m ight be determ ined by pre-ECMO, as well as ECMO-related 
events or conditions (3,8). Pre-ECMO conditions like hypoxia, asphyxia, acidosis, hypercapnia, and 
cardiovascular instability, including cardio-pulm onary resuscitation are considered to increase the 
risk for cerebral in jury by d irect damage to the brain and potential disturbance o f cerebral au to­
regulation. Once on ECMO, heparinization, m icrothrom bi and disturbances o f cerebral blood flow  
(patterns) and autoregulation are supposed to be other risk factors. Understanding of physiologic 
processes in the patient as a response to  the ECMO-treatment is crucial to avoid potential harm­
ful events. Part o f the va-ECMO system is "a bridge" between the arterial and venous cannula (VA 
bridge). In the event o f emergencies the arterial and venous cannula can be clamped and the va- 
bridge opened to allow  continuation o f circulation through the ECMO system, while the patient 
is taken o ff from ECMO. Under normal conditions the VA bridge is clamped. To prevent c lo tting in 
the VA bridge because of blood stasis, it has been recommended to release the clamp on the VA 
bridge every 15 to 60 minutes during the course o f ECMO (9-11). There is, however, a lim ited number 
o f studies concerning the im pact o f this procedure. Inqyinn et al. found a decrease in blood pres­
sure and renal blood flow  during opening of the VA bridge (12). Our group previously reported on 
the disturbance o f cerebral oxygenation and hemodynamics fo llow ing opening of the VA bridge 
during the course of VA-ECMO treatm ent. In piglets and newborn infants, Liem et al, using near in ­
frared spectrophotom etry (NIRS) found tha t opening of the VA bridge resulted in a decrease in ce­
rebral blood volume and cerebral oxygen supply. A fter this in itial decrease there is a compensatory 
increase in cerebral oxygen extraction and vasodilatation (13). In a consecutive study in lambs, van 
Heijst et al described tha t opening o f the VA bridge during VA-ECMO resulted in a massive shunt of 
blood from  the arterial side o f the circuit to the venous side, causing significant changes in blood 
pressure, cerebral oxygenation and hemodynamics in lambs(14). These changes were found to be 
present at different ECMO flow  rates and opening times o f the VA bridge. As there is an ongoing 
discussion about how to use the VA bridge, additive studies, other than the NIRS studies discussed 
above may further demonstrate the potential harm o f in te rm itten t opening o f the VA bridge.
The aim o f this prospective study was to describe the effect o f opening and closure o f the VA 
bridge on cerebral b lood flow  ve locity (CBFV) in a term inal artery to the brain, as measured 
by Doppler-u ltrasound, in human newborn infants. In addition, the relationship between the 
changes in CBFV and the duration o f ECMO treatm ent and ECMO flow  rate were also studied.
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Methods
In a prospective study over a one-year period, 22 consecutive patients treated w ith  VA-ECMO in our 
university medical center were enrolled to study the effects o f opening and closure o f the VA bridge 
o f the VA-ECMO system on CBFV. Approval was obtained from  the Institutional Review Board and 
Ethics Committee. CBFV in the pericallosal artery, a term inal branch o f the anterior cerebral artery, 
was measured by Doppler-ultrasound (HDI-3000, ATL ultrasound, Inc., Bothwell, WA, USA) through 
the anterior fontanel (15,16). Measurements were perform ed jus t before opening (unclamping), 
during opening and after closure (clamping) o f the VA bridge, which was opened for 2 to 3 seconds 
to achieve a clear visible flow  through the VA bridge in accordance w ith  our standard clinical 
protocol, which was used th roughou t the study period. Measurements were perform ed in duplo in 
each patient, w ith  a 15-minute interval and repeated on day 1, 2, 3, and 5 by the same investigator 
(AFJvH) during the consecutive days o f the ECMO treatm ent and thus at d ifferent ECMO flow  rates. 
Additionally measurements were also perform ed at a low ECMO flow  defined as 50 to  150 m l/m in, 
when this was not already achieved at day 5. The ECMO circuit itse lf consisted o f a custom packed 
% inch flexible po lyvinylch loride tub ing (Baxter, Uden, The Netherlands), w ith  a silicone reservoir, 
the bladderbox (Seabrook Medical System, Værlose, Denmark), a 0.6 m2 membrane oxygenator 
(Scimed Life Systems, Minneapolis, MN, USA), a heat exchanger (Cincinnati Sub Zero, Cincinnati, 
OH, USA) and a rollerpum p (Polystan A/S, Denmark). To describe possible changes in CBFV we stud­
ied the peak systolic flow  velocity (PSV), end diastolic flow  velocity (EDV) and tim e averaged mean 
flow  velocity (TAM), all in centimeters per second (cm/s). All parameters were determ ined as the 
average value measured over three consecutive heart cycles. For analysis purposes, we used the 
averaged value o f the duplo measurements. Changes in CBFV during opening and after closure of 
the bridge were expressed as mean percentage o f change ± standard deviation (SD) o f the CBFV 
as compared to the value before opening. Statistical analysis was perform ed using paired t-tests 
(SPSS 12.0). A p-value < 0,05 was considered statistically significant. We defined changes in CBFV 
o f more than 25% to be relevant. By repeating the measurements during the consecutive days of 
treatm ent, we looked at the relationship between the magnitude of changes in CBFV and the du­
ration o f ECMO treatm ent in days. Finally, we studied the relationship between the magnitude of 
changes in CBFV during opening of the bridge and the ECMO flow  rate. For this purpose data o f all 
days o f ECMO and at low ECMO flow  rate were combined. Changes in CBFV were analyzed in their 
relationship to the ECMO flow  rate expressed in m l/m in /kg (Pearson correlation, SPSS 12.0). Correla­
tions were considered statistically significant at a p-value< 0.01 (2-tailed).
Results
Of the 22 newborns included in our study, 10 patients suffered from  m econium aspiration syn­
drome. O ther diagnoses were: 5 cases o f congenita l d iaphragm atic hernia; 1 o f sepsis; 1 o f respi­
ratory distress syndrome; 1 o f to ta l abnorm al pu lm onary venous return; and fina lly 4 patients had 
an id iopath ic  pu lm onary hypertension. Mean b irthw e igh t (±SD) was 3474 (± 443) grams, mean 
gestational age (±SD) was 276 (± 19) days and mean ECMO runtim e (±SD) was 152 (± 44) hours.
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Figure 1.
Doppler-ultrasound signal o f  cerebral blood flow  velocity during opening o f the veno-arterial bridge 
during extracorporeal membrane oxygenation. Arrow: opening o f the va-bridge.
On day one of the ECMO treatm ent we found a significant decrease in PSV (35 ± 18%), EDV (93 ± 15%) 
and TAM (68 ± 13%) after opening o f the VA bridge (Fig. 1). All changes were statistically significant 
(p<0.001). In 9 patients no end diastolic flow  was detected while the VA bridge was opened (EDV=0). 
In 2 patients even a backward end diastolic flow  (negative EDV) was found w ith  a 112 and 120 per­
cent decrease compared to the pre-opening EDV value. The effects on PSV, EDV and TAM during the 
consecutive days and at low flows while unclamping and clamping the va-bridge are shown in Table 1. 
Changes in PSV, EDV and TAM found at day 2 and 3 of the ECMO-treatment were equal to the results 
at day 1. Again there was no end diastolic flow  over the pericallosal artery in 6 patients on both days 
and a backward flow  w ith negative EDV was measured in 1 patient on both days.
Opening o f the VA bridge on day 5 o f the ECMO treatm ent still resulted in a statistically sign ifi­
cant decrease in PSV (23 ± 23%), EDV (85 ± 23%) and TAM (61 ± 15%), which was also relevant for 
EDV and TAM. This effect was lower compared to  the first three days. If, however, on ly patients 
are analyzed w ho had an ECMO flow  rate o f 250 m l/m in or more on day 5, changes in PSV, EDV 
and TAM were equal to the results on day 1 through 3. Fluctuations in PSV (15 ± 7%), EDV (76 ± 21%) 
and TAM (40 ± 12%) measured at low ECMO flow  o f 50 to  150 m l/m in were less pronounced 
than during the firs t 5 days o f treatm ent. All changes, however, remained statistically significant 
(p<0.001) and were relevant fo r EDV and TAM. There were tw o  missing measurements fo r values 
after closure o f the VA bridge on day 1 and 2. Four patients could not be analyzed on day 5 as 
three o f them  were already decannulated a fte r successful ECMO trea tm ent and one died at day
4 o f ECMO. Add itional measurements at low  ECMO flow  were perform ed in 14 patients, while 
this was not possible in 4 patients. In some patients the measurement at low ECMO flow  rate 
was already achieved at day 5. By com bin ing all the data from  day 1, 2, 3 and 5 and the data o f ad 
d itional measurements at low ECMO flow  we studied the relationship between ECMO flow  
rate (m l/m in /kg) and the m agnitude o f changes in CBFV. A statistically significant linear cor­
relation between the ECMO flow  rate and the m agnitude o f changes in CBFV was found for
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Table 1. changes in percentages in peak systolic flow  ve loc ity  (APSV), end diastolic flow  velocity 
(AEDV) and tim e averaged mean flow  ve loc ity  (ATAM)
Changes in PSV, EDV, and TAM after opening o f the va-bridge compared to pre­
opening values.
APSV (%) p-value AEDV (%) p-value ATAM (%) p-value
Mean SD Mean SD Mean SD
Day 1 - 35 18 <0.001 - 93 15 <0.001 - 68 13 <0.001
Day 2 - 34 16 <0.001 - 93 12 <0.001 - 68 14 <0.001
Day 3 - 38 14 <0.001 - 91 13 <0.001 - 69 15 <0.001
Day 5 - 23 23 <0.001 - 85 23 <0.001 - 61 15 <0.001
LowFlow -15 7 <0.001 - 76 21 <0.001 - 40 12 <0.001
Changes in PSV, EDV, and TAM after closure of the va-bridge compared to 
pre-opening values.
APSV (%) p-value AEDV (%) p-value ATAM (%) p-value
Mean SD Mean SD Mean SD
Day 1 2 25 0.41 - 6 16 0.04 2 22 0.69
Day 2 - 5 13 0.07 - 16 18 0.02 - 7 16 0.07
Day 3 - 9 11 0.03 - 18 16 <0.01 - 11 14 0.02
Day 5 - 4 10 0.22 - 10 12 <0.01 - 6 1 0.49
LowFlow - 7 15 0.10 - 9 10 0.01 - 9 13 0.02
Changes in percentages in peak systolic flow  velocity (APSV), end diastolic flow  velocity (AEDV) and 
time averaged mean flow  velocity (ATAM). SD = standard deviation.
PSV (Pearson correlation 0.43, p<0.001), EDV (Pearson corre lation 0.31, p= 0.009) and TAM (Pear­
son corre lation 0.55, p<0.001). A fte r d ichotom ization it became clear tha t fo r ECMO flow  rates 
>100 m l/m in /kg  the Pearson correlations were no t statistically s ignificant in PSV (Pearson correla­
tion  0.07, p=0.60) and TAM (Pearson corre lation -0.13, p=0.37). For ECMO flow  rates <100 m l/m in / 
kg the Pearson correlation was higher than for all com bined data and statistically significant for 
PSV (Pearson corre lation 0.59, p=0.004) and TAM (Pearson corre lation 0.59, p=0.009). A lthough 
the Pearson corre lation fo r EDV fo r ECMO flow  rates <100 m l/m in /kg  was higher than fo r ECMO 
flow  rates > 100 m l/m in /kg  (0.25 vs. -0.14) neither was statistically significant (p=0.31 and 0.34 
respectively). Figure 2 shows the decrease in TAM related to  the ECMO flow  rate.
A fte r closure o f the VA bridge there is an im m ediate recovery o f PSV, EDV and TAM. A few  seconds 
after closure, at the end o f our measurement, however, we still found some decrease in all three
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parameters compared to  pre-opening values. Especially changes in EDV still showed a statisti­
cally significant decrease compared to pre-opening values (Tab. 1.).
F igu re  2.
Decrease in TAM related to ECMO flow rate
100 i---------------------------------------------------------
10
0  -I--------------------------- 1--------------------------- 1--------------------------- 1--------------------------- 1--------------------------- 1---------------
0 50 100 150 200 250 300
ECMO flow rate (ml/min/kg)
Decrease in Time Averaged Mean flow  velocity (TAM) in relation to the flow  rate during veno-arterial 
extracorporeal membrane oxygenation (ECMO). The correlation curves are given for ECMO flow  rates 
<100 m l/m in /kg (Pearson correlation 0.59, p=0.009) and for ECMO flow  rates >100 m l/m in /kg (Pear­
son correlation -0.13, p=0.37).
Discussion
Cerebral Doppler-u ltrasound through the anterio r fon tanel as an acoustic w indow  has been used 
in d iffe rent clinical settings and treatm ents to  investigate fluctuations in CBFV (17,18). Our study 
is the first to  use this m ethod in human newborns on consecutive days o f VA-ECMO to describe 
the effects o f opening and closure o f the VA bridge, which is considered to  be controversial, as 
m entioned above. The pericallosal artery is a term inal branch o f the anterio r cerebral artery and 
frequently  used in (ECMO) literature to  describe changes in cerebral blood flow  patterns or ve­
loc ity  to  a part o f the brain (19,20). Changes in cerebral b lood flow  (CBF) in this vessel cannot be 
compensated by other arteries.
We found a very acute and relevant decrease in PSV, EDV and TAM after opening o f the va-bridge,
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which was statistically significant. A fte r closing the VA bridge again, there was an im m ediate re­
covery o f CBFV, although at the end o f our measurements CBFV parameters were not com plete ly 
normalized to pre-opening values.
In general, changes in CBFV are considered to be a con tribu ting  risk factor fo r cerebral hem or­
rhage and ischemia. Regarding a mean ECMO runtim e o f 152 hours in our study popu lation, in 
which the bridge is opened fou r tim es per hour, acute changes in CBFV occurred more than 
600 tim es during a com plete ECMO treatm ent. The earlier study o f our group by van Heijst et al 
(14) describes the underlying flow  changes in the ECMO circu it and changes in hemodynamics 
and cerebral oxygenation in lambs. When unclam ping the va-bridge, blood is shunting from  the 
arterial cannula towards the venous cannula over the bridge. This results in reversed flows on 
either side o f the VA bridge w ith  a consecutive decrease in mean arterial blood pressure and a 
rise in central venous pressure. As the diam eter o f the cerebral arteries cannot be determ ined by 
Doppler-u ltrasound we only measured the ve loc ity  o f the CBF. However, we assume tha t the de­
crease in cerebral oxygenation during the opening o f the VA bridge, earlier dem onstrated in the 
NIRS studies o f Liem and van Heijst, is caused by a decrease in cerebral b lood flow. This results in 
a significant and acute decrease in b lood supply to the brain as measured in arterial branches like 
the pericallosal artery, which is po tentia lly  harm ful to  brain tissue. This m ight be true fo r the fast 
recovery o f CBFV a fte r closure o f the VA bridge as well. Measuring CBFV by Doppler-u ltrasound 
and cerebral oxygenation by NIRS sim ultaneously m igh t have been o f con tribu ting  value. Due 
to  the fixed position o f the head during ECMO and lim ited space on the head it is d ifficu lt to 
com bine both techniques. Next to this the NIRS signal is influenced by movements o f the head 
possibly induced by perform ing Doppler ultrasound. Finally our g roup dem onstrated changes in 
cerebral hemodynamics and oxygenation during the perform ance o f cranial ultrasound itself, at 
least in preterm infants (21, subm itted). This makes the in te rpre ta tion  o f data d ifficu lt.
The study o f Inqyinn et al (12) referred to previously showed tha t cerebral perfusion disturbances 
in lambs are substantially less severe in veno-venous ECMO (VV-ECMO), bu t because the design 
and use o f the bridge was already adapted when we started VV ECMO in our center this was 
som ething we could no t analyze.
In normal, healthy subjects, cerebral au toregula tion (AR) maintains CBF over a w ide range of 
cerebral perfusion pressures (22). However, the changes in CBFV dem onstrated in this study are 
too  acute and too  huge to make AR possible. The autoregula tory contraregulation response after 
sudden blood pressure changes occurs w ith  a delay o f 2 seconds (23-25) and in this study CBF 
decreases beyond the normal au toregula tory range. Beside this it has been shown, tha t AR is 
d isturbed in severely ill term  infants (26) and also in newborn lambs placed on VA ECMO after 
pro longed hypoxia (27-29).
This is the firs t study describing a corre lation between the ECMO flow  rate and the m agnitude of 
changes in CBFV during opening o f the va-bridge. The statistically significant overall correlation 
between the changes in CBFV and the ECMO flow  rate found in our study is m ainly caused by 
flow  dependent fluctuations in CBFV at lower ECMO flows, up to 100 m l/m in /kg . A t lower ECMO
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flow  rate the arterio-venous shunt across the va-bridge m ight be less severe. In add ition , we 
suppose tha t at lower ECMO flow  the con tribu tion  o f the patient's own cardiac o u tp u t to  organ 
perfusion is relatively h igher thereby preventing the dram atic changes tha t occurred at higher 
flow  rates.
To avoid the repetitive acute changes in CBFV, we have made a construction by which regular 
unclam ping o f the VA bridge can be om itted . We use stopcocks on both sides, w h ile the bridge is 
filled w ith  normal saline. Flushing o f the bridge can be avoided, w h ile the benefit in emergency 
circumstances is retained. Based on our studies we seriously recommend this technique, which is 
becom ing more com m on, bu t is not generally used, in ECMO com m unity  (11).
We conclude tha t a lthough a d irect relationship between opening and closure o f the VA bridge 
and cerebral hemorrhage or ischemia has never been proven, it  seems to be reasonable to use 
the VA bridge in such a way to be able to om it regular unclam ping and prevent significant chang­
es in CBFV, a potentia l threat to the brain.
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Chapter 4
Volume adm inistration and bladderbox alarms and their relation to 
cerebral oxygenation and hemodynamic
4.1 Intravascular Volume Adm inistra tion: A Contributing Risk Factor fo r Intracranial Hemor­
rhage During Extracorporeal Membrane Oxygenation?
4.2 The effect o f bladderbox alarms during veno-arterial extracorporeal membrane oxygen­
ation on cerebral oxygenation and hem odynamics in lambs.
4.3 The effect o f intravascular volum e adm in istra tion on cerebral oxygenation and hem ody­
namics during veno-arterial extracorporeal m embrane oxygenation in human newborns.
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Abstract
O b je c tive . The objective o f this study was to  determ ine the relationship between the frequency 
and to ta l volum e o f intravascular volum e adm in istra tion and the developm ent o f intra cranial 
hem orrhage during veno-arterial extracorporeal membrane oxygenation.
P a tien ts  and M e tho ds . In a retrospective matched case-control study 24 newborns w ho devel­
oped an intracranial hemorrhage during veno-arterial extracorporeal m embrane oxygenation 
trea tm ent were compared w ith  40 contro l subjects. Both groups were analyzed for gestational 
age, gender, race, Apgar scores at 1 and 5 minutes, b irth  w e igh t, card iopulm onary resuscitation 
before veno-arterial extracorporeal m embrane oxygenation, age at the start o f treatm ent, dura­
tion  o f treatm ent, w orst arterial blood gas sample preceding treatm ent, activated c lo tting  tim e 
values, need o f p late let transfusions, mean blood pressure and the use o f inotrop ics and steroids 
before the treatm ent. For both groups, to ta l num ber and volum e o f intravascular infusions of 
normal saline, pasteurized plasma prote in solution, erythrocytes and platelets during the first 24 
hours o f trea tm ent were determ ined. Variables were analyzed in the ir relationship to  intracranial 
hem orrhage using univariate and m ultivariate conditional logistic regression.
Results.The only statistically significant difference in patien t characteristics between the case 
patients and contro l subjects was arterial blood gas values. Newborns w ho developed intracra­
nial hem orrhage during the trea tm ent received both a statistically s ignificantly higher num ber 
and a statistically higher to ta l volum e o f intravascular volum e adm inistrations compared w ith 
contro l patients. A fte r ad justm ent fo r pH, paCO2 and paO2 in the m ultivaria te analysis, we found 
a significant relation between the developm ent o f intracranial hem orrhage and >8 infusions or 
>300 mL o f volume infusion in the first 8 hours and >10 infusions in the first 24 hours o f treatment. 
C onc lus ion . The num ber and to ta l volum e o f intravacular volum e adm in istra tion in the firs t 8 
and 24 hours o f veno-arterial extracorporeal membrane trea tm ent are statistically significantly 
related to  the developm ent o f intracranial hemorrhage.
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Introduction
Since Bartle tt and colleagues in 1976 treated the firs t newborn successfully w ith  veno-arterial 
extracorporeal membrane oxygenation (va-ECMO)1, ECMO has become a rescue therapy for 
neonates w ith  severe, bu t po tentia lly  reversible, respiratory failure when maximal conventional 
therapy has failed. W ithou t ECMO, the m orta lity  rate is high.2,3 More than 22.000 neonates have 
been treated w ith  ECMO, 15.000 o f whom  were treated w ith  va-ECMO, w ith  an overall survival 
rate o f 80%.4 Although ECMO has increased survival, the occurrence o f hemorrhagic and ischemic 
cerebral lesions, resulting in fu ture  neurological and neurodevelopm ental dysfunction are 
major com plications.56 Imaging studies revealed intracranial hemorrhage (ICH) or ischemic ab­
norm alities in 10 up to  even 52% o f the patients.7-9 The cause o f ICH occurring during va-ECMO 
treatm ent is probably m ultifactoria l and m ight be determ ined by pre-ECMO- as well as ECMO- 
related events or conditions.10 O ptim izing neurological outcom e remains 1 o f the priorities in 
ECMO research. The popu lation at greatest risk for ICH is however no t clearly defined. Hardart 
et al1112 determ ined gestational age, postconceptional age, acidosis, sepsis, coagulopathy and 
trea tm ent w ith  epinephrine as independent factors associated w ith  ICH in neonates w ho were 
treated w ith  ECMO. A study o f Dela Cruz et al13 dem onstrated tha t an elevated activated clo tting  
tim e (ACT) and low  pla te le t counts requiring transfusion were statistically associated w ith  an 
increase in the developm ent o f ICH. H irth ler et al14 reviewed tha t ins tab ility  o f ACT and platelet 
count are early predictors o f ICH. Finally lactate before ECMO treatm ent was found to be a useful 
marker fo r the developm ent o f ICH during ECMO.15
Especially during the firs t days o f ECMO intravascular volum e adm in istra tion is regularly re­
quired. One reason is the occurrence o f b ladderbox alarms, as a sign o f inadequate venous dra in­
age from  the righ t atrium  to  m aintain the required flow  o f the ECMO system which is aimed fo r to 
realize adequate oxygenation o f the patient. In a reaction, volum e adm in istra tion is o ften given 
when other causes o f b ladderbox alarms are ruled out. Next to  this anemia or throm bocytopen ia 
are reasons to add volum e w ith  blood products. From our clinical experience we had the impres­
sion tha t neonates, who required frequent volum e adm in istra tion during the first days o f the 
va-ECMO treatm ent developed ICH more frequently.
The objective o f this study was to investigate w hether there is a relationship between in tra­
vascular volum e adm in istra tion and the occurrence o f ICH in the neonate, during trea tm ent w ith  
va-ECMO.
Methods
From September 1989 through November 2005, 236 newborns (64% boys, 36% girls) were treated 
w ith  va-ECMO at the Radboud University Nijmegen Medical Centre. Overall survival rate was 
77% and ICH occurred in 25 patients (11%). All patients w ith  ICH were analyzed to  partic ipate in 
a matched case-control study. One patien t was excluded because o f congenita l abnorm ality  of 
the heart, so 24 patients w ith  ICH were included in the study. ICH was diagnosed either by cere­
bral ultrasound, perform ed daily during the ECMO trea tm ent (n=18), by com puter tom ography
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(CT) or magnetic resonance imaging (MRI) in the period directly after decannulation (n=6). The 
24 newborns tha t developed an ICH related to va-ECMO treatm ent (case patients) were matched 
w ith  40 patients who did not develop ICH (control subjects). Each pair o f 1 case patient and 1 or 2 
control subjects was matched for diagnosis, gestational age (± 1 week) and birth w e ight (±500 g). 
For statistical reasons we aimed fo r 2 controls fo r each case patient. If >2 possible candidates were 
available, the patients whose dates of b irth  were closest to tha t o f the case patient were selected as 
control subjects. Newborns were excluded from  the study if there were congenital abnormalities 
other than congenital diaphragmatic hernia; a second ECMO treatm ent; ICH before the in itiation 
o f ECMO; or coagulation disorders as screened fo r by the determ ination of protrom bine tim e, acti­
vated partial throm boplastine tim e and platelet count. Cerebral ultrasound, none o f them showing 
ICH, was performed for all patients, case patients as well as control subjects, before the ECMO treat­
ment. Before the in itia tion o f ECMO inform ed consent from  the parents was obtained and all case 
patients and control subjects met institu tional criteria for ECMO treatm ent, which did not change 
during the study period. All patients were treated w ith  va-ECMO. The ECMO circuit itself consisted 
o f a custom packed %-in flexible polyvinylchloride tub ing (Baxter, Uden, The Netherlands), w ith  a 
silicone reservoir, the bladderbox (Seabrook Medical System, V^rlose, Denmark), a 0.6 m2 m em ­
brane oxygenator (Scimed Life Systems, Minneapolis, MN, USA), a heat exchanger (Cincinnati Sub 
Zero, Cincinnati, OH, USA) and a rollerpum p (Polystan A/S, Copenhagen, Denmark).
A loading dose o f heparin was given before cannulation to  achieve an activated c lo tting  tim e 
(ACT) o f >300 seconds. A fte r this heparinization was checked every hour by measurement o f the 
ACT aim ing fo r values between 200 and 220 seconds (Hemochron). During the course o f ECMO 
plate le t transfusions were given to maintain a p late let count > 80.000/m m 3. Erythrocyte transfu­
sions were given to m aintain a hem oglobin level > 8.0 m m ol/l and a hem atocrit value > 0.40 l/l. 
H em oglobin level and pla te le t count were determ ined every 4 hours. Normal saline (NaCl 0.9%) 
and pasteurized plasma prote in solution (albumin 3,8%) were used to restore the ECMO flow  
after bladderbox alarms caused by insuffic ient b lood drainage from  the righ t atrium.
Cerebral ultrasound im aging through the anterio r fontanel (Philips HDI-3000, Ultrasound, Inc 
Bothell, WA, USA) was perform ed daily to  check fo r ICH. Images were in terpre ted by the neo- 
na to log ist and the pediatric neurologist. A fte r decannulation, CT or MRI was perform ed on all 
patients and analyzed by the neuroradiologists.
To check the matching procedure and possible differences between the case patients and the 
contro l subjects, both groups were analyzed fo r gestational age, gender, race, Apgar scores at 1 
and 5 minutes, b irth  w e ight, card iopulm onary resuscitation (CPR) before ECMO, age at the start 
o f ECMO, duration o f ECMO treatm ent, survival, w orst arterial blood gas sample in the six hours 
preceding ECMO, num ber and volum e o f required th rom bocyte  transfusions, ACT value a fte r the 
loading dose at the start o f ECMO, mean o f ACT and mean blood pressure values as well as the 
coeffic ient o f variation for ACT and mean blood pressure during the first 8 and 24 hours o f ECMO 
and the use o f inotrop ics (dopamine, dobutam ine, epinephrine, nor-epinephrine) and steroids 
before the start o f ECMO.
Veno-Arterial Extracorporeal Membrane Oxygenation in Relation to the Brain | 75
To investigate the relationship between intravascular volum e adm in istra tion and the occurrence 
o f ICH we analyzed the num ber and volum e o f intravascular infusions o f normal saline, pasteur­
ized plasma prote in solution, erythrocytes and platelets during the first 8 and 24 hours o f ECMO 
treatm ent. Data were collected from  the in ternational Extracorporeal Life Support Organization 
(ELSO) forms, patien t files and patien t medical checklists in which physiological parameters, 
laboratory results and ACT values were w ritten  down every hour and all volum e adm inistrations 
are registered.
Statistical analysis was perform ed by using SPSS 13.0 (SPSS Inc., Chicago, USA). Patient character­
istics were analyzed by Student's t tests for comparison o f means (P < .05) and x2 tests (P < .05) 
fo r dichotom ized characteristics. Univariate and m ultivariate testing o f variables in the ir relation 
to  ICH was perform ed by use o f conditional logistic regression. For several variables, the cuto ff 
points fo r which dichotom ization o f the variable leads to a statistically significant odds ratio (OR) 
at univariate analysis were determ ined by stepwise changing the segregation value fo r d icho to ­
m ization. Steps were 0.1 fo r pH, 5 mmHg fo r paCO2 and paO2, 100 mL fo r the volum e o f infusions 
and 1 for the num ber o f infusions. Variables tha t were found to  have a significant relationship 
w ith  the developm ent o f ICH in the univariate analysis were fu rthe r used in the m ultivaria te con­
d itional logistic regression. ORs and 95% confidence intervals (CIs) were determ ined. Because 
CPR, gestational age and age at the start o f ECMO are generally considered to  be im portan t in 
the ir relation to ICH, we perform ed an univariate as well as a m ultivaria te analysis fo r these terms. 
In the latter, the outcom e for volum e adm in istra tion was corrected fo r each separate parameter, 
CPR, gestational age and age at the start o f ECMO.
Results
All 24 newborns tha t developed an ICH during va-ECMO trea tm ent could be matched w ith  one 
or tw o  contro l patients w ith  the same prim ary diagnosis. Primary diagnoses fo r the case pa­
tien ts in this study were as follows: congenita l d iaphragm atic hernia in 8 (33%), sepsis in 8 (33%), 
m econium  aspiration syndrom e in 5 (21%) and prim ary pu lm onary hypertension in 3 (13%). The 
o ther m atching parameters used (gestational age and b irth  weight) were no t sign ificantly d if­
feren t between the case patients and contro l subjects (Table 1). Maxim um  tim e span between 
a case pa tien t and its contro l subject was 8 months. In this study we found the fo llow ing  types 
o f ICH: parenchymal 10 (42%), in traven tricu la r 9 (38%), subependym al 3 (13%) petecchial 1 (4%) 
and 1 ICH in the posterio r fossa (4%). Of these 24 cases o f ICH, 18 were diagnosed by cerebral 
u ltrasound during va-ECMO and 6 were diagnosed by e ither CT or MRI a fte r decannulation. Of 
the 18 cases o f ICH on cerebral ultrasound 8 (44%) were dem onstrated w ith in  24 hours a fte r the 
start o f va-ECMO and 14 (78%) w ith in  72 hours. Also fo r o ther than the m atching variables we 
found no statistica lly sign ificant differences in pa tien t characteristics, except fo r pH and sur­
vival (Table 1). Next to  these characteristics we found no sign ificant differences in ACT values, 
p la te le t requirem ent, b lood pressures and the use o f ino trop ics and steroids nor in race o f the 
patients.
76 | Chapter 4
Table 1. Patient Characteristics o f Newborns W ith ICH (Case Patients) and Newborns W ithou t ICH 
(Control subjects) During ECMO Treatment




Mean SD Mean SD P
birthw eight (kg) 3.3 0.5 3.3 0.5 .79
gestational age (wks) 38 3 39 2 .64
age at start o f ECMO (hours) 35 30 53 64 .20
duration o f ECMO (hours) 155 76 171 81 .43
median Apgar at 1 minute 6.0 2.6 6.1 2.5 .94
median Apgar at 5 minutes 7.0 2.0 7.1 2.1 .82
pH 7.23 0.15 7.33 0.15 .01
paCO2 (mmHg) 45.8 13.9 42.7 16.7 .46
paO2 (mmHg) 48.1 29.6 53.7 19.1 .36
gender (male/female) 17/7 28/12 .93
CPR before ECMO 3/24 3/40 .51
Survival 11/24 32/40 <.01
Number platelet T24 2.1 1.2 1.6 1.2 .64
Volume platelet T24(ml) 85 48 67 48 .18
loading ACT 399 136 397 1 61 .96
ACT first 8 hours 276 35 266 54 .42
ACT first 24 hours 258 34 246 34 .19
CoV ACT first 8 hours 0.17 0.09 0.15 0.09 .41
CoV ACT first 24 hours 0.15 0.07 0.15 0.10 .75
mean MAP first 8 hours 53 10 56 7 .24
Mean MAP first 24 hours 52 8 53 7 .63
CoV MAP first 8 hours 0.13 0.06 0.14 0.06 .60
CoV MAP first 24 hours 0.13 0.07 0.15 0.06 .42
Use of steroids 3/24 5/40 .82
Use of inotropic 21/24 8/40 .31
Number and volume plate let T24= number and to ta l volumes (mL) o f p late let transfusions to keep 
plate let counts a t > 80.000/mm3 in first 24 hours o f  ECMO. Inotropics used were dopamine, dobuta­
mine, epinephrine and norepinephrine. CV indicates coefficient o f  variation; MAP, mean arterial blood 
pressure
At d ichotom ization, we found the fo llow ing  statistically significant values in the univariate con­
d itional logistic regression fo r the w orst arterial blood gas samples in the 6 hours preceding the 
ECMO treatm ent in relation to the developm ent o f ICH: pH < 7.3, paCO2 > 45 mm Hg and paO2 <
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50 mm Hg (Table 2). These parameters were fu rthe r used in the m ultivaria te conditiona l logistic 
regression.
Table 2. ORs and CIs fo r the Relation Between pH, paCO2, paO2, and the Number and Total Vol­
ume o f Intravascular Infusion in the First 8 and 24 Hours o f ECMO Treatment and the Develop­
m ent o f ICH.
Univariate analysis Multivariate analysis
OR (95% CI) OR (95% CI) P
pH < 7.3 worst arterial gas 4.5 (1.4-14.0)
paCO2 > 45 mmHg worst arterial gas 3.3 (1.0-10.9)
paO2 < 50 mmHg worst arterial gas 5.3 (1.5-19.0)
Every 100 ml o f volume first 8 hours 1.5 (1.1-2.2) 1,6 (1.0-2.6) .06
>300 ml first 8 hours 6.3 (1 .4-29.1 ) 10.0 (1.9-83.5) .03
Every single infusion first 8 hours 1.2 (1.0-1.5) 1.3 (1.0-1 .6) .04
>8 infusions first 8 hours 13.6 (1.7-106.3) 26.0 (1.6-430.2) .02
Every 100 ml o f volume first 24 hours 1.4 (1.1-1.8) 1.6 (1.0-2.4) .04
>400 ml first 24 hours 5.7 (1.3-25.6) 6.4 (0.5-77.1) NS
Every single infusion first 24 hours 1.1 (1.0-1.3) 1.2 (1.0-1 .4) .04
>10 infusions first 24 hours 3.6 (1.1-11.2) 8.5 (1.2-59.2) .03
Results are given for the univariate analysis and the multivariate analysis (adjustment for pH, paCO2 
and paO2 mentioned) for the first 8 and 24 hours o f the treatment w ith va-ECMO. NS indicates not 
statistically significant.
Single infusions o f intravascular volum e adm in istra tion ranged from  20 to  50 mL. In Fig 1, it  is 
shown tha t the newborns, w ho developed ICH during the trea tm ent w ith  va-ECMO had received 
both a statistically s ignificantly higher num ber as well as a statistically s ignificantly h igher total 
volum e o f intravascular volum e adm inistrations during the first 8 and 24 hours o f the treatm ent 
w ith  va-ECMO, compared to the matched contro l patients. Statistically, there was a significant in ­
crease in the risk o f ICH fo r every single extra infusion in the firs t 8 and 24 hours o f trea tm ent w ith  
va-ECMO. This was also true fo r every 100 ml o f extra volum e adm in istra tion in the firs t 8 and 24 
hours (Table 2). A fte r d ichotom ization and ad justm ent for pH, paCO2 and paO2 in the m ultivariate 
conditiona l regression we found the fo llow ing  conditions to be significantly related to the devel­
opm ent o f ICH during the va-ECMO treatm ent; >8 infusions or >300 mL o f intravascular infusion 
in the firs t 8 hours o f va-ECMO and >10 infusions in the firs t 24 hours o f va-ECMO. An overview  of 
ORs and 95% CIs for the univariate and m ultivaria te analysis is shown in tab le 2.
In the univariate analysis CPR, gestational age and age at the start o f ECMO did no t seem to  be
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significant risk factors fo r the development of ICH. ORs and CIs were 2.0 (0.4 -  9.0), 0.4 (0.1 -  1.4) and 
1.0 (0.9 -  1.0) respectively. When these terms were used in a straight multivariate conditional regres­
sion, data found for volume administration, as shown in Table 2, were still statistically significant.
F igu re  1.
To ta l n u m b e r and v o lu m e  o f  in tra va scu la r v o lu m e  su p p le tio n s  in  th e  f irs t  8 and 24 Hours 
b e tw ee n  p a tie n ts  w ith  and w ith o u t  ICH d u r in g  th e  t re a tm e n t w ith  ECMO
H ICH (n=24)









first 8 hrs of ECMO first 24 hrs of ECMO first 8 hrs of ECMO first 24 hrs of ECMO
TT
ICH = intracranial hemorrhage, ECMO = veno-arterial extracorporeal membrane oxygenation. 
#, p=0.03; t, p=0.005; t ,  p=0.04
Discussion
Because ICH is one o f the m ost devastating com plications o f ECMO, it is o f ongo ing im portance 
to  fu rth e r id en tify  those patients m ost at risk and elim inate risk factors as much as possible. 
This matched case-control study is the first to  describe a statistica lly s ignificant relationship 
between the to ta l num ber and volum e o f intravascular volum e adm in istra tions and the de­
ve lopm ent o f ICH during the trea tm ent w ith  va-ECMO. We found tha t neonates, receiving >8 
infusions or >300 ml o f volum e infusion during the firs t 8 hours or >10 infusions during the first 
24 hours o f va-ECMO were statistica lly sign ificant more at risk to  develop an ICH. We stress, tha t 
this re lationship does no t have to  be necessarily causal. A hypothetica l exp lanation, however, 
m igh t be found in disturbances o f cerebral hem odynam ics caused by the infusions o f in tra ­
vascular volum e adm in is tra tion and/or the often preceding bladderbox alarms w ith  consecu­
tive acute in te rrup tion  o f the ro lle rpum p resulting in in te rrup tion  o f blood flow  to the patient. 
In norm al, healthy situations cerebral au toregu la tion  m aintains the cerebral b lood flow  over a 
w ide range o f cerebral perfusions pressures w ith  a contraregula tion response occurring w ith  a 
delay o f 2 seconds a fte r sudden changes in b lood pressure. It has been shown, however, tha t au­
to regu la tion  is d isturbed in severely ill term  infants.16-19 A dd itiona lly  studies o f newborn lambs 
showed tha t pro longed hypoxia and/or the ECMO trea tm ent itse lf w ill s ign ificantly d is tu rb  the
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autoregulation20-23; therefore, frequent in terruption of the roller pump, followed by infusion of 
intravascular volume adm inistration may result in frequent fluctuations in cerebral blood flow, a 
known risk factor for ICH. Besides this, possible disturbances in cerebral blood flow  at bladderbox 
alarms m ight be to acute to be compensated for by the autoregulation system, even if not dis­
turbed. The com bination o f most bladderbox alarms and intravascular volume infusion in the first 
24 hours and disturbed autoregulation may be a part o f the explanation o f why most ICHs occur in 
the first few days of the ECMO treatm ent; however, another explanation of the relationship found 
in this study m ight be tha t the pathological process which leads to ICH also causes the inadequate 
venous drainage to the ECMO circuit, which in turn leads to the need for volume administration. 
Birth w e igh t and gestational age were no t s ign ificantly  d iffe rent between the ICH group and the 
group w ith o u t ICH, which suggests tha t the m atching procedure was successfully perform ed. 
The s ignificant re lationship between pH, paCO2 and paO2 and ICH found in this study confirms 
the find ings o f previous studies.121315 C onfirm ation o f acidosis using lactate as o ther variable was 
no t possible, as this was no t always rou tine ly  determ ined.
In con trad iction  to the study o f Dela Cruz e t al,13 ACT levels, analyzed fo r the firs t 8 and 24 hours 
between case patients and contro l subjects, were no t sign ificantly d ifferent. Instab ility  o f ACT 
during the ECMO trea tm ent was described by H irth le r et al,14 bu t no t fu rthe r confirm ed in this 
study, ne ither by the mean ACT nor by the coeffic ient o f variation o f the ACT. Because the exact 
tim e o f ICH occurrence is no t known, in s ta b ility  o f ACT could be a risk factor as well as a conse­
quence o f the ICH. This could also be the question fo r possible differences in p la te le t counts. 
In all our patients, case patients and contro l subjects, p la te le t counts were kept s tric tly  above 
80.000/m m 3. P latelet requirem ent was s ligh tly  h igher in the group o f patients developing an 
ICH, which seems to  f it  w ith  the previous studies described. In our study this was however not 
sta tistica lly significant. We did no t find a sta tistica lly s ignificant difference in the use o f ep ineph­
rine as was found in the study o f Hardart et al,12 or in the use o f o ther ino trop ic  m edication or 
steroids before the ECMO trea tm ent used to trea t hypotension.
A lthough any con founding factor is no t com ple te ly excluded, we th in k  tha t th is matched case- 
contro l study shows an im p o rtan t re lationship between intravascular volum e adm in istra tion 
and the developm ent o f ICH. The results o f this study can be translated to clinical practice. Any 
newborn treated w ith  va-ECMO and requires high am ounts or num ber o f intravascular volum e 
adm in is tra tion should a lert the ECMO team. Because o f the increased chance o f ICH more fre ­
quen t neuro log ic assessment and cerebral ultrasounds are recom m ended to  de tect any ICH in 
an early stage and if possible avoid extension o f the hemorrhage.
A dd itiona l prospective studies, as currently  in itia ted in our ECMO center, are required to ana­
lyze the mechanisms by which volum e adm in istra tion and/or the often preceding bladderbox 
alarms are related to  the developm ent o f ICH. Knowledge o f these mechanisms may be useful 
fo r the deve lopm ent o f strategies to reduce the risk o f ICH during the va-ECMO treatm ent, such 
as how to  react on b ladderbox alarms and w hethe r it m igh t be indicated to be cautious w ith 
intravascular volum e adm in istra tion.
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Conclusion
To our knowledge, this is the firs t study to show a statistically significant relationship between 
the to ta l am ount and num ber o f intravascular volum e adm in istra tion and the developm ent of 
ICH during va-ECMO treatm ent. Add itional studies are needed to investigate the pathophysi­
ological mechanisms o f this relationship.
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Abstract
To determ ine the effects o f bladderbox alarms during veno-arterial extracorporeal membrane 
oxygenation (va-ECMO) on cerebral oxygenation and hemodynamics, six lambs were prospec­
tive ly  treated w ith  va-ECMO and bladderbox alarms were simulated. Changes in concentrations 
o f oxyhem oglobin (AcO2Hb), deoxyhem oglobin (AcHHb) and to ta l Hb (ActHb) were measured 
using near infrared spectrophotom etry. Fluctuations in hem oglob in oxygenation index (AHbD) 
and cerebral blood volum e (ACBV) were calculated. Heart rate (HR), mean arterial pressure (MAP), 
b lood flow  in the le ft carotid artery (Qcar) and central venous pressure (CVP) were registered. 
B ladderbox alarms were simulated by increasing the ECMO flow  or partia lly clam ping the venous 
cannula and resolved by decreasing the ECMO flow, unclam ping the cannula or intravascular vo l­
ume adm in istra tion. CBV, HbD, MAP and Qcar decreased significantly during bladderbox alarms, 
whereas HR and CVP increased. A fte r the b ladderbox alarms, CBV and HbD increased sign ifi­
cantly to values above baseline. For HbD this increase was higher during intravascular volume 
adm in istra tion. MAP, Qcar and CVP recovered to  preexperim ent values, bu t increased fu rther 
w ith  volum e adm in istra tion. HR was increased at the end o f our measurements. We conclude 
tha t bladderbox alarms during va-ECMO trea tm ent result in significant fluctuations in cerebral 
oxygenation and hemodynamics, a possible risk factor fo r intracranial lesions.
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Introduction
Extracorporeal membrane oxygenation (ECMO) has become a rescue therapy fo r neonates w ith  
severe, bu t po tentia lly  reversible, respiratory failure when maximal conventional therapy has 
failed. W ithou t ECMO there is a high m orta lity  rate (1,2). Since the firs t newborn was successfully 
treated w ith  veno-arterial extracorporeal m embrane oxygenation (va-ECMO) by Bartle tt et al. 
in 1976 (3), over 22,000 neonates have been treated w ith  ECMO, o f which 15,000 w ith  va-ECMO, 
w ith  an overall survival rate o f 80% (4). A lthough ECMO has increased survival, the occurrence 
o f hem orrhagic and ischemic cerebral lesions resulting in fu ture neuro log ic and neurodevelop­
mental dysfunction are o f major concern (5,6). Imaging studies revealed hem orrhagic or isch­
emic intracranial abnorm alities in 10 up to even 52% o f the patients (7-9). These complications 
ju s tify  a continuous search for factors related to  intracranial hem orrhage and ischemia and treat­
m ent strategies aimed to im prove outcome.
Part o f the va-ECMO system is a bladderbox, which is situated between the venous cannula and 
the ro llerpum p o f the extracorporeal system. The bladderbox controls venous drainage o f blood 
from  the righ t atrium  o f the patient. If the venous drainage becomes inadequate to  m aintain the 
established flow  o f the ECMO system, the bladderbox w ill give an alarm, slow down the pump, 
and fina lly cause an acute in te rrup tion  o f the ro llerpum p resulting in in te rrup tion  o f blood flow  
to  the patient. If other causes o f inadequate venous drainage from  the righ t atrium  and consecu­
tive bladderbox alarms, like d isturbed position o f the cannula, are ruled out, intravascular volume 
adm in istra tion is often given to restore the circulation th rough the ECMO system and the patient. 
Recently, our g roup firs t showed a statistically significant relation between the to ta l num ber and 
volum e o f intravascular volum e adm in istra tion and the occurrence o f intracranial hemorrhage 
(ICH) during va-ECMO treatm ent (10). We hypothesize tha t this relation may be explained by 
fluctuations in cerebral oxygenation and hem odynamics caused by e ither the bladderbox alarms 
w ith  a consecutive in te rrup tion  o f the ECMO blood flow  to the patien t or by intravascular volume 
adm in istra tion itself. Both m igh t be a con tribu ting  risk factor fo r intracranial hem orrhage and 
ischemia. The aim o f this study is to  describe possible fluctuations in cerebral oxygenation and 
hemodynamics, as measured by near infrared spectrophotom etry (NIRS), caused by simulated 
bladderbox alarms during va-ECMO in lambs.
Methods
Study population and ECMO
In a prospective in terventiona l setting, six healthy lambs were studied fo r changes in cerebral 
oxygenation and hemodynamics caused by bladderbox alarms during va-ECMO. The Lambs 
were obtained from  local farmers, and the Ethical Com m ittee on Animal Research o f the Rad­
boud University o f N ijmegen approved the study. The care and handling o f the animals were in 
accordance w ith  the guidelines issued by the National Institutes o f Health. Experimental settings 
were mainly based on earlier research in our group (11). General anesthesia was induced by in tra ­
venous adm in istra tion o f m idazolam 0.2 mg.kg-1, ketamine 15 mg.kg-1, atrop ine 0.01 m g.kg-1 and
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pentobarb ita l 20 m g.kg-1. Muscle relaxation was obtained w ith  0.02 m g.kg-1 pancuronium . A fter 
endotracheal in tuba tion , mechanical ven tila tion was started using a Babylog 8000 (Dräger, Lü­
beck, Germany) to m aintain normal b lood gas values (pH 7.30-7.40; paO2 10-15 kPa; paCO2 4.5-5.5 
kPa). During mechanical ventila tion, anesthesia was m aintained by infusion o f midazolam (0.2 
m g.kg-1.h-1), ketamine (10 mg.kg-1.h-1), sufentanyl (20 mg.kg-1.h-1) and pancuronium  (0.02 m g.kg- 
1.h-1). Heart rate (HR) was m onitored by needle electrodes on the chest wall. Central tem perature 
was measured w ith  a rectal probe and m aintained between 38.5 and 39.5 oC. A catheter was 
placed in the aorta th rough the righ t femoral artery fo r continuous measurement o f mean ar­
terial blood pressure (MAP). The righ t femoral vein was used to place a 7.5-Fr catheter in to  the 
in fe rio r caval vein to create a venous access fo r m edication and measurement o f central venous 
pressure (CVP). Both MAP and CVP were represented on one m on ito r (HP 68S, Hew le tt Packard, 
Boeblingen, Germany). Blood flow  in the le ft com m on carotid artery (Qcar) was measured using 
an ultrasonic flow m eter (Transonic Systems Inc, NY, USA). Finally arterial oxygen saturation (Sao2) 
and end-tidal CO2 were continuously registered.
Before veno-arterial cannulation, the ECMO circuit was primed w ith  full fresh sheep blood. The 
right common carotid artery was cannulated w ith  an arterial catheter (8-12 Fr) and the righ t inter­
nal jugu lar vein w ith  a venous catheter 10-12 Fr (both Biomedicus, Medtronics Bio-Medicus, Eden 
Prairie, MN). Thereafter, va-ECMO was initiated. During the cannulation procedure a loading dose 
o f heparin was administered (150 IU.kg-1) followed by continuous i.v. infusion o f heparin (100-200 
IU.kg-1. h-1) to maintain the activated clo tting  tim e between 200 and 250 s (Hemochron, Edison, NJ). 
The ECMO circu it itse lf consisted o f a custom packed %-inch flexib le po lyv iny lch loride tub ing 
(Baxter, Uden, The Netherlands), w ith  a silicone reservoir, the bladderbox (Seabrook Medical Sys­
tems, Inc, Cincinnati, OH), a ho llow  fibe r membrane oxygenator w ith  integrated heat-exchanger 
(Medos Hilite 2400LT, Medos, Stolberg Germany), and a ro llerpum p (Jostra RPM 20-320, Lung, 
Sweden). An ultrasonic flow  meter (Transonic Systems, Ithaca, NY) was placed on the venous site 
o f the ECMO-system continuously measuring actual flow  in the circuit. Aimed flow  rate o f the 
ECMO pum p was 100-150 m l.kg-1.m in-1.
Near infrared spectrophotometry (NIRS)
Cerebral Oxygenation and hem odynamics were studied w ith  NIRS. The NIRS equ ipm ent (OXY- 
MON") used was developed by the instrum enta tion departm ent and the departm ent o f physiol­
ogy o f the Radboud University N ijmegen Medical Centre, The Netherlands (12). The technique 
is based on the spectrophotom etric  measurement o f changes in the absorption properties of 
Hb in the near infrared region, depending on its oxygenation state, firs t described by Jöbsis in 
1977 (13). The NIRS procedure used in our ECMO center has been described to  more extend in 
earlier studies o f our research group (14,15). From an optode, placed fronta l in the m id line o f the 
skull, three wavelengths o f near infrared ligh t (905, 850 and 767 nm) were transm itted through 
the head and received by tw o  o ther optodes placed both on the le ft and righ t parietotem poral 
region o f the skull, to  evaluate the oxygenation and hem odynamics in each hemisphere sepa­
Veno-Arterial Extracorporeal Membrane Oxygenation in Relation to the Brain | 89
rately. Concentration changes o f oxyhem oglobin (AcO2Hb) and deoxyhem oglobin (AcHHb) were 
calculated from  changes in ligh t absorption using the m odified Lambert-Beer law. We used the 
Keele absorption m atrix and a constant path length m u ltip lie r factor o f 4.27 times the distance 
between both optodes (16-18). Using a value o f 1.05 g.mL-1 for brain specific mass, concentration 
changes are expressed in |jmol.100.g-1 (19). AcO2Hb and AcHHb reflect changes in cerebral oxygen 
supply, if oxygen consum ption remains constant. Differences between AcO2Hb and AcHHb were 
calculated and indicated as changes in the hem oglob in oxygenation index (AHbD, where AHbD 
= AcO2Hb - AcHHb in |jmol.100.g-1). Concentration changes in to ta l hem oglob in (ActHb) were cal­
culated as the sum o f AcO2Hb and AcHHb (ActHb = AcO2Hb + AcHHb). AHbD represents changes 
in cerebral b lood flow  (20), whereas ActHb reflects changes in cerebral blood volum e (ACBV), 
which are calculated from  the form ula: DCBV = 4 x ActHb/0.69 x cHb, expressed in mL.100.g-1. In 
this form ula cHb is the hem oglob in concentration in circulating b lood (mmol/L), 0.69 is the ce­
rebral-arterial hem atocrit ratio and 4 is a correction factor. Also because ctHb is calculated from 
changes in ligh t absorption using an extinction  coeffic ient based on the tetrahaem e molecule, 
whereas cHb determ ination is based on the m onohaem e m olecule (21).
Experimental procedures
Afte r the in itia tion  o f va-ECMO, we waited for a stable NIRS signal. Once this was established 
bladderbox alarms were simulated. During the first experim ent (experim ent A) the ECMO flow  
rate o f the ro llerpum p was increased stepwise w ith  10 mL.kg-1.m in-1 until b ladderbox alarms oc­
curred. A fte r 10 s, the ECMO flow  rate was decreased to the preexperim ent value and bladderbox 
alarms were thereby resolved. Experiment A was repeated three tim es in each lamb w ith  a m in i­
mal tim e-in terva l o f 2 min to  obtain a stable NIRS signal before each experim ent fo r at least 30 s. 
During the second experim ent (experim ent B), the venous cannula o f the ECMO circu it was par­
tia lly  occluded by a nonocclusive clamp tha t was developed fo r this experim ent. Bladderbox 
alarms occurred as result o f insuffic ient venous drainage and a fte r 10 s, the clamp was removed 
to  restore the preexperim ent ECMO flow  and resolve the bladderbox alarms. Again experim ent B 
was repeated three tim es in each lamb w ith  a m inimal tim e interval o f 2 min.
During the th ird  experim ent (experim ent C) bladderbox alarms were simulated sim ilar to  experi­
m ent A. However, a fter 10 s, bladderbox alarms were resolved by starting intravascular volume 
adm in istra tion w ith  50 mL o f normal saline. To avoid an overload o f intravascular volum e adm in­
istration, experim ent C was repeated tw o  times in each lamb, w ith  a tim e interval long enough 
to  obtain at least a 30 second stable NIRS signal.
Arterial blood samples were obtained before and after each experim ent to check for changes in 
pH, paO2, paCO2 and cHb values.
Data analysis
All physio logic parameters were registered by a data acquisition system (Poly®, Inspector Re­
search System, Amsterdam, The Netherlands) w ith  a sampling frequency o f 1 Hz and synchro­
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nized w ith  the NIRS data. Baseline values (mean ± SD) o f cO2Hb, cHHb, ctHb and physiological pa­
rameters were determ ined during a 15-s period during the stable NIRS signal before (t = 0) each 
single experim ent (A,B and C). Maximal changes in cO2Hb, cHHb, ctHb and physiological param­
eters were searched by a com puter analysis during (t = 1) and after resolving (t = 2) the bladder­
box alarms as mean values during a 3-s period. Because o f the continuous registration, related 
changes in physiological data could be described during changes o f the NIRS signals. Changes 
in HbD and CBV were calculated by using the formulas m entioned earlier. All changes were de­
scribed separately fo r the le ft and righ t hemisphere o f the brain. Therefore AHbD is expressed as 
AHbDright and AHbDleft, w h ile ACBV is expressed as ACBVright and ACBVleft. Statistical analysis was 
perform ed fo r maximal changes at t = 1 and t = 2 compared w ith  the baseline values by using 
W ilcoxon signed ranks tests and p  values < 0.05 were considered to  be statistically significant.
Results
All the three experiments A, B and C were successfully perform ed in six lambs, w e igh t (mean ± 
SD) 5.2 ± 1.1 kg. The flow  rate o f the ECMO pum p aimed fo r (100-150 m l.kg-1.m in-1.) was reached in
5 lambs. In one lamb maximal flow  rate o f the ECMO pum p was 90 m l.kg-1.m in-1. As measured by 
arterial b lood gas samples, all lambs had blood gas values w ith in  the normal range before and 
after each experim ent. For each experim ent, cHb could be determ ined and used for calculations 
o f ACBV. An overview o f mean changes in im portan t physiological parameters, HbD and CBV is 
given in Table 1, w h ile Figure 1 shows the typica l pattern o f cO2Hb, cHHb, HbD and CBV during 
and after bladderbox alarms in one lamb.
Baseline HbD and CBV values, calculated during a 15-s period showed a baseline variab ility  w ith 
a mean SD o f 0.03 ± 0.01 |jm ol.100g-1 and 0.02 ± 0.01 mL.100g-1 respectively. Significant changes 
in Sao2 and end-tidal CO2 were no t observed.
B ladderbox alarms caused a significant and acute decrease in O2Hb and increase in HHb. A fter 
the acute decrease, there was a s light increase in O2Hb during the period o f b ladderbox alarms, 
fo llow ed by an acute increase to  values above baseline values when bladderbox alarms were 
resolved. A fte r the acute increase, HHb did show a fu rthe r very slight increase during the period 
o f b ladderbox alarms as well, fo llow ed by a more acute decrease to  values lower than baseline 
values after the b ladderbox alarms were resolved.
Bladderbox alarms caused a significant and acute decrease in HbD, CBV, MAP and Qcar. There was a 
significant increase in CVP. During the 10 s course o f bladderbox alarms HR increased as did HbD, CBV, 
MAP and Qcar; however, just before resolving the bladderbox alarms, values were still lower than pre­
experiment baseline values. Patterns for all parameters were not different between those bladderbox 
alarms simulated by increasing the ECMO flow  rate and those simulated by partially clamping of the 
venous cannula. We did not find any significant difference between AHbDright and AHbDleft or between 
ACBVright and ACBVleft . The decrease in HbD, when simulating bladderbox alarms, ranged from -0.05 to 
-0.45 |jmol.100g-1, while the decrease in CBV ranged from 0 to -0.20 mL.100.g-1.
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Table 1. Changes in hem oglob in oxygenation index (HbD), cerebral blood volum e (CBV), mean 
arterial pressure (MAP), b lood flow  in the le ft carotid artery (Qcar), heart rate (HR) and central 





(t = 1) Change
After recovery 
(t = 2) Change
A HbDright (|jmol.100g-1) NA -0.20±0.10* 0.11±0.12#
HbDleft (|jmol.100g-1) NA -0.20t0.10* 0.10±0.11#
CBVright (ml.100g-1) NA -0.11t0.05* 0.13±0.11*
CBVleft (ml.100g-1) NA -0.11t0.05* 0.12±0.08*
MAP (mmHg) 65±11 -9.8±5.8* -0.4±1.2
Qcar (mL/min) 119±63 -19.2±13.6* 0.7t3.9
HR (beats.min-1) 147±36 5 t4 * 7 t6 *
CVP (mmHg) 5.2t2.7 0.7t0.9# -0.3t0.5
B HbDright (|jmol.100g-1) NA -0.17t0.05* 0.14±0.07*
HbDleft (|jmol.100g-1) NA -0.13t0.05* 0.11±0.05*
CBVright (ml.100g-1) NA -0.11t0.05* 0.10±0.05*
CBVleft (ml.100g-1) NA -0.09t0.04* 0.08t0.06*
MAP (mmHg) 62±10 -9.3±1.7* 0.2±1.6
Qcar (mL/min) 102±58 -12.1±9.0* 1.7±3.7
HR (beats.min-1) 158±42 3 t3 # 4 t3 *
CVP (mmHg) 5.8t2.9 0.9t0.6# -0.6t0 .4#
C HbDright (|jmol.100g-1) NA -0.21t0.11* 0.33±0.17*
HbDleft (|jmol.100g-1) NA -0.21t0.15* 0.33t0.24*
MAP (mmHg) 67±15 -8.3t3.5# 13.6±5.5#
Qcar (mL/min) 102±48 -11.2±8.5# 34.5±23.2#
HR (beats.min-1) 155±35 3±4+ 3 t3 +
CVP (mmHg) 6.5t3.8 0.6t0.5+ 2.6t0.8#
Values are expressed as mean ± SD. In Exp A and C, bladderbox alarms are simulated by increase o f the 
ECMO flow  rate. In Exp B, bladderbox alarms are simulated by pa rtia lly  clamping the venous cannula.. 
A ll changes are compared to baseline values.
* p < 0.001.
#p < 0.01. 
f p < 0.05.
NA = no t available.
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F igu re  1. Typical pattern o f changes in cerebral oxyhem oglobin (AcO2Hb), deoxyhem oglobin 
(AcHHb), hem oglob in oxygenation index (AHbD) and cerebral b lood volum e (ACBV) during and 
after bladderbox alarms.
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When resolving the bladderbox alarms there was a fast increase in HbD to values significantly 
h igher than baseline values before the experim ent. In experim ent C, when bladderbox alarms 
were resolved by the adm in istra tion o f intravascular volum e, this increase in HbD (range 0.09 
to  0.84 |jm ol.100g-1) was significantly larger than in experiments A and B [range -0.06 to 0.35 
|jm ol.100g-1 (p<0.05)]. Because normal saline is used as intravascular volum e adm in istra tion to 
resolve bladderbox alarms in experim ent C, this w ill result in hem odilu tion 
(decrease o f cHb). Therefore changes in CBV cannot be reliably calculated. However, in experi­
m ent A and B, CBV increased to  values significantly h igher than baseline values (range 0 to 0.26 
ml.100g-1). MAP and Qcar recovered to  baseline values in experiments A and B, bu t increased 
significantly when intravascular volum e was adm inistered (experim ent C). CVP tends to  decrease 
after bladderbox alarms are resolved, bu t increases during intravascular volum e adm inistration. 
HR was still increased at the end o f each experim ent. Again, we did not find any significant d iffe r­
ence between A H b D  . and AHbD , or between ACBV . and ACBV , .right left right left
Discussion
Because cerebral hem orrhage and ischemia belong to  the devastating com plications o f ECMO 
treatm ent, it  is im portan t to iden tify  risk factors related to  the use o f the ECMO technique itself 
and elim inate these as much as possible. A fte r describing a significant relation between in tra ­
vascular volum e adm in istra tion during va-ECMO treatm ent and ICH (10), this is the firs t study to 
describe statistically significant changes in cerebral oxygenation and hemodynamics, expressed 
by AHbD and ACBV, in relation to bladderbox alarms. These alarms often precede the need for 
intravascular volum e adm inistration.
B ladderbox alarms cause a stop o f the ECMO pum p, which results in an acute in te rrup tion  o f the 
arterial circulation and an acute decrease in MAP, Qcar, HbD and CBV. W hile bladderbox alarms 
persist, several mechanisms m ight explain observed find ings o f our study. First, in an a ttem pt 
to  restore the circulation, the body w ill try  to increase cardiac o u tp u t w ith  an increase in HR. 
Especially, as lambs in our study have healthy lungs, an increase in cardiac ou tpu t w ill result in an 
increased arterial blood flow, which explains the increase in MAP, Qcar, HbD and CBV.
When the ECMO pum p is in te rrup ted, venous drainage from  the righ t atrium  w ill be reduced and 
CVP w ill increase, resulting in less venous drainage from  the brain. This m ight con tribu te  to  an 
increase in CBV. Finally, cerebral vasodilatation m igh t occur as com pensation fo r decreased CBF 
during bladderbox alarms. When bladderbox alarms are resolved, an acute recovery o f ECMO 
flow  w ill occur w ith  a consecutive increase in MAP and Qcar, occurring w h ile the system was just 
adapting to  reduced CBF by vasodilatation. This m ight, partially, explain why there is an over­
shoot in HbD and CBV to  values higher than baseline values. Once intravascular volum e adm inis­
tra tion  is used, there is a fu rthe r increase o f MAP, Qcar and cerebral b lood flow  w ith  a consecutive 
fu rthe r increase in HbD.
Several authors reported tha t the m ajority  o f cases o f ICH occurred w ith in  72 h after the start 
o f ECMO (22-24). This m ight f it  w ith  our findings, as the m ajority  o f bladderbox alarms occur
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in the firs t days o f ECMO treatm ent, when a relatively high ECMO flow  rate is required to m ain­
tain adequate arterial oxygen saturation in a period tha t the patients lung is passing a phase of 
"w h ite  ou t" and the patien t is still hem odynam ically stabilizing. Next to this the acute changes 
in HbD and CBV, related to bladderbox alarms in the firs t days, occur w h ile  cerebral au toregu­
lation (AR) in the patien t seems to be disturbed. In normal, healthy infants, AR maintains the 
cerebral blood flow  over a w ide range o f cerebral perfusion pressures w ith  a contra-regulation 
response occurring w ith  a delay o f 2 seconds after sudden changes in b lood pressure. However, 
it  has been shown, tha t AR is d isturbed in severely ill term  infants (25-28). Add itional studies in 
newborn lambs showed tha t pro longed hypoxia and/or the ECMO treatm ent itse lf significantly 
disturbs the AR (29-32). These studies dem onstrated tha t AR in lambs placed on ECMO was more 
disturbed in animals tha t had hypoxia before ECMO compared w ith  animals w ith o u t preceding 
hypoxia. Therefore, the hem odynam ic changes tha t occur during bladderbox alarms as dem ­
onstrated in our study could even be more profound in the clinical situation o f newborns w ith  
respiratory and/or c ircu latory distress.
Large prospective randomized studies in human newborns to  investigate the relation between 
(simulated) b ladderbox alarms and the occurrence rate o f intracranial lesions during treatm ent 
w ith  ECMO are im possible to perform . Therefore, it  is im portan t to  establish observational in te r­
vention studies. The most im portan t lim ita tion  o f using NIRS, w ith  its variables like HbD and CBV, 
is the lack o f reference values below  which global cerebral oxygenation and hemodynamics are 
com prom ised and clin ically relevant fo r the indiv idual patient. Findings can be used to  describe 
trends in a group o f patients and the relevance can only be suspected when compared w ith  stud­
ies where known risk factors fo r the brain are related to changes in NIRS variables. Baseline vari­
ab ility  o f HbD has been described to range from  -0.12 to  +0.13 |jm ol.100g-1 (33). W ith a variab ility  
o f 0.03±0.01 this was lower in our study. In the same study a decrease in HbD o f > 0.3 |jm ol.100g-1 
is likely to  be clinically relevant since this was found to  correspond w ith  the effect o f reducing 
Sao2 by approxim ately 12%. Compared w ith  these values, mean changes in HbD o f 0.11 to 0.33 
|jmol.100.g-1 and changes for indiv idual lambs in HbD up to  0.45 |jmol.100.g-1 in experiments A 
and B and up to  0.84 |jmol.100.g-1 when intravascular volum e adm in istra tion was used could be 
im portan t. F luctuation o f HbD, expressed as changes between maximal decrease in HbD and 
the consecutive maximal increase in HbD are even more profound. For ACBV, changes have been 
compared w ith  usual physio logic parameters like changes in Paco2 and MAP. During hypercapnia 
in norm oxem ic piglets on ECMO, a mean ACBV o f 0.03 mL.100.g-1.kPa-1 occurred (34). In another 
study, ACBV was calculated in relation to  changes in MAP in newborn lambs to  be 0.07 mL.100.g-1. 
m m Hg-1 (35). Compared w ith  these values a mean change in CBV o f 0.11 to 0.13 mL.100g-1 and 
changes fo r individual lambs in CBV up to  0.26 mL.100.g-1 as found in our study could be im ­
portant. Changes between the maximal decrease in CBV and consecutive maximal increase in 
CBV are more profound. Finally, the value o f CBV in lambs has been found to  be 2.5 mL.100.gr-1 
(36). Changes in CBV found in our study are up to  10%. Besides the m agnitude, changes in HbD 
and CBV occur very acute, which m igh t be an additiona l risk factor fo r cerebral lesions by itself.
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Some authors describe predom inance o f cerebral lesions in especially the righ t hemisphere of 
the brain, w h ile in o ther studies this predominance, possibly related to  ligation o f the righ t ca­
rotid artery and righ t internal jugu la r vein, could no t be confirm ed (37-43). To study differences 
between both hemispheres we used tw o  receiving NIRS optodes. However, changes in HbD and 
CBV were not d iffe rent between the le ft and righ t hemisphere o f the brain.
Cerebral hem orrhage and ischemia are generally considered to  be caused by pre-ECMO as well 
as ECMO-related factors. We showed a significant relation between bladderbox alarms and 
changes in cerebral oxygenation and hemodynamics. This m ight play a role in the developm ent 
o f neurological sequelae. As changes in HbD and CBV are more extended when bladderbox 
alarms are resolved by adm in istra tion o f normal saline it would be interesting to  fu rthe r study 
the effects on cerebral oxygenation and hem odynamics o f intravascular volum e adm inistration 
by itse lf as well. The results o f our study are lim ited to  ECMO systems w ith  a ro llerpum p and a 
bladderbox and m ight support the use o f centrifugal pumps, systems w ith o u t a bladderbox or 
ECMO strategies w ith  reduced bladderbox alarms. However, more research is needed fo r other 
systems as well to study, fo r example, the effects o f less contro lled drainage from  the righ t atrium 
o f the patien t and cerebral oxygenation and hemodynamics. On the basis o f this study we con­
clude tha t bladderbox alarms during trea tm ent w ith  va-ECMO result in statistically significant 
fluctuations in cerebral oxygenation and hemodynamics. This m ight be an additional risk factor 
fo r the occurrence o f intracranial hem orrhage and ischemia.
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Chapter 4.3
The e ffe c t o f  in tra va scu la r v o lu m e  a d m in is tra t io n  on ce reb ra l o x y g e n a tio n  and h e m o d y ­
nam ics d u r in g  v e n o -a rte r ia l e x tra c o rp o re a l m em brane  o x y g e n a tio n  in  hum an new borns
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D epartm ent o f Pediatrics, Division o f N eonatology1 and Laboratory o f Clinical Physics3, Rad­
boud University N ijmegen Medical Centre, The Netherlands. D epartm ent o f Pediatrics, A lbert 
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Abstract
O b je c tive : This study determ ines the possible relation between intravascular volum e adm inis­
tra tion  (IVA) and cerebral oxygenation and hemodynamics during veno-arterial extracorporeal 
m embrane oxygenation (va-ECMO) in human newborns.
P a tien ts  and M e tho ds : In a prospective observational study human newborns on the first 
day o f va-ECMO were studied during IVAs. Adm inistra tion o f normal saline, throm bocytes and 
erythrocytes was needed due to bladderbox alarms, low pla te le t count or low hem oglobin level. 
Changes in concentrations o f oxyhem oglobin and deoxyhem oglobin were measured using near 
infrared spectrophotom etry. Changes in to ta l Hb (ctHb) and hem oglob in oxygenation index 
(cHbD) were calculated. cHbD represents cerebral b lood flow, ctHb reflects cerebral blood vo l­
ume. Heart rate and mean arterial b lood pressure were measured continuously. Of the studied 
variables maximal changes during and 2 m inutes after flu id  adm in istra tion were compared to 
baseline values by using Student-f tests. Values are expressed as mean ± SD.
Results: 51 IVAs were observed in 10 neonates. The mean volum e adm inistered was 42 ± 11 ml, 
the mean adm in istra tion ve locity was 0.41 ± 0.25 ml.s-1. IVA resulted in a significant increase of 
mean arterial blood pressure, ctHb and cHbD and a significant decrease o f HR.
C onclus ion : IVA on the first day during va-ECMO results in fluctuation  o f cerebral oxygenation 
and hemodynamics. This m igh t be an additional risk factor fo r brain damage.
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Introduction
Veno-arterial extracorporeal membrane oxygenation (va-ECMO) is a rescue therapy fo r (near) 
term  newborns w ith  severe bu t po tentia lly  reversible cardiorespiratory insufficiency unrespon­
sive to  maximal conventional therapy (1,2). It tem porarily  provides partial card iopulm onary by­
pass by supporting the cardiac o u tpu t and im proving oxygen uptake via an artific ia l lung. The use 
o f partial card iopulm onary bypass w ill a lter the card iopulm onary hemodynamics. The ligation of 
the righ t com m on carotid artery and righ t internal jugu la r vein in com bination w ith  decreased 
arterial pu lsa tility  due to the use o f a ro llerpum p m ight also a lter the cerebral hem odynamics (3). 
The most devastating com plication o f ECMO is the occurrence o f cerebral vascular in jury, both 
hem orrhagic and ischemic (4,5). The orig in o f cerebral in ju ry  in ECMO treated newborns is p rob­
ably a com bination o f factors, includ ing pre-ECMO, patien t and disease related factors, as well as 
factors related to  the ECMO trea tm ent itse lf and a com bination o f both (5,6).
Part o f the va-ECMO system is the bladderbox, which is situated between the venous cannula 
and the ro llerpum p o f the ECMO system. The bladderbox controls venous drainage o f blood 
from  the righ t atrium  o f the patient. In case o f inadequate drainage to  m aintain the established 
flow  o f the ro llerpum p, the bladderbox w ill give an alarm, slow down the pump, and finally 
cause an acute in te rrup tion  o f the rollerpum p. This results in an acute in te rrup tion  o f blood flow  
from  the ECMO system to  the patient. If o ther causes o f inadequate venous drainage from  the 
righ t atrium , like d isturbed position o f the cannula, are ruled out, intravascular volum e is often 
adm inistered to  restore the circulation th rough the ECMO system and the patient. Recently, our 
group first showed a statistically significant relationship between the to ta l num ber and volume 
o f intravascular volum e adm in istra tion (IVA) and the occurrence o f intracranial hem orrhage (ICH) 
during va-ECMO treatm ent (7). In a consecutive study in lambs we dem onstrated tha t b ladder­
box alarms are s ignificantly related to  fluctuations in cerebral oxygenation and hem odynam ­
ics (8). These fluctuations were larger if b ladderbox alarms were resolved by IVA. The princip le 
aim o f this consecutive study is to  fu rthe r determ ine the relation between d iffe rent kinds o f IVA 
and changes in cerebral oxygenation and hem odynamics in daily practice in human newborns 
treated w ith  va-ECMO.
Patients and Methods
Study population and setting
In a prospective observational study between novem ber 2006 and decem ber 2008 human new­
borns on va-ECMO were studied fo r changes in cerebral oxygenation and hem odynamics re­
lated to  IVA. The study was approved by the Radboud University N ijmegen Medical Centre ethics 
com m ittee and parental in form ed consent was obtained before measurements. The study was 
perform ed on the first day o f ECMO when usually adm in istra tion o f normal saline, throm bocytes 
and erythrocytes is needed m ost frequently  due to  b ladderbox alarms, low pla te le t count or low 
hem oglob in level.
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ECMO
All patients m et institu tiona l criteria fo r ECMO treatm ent, which did no t change during the study 
period and were treated w ith  va-ECMO (9). The ECMO circu it itse lf consisted o f a custom packed 
flexible po lyv iny lch loride tub ing  (Baxter, Uden, The Netherlands), w ith  a silicone reservoir, 
the b ladderbox (Seabrook Medical Systems, Inc, Cincinnati, Ohio, USA), an artific ia l lung w ith  
integrated heat-exchanger (Medos Hilite 2400LT, Medos, Stolberg Germany), and a ro llerpum p 
(Jostra RPM 20-320, Lung, Sweden). A imed flow  rate o f the ECMO pum p was 100-150 m l.kg-1.m in-1. 
Normal saline (NaCl 0.9%) was used to  restore the ECMO flow  after b ladderbox alarms. During the 
course o f ECMO, th rom bocyte  transfusions were given at throm bocytes count < 80,000.mm-3. 
E rythrocyte transfusions were given at a hem oglob in level < 8.0 mmol.L-1 and a hem atocrit value 
< 0.40 L.L-1. Hem oglobin level and throm bocyte  count were determ ined every 4 hours. The in d i­
cation fo r adm in istra tion o f NaCl 0.9%, throm bocytes or erythrocytes was made by the a ttending 
physician. The adm in istra tion o f these fluids was perform ed m anually by the attend ing nurse.
NIRS
Cerebral oxygenation and hem odynamics were studied by using NIRS during the firs t 24 hours 
after the start o f ECMO. The NIRS equ ipm ent used (OXYMON') was developed by the instrum en­
ta tion  departm ent and the departm ent o f physio logy o f the Radboud University Nijmegen M edi­
cal Centre, The Netherlands (10). The technique is based on the spectrophotom etric  measure­
m ent o f changes in the absorption properties o f hem oglob in in the near infrared region, which 
is dependent on its oxygenation state, firs t described by Jobsis in 1977 (11). The NIRS procedure 
used in our ECMO centre has been described in earlier studies o f our research group (12-14). From 
an optode, placed fronta l in the m idline o f the skull, three wavelengths o f near infrared ligh t (908, 
857 and 783 nm) were transm itted th rough the head and received by tw o  other optodes placed 
on the le ft and righ t parie to tem pora l region o f the skull, in order to evaluate the oxygenation 
and hem odynamics in each hemisphere separately. Concentration changes o f oxyhem oglobin 
(AcO2Hb) and deoxyhem oglobin (AcHHb) were calculated from  changes in ligh t absorption us­
ing the m odified Lambert-Beer law. We used the Keele absorption m atrix and a constant path 
length m u ltip lie r factor o f 4.27 tim es the distance between both optodes (15-17). Using a value 
o f 1.05 g.m l-1 fo r brain specific mass, concentration changes are expressed in |jm ol.100g-1 (18). 
AcO2Hb and AcHHb reflect changes in cerebral oxygen supply, if oxygen consum ption remains 
constant. Differences between AcO2Hb and AcHHb were calculated and indicated as changes in 
the hem oglob in oxygenation index (AcHbD, where AcHbD = AcO2Hb - AcHHb in |jm ol.100g-1). 
AcHbD represents changes in cerebral blood flow  (CBF) (19). Concentration changes in to ta l he­
m og lob in (ActHb) were calculated as the sum o f AcO2Hb and AcHHb (ActHb = AcO2Hb + AcHHb). 
ActHb reflects changes in cerebral blood volum e (CBV). The NIRS variables were registered at a 
sample rate o f 5 Hz.
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Other measurements
Using a neonatal m on ito r (Philips Intellivue) arterial oxygen saturation (saO2), mean arterial blood 
pressure (MABP) and heart rate (HR) were measured continuously. All variables were registered at 
a sample rate o f 1 Hz and were synchronized w ith  the NIRS registration.
Data management and analysis
We selected data in the tim e period from  15 seconds before the start o f volum e adm inistration 
until 2 m inutes after the end o f IVA. The tim e span o f 2 m inutes was chosen to  evaluate the final 
effect o f the IVA. Baseline values (mean ± SD) o f cHbD, ctHb and physiological variables were 
determ ined over a 15 seconds period before each single IVA during which the NIRS signal was 
stable. Maximal changes in cHbD, ctHb, MABP and HR were determ ined as mean values during 
a 3 seconds period o f maximal deviation during the period o f tim e between the start o f each 
single IVA until 2 m inutes after the end o f IVA and compared to baseline values. Two minutes 
after IVA changes o f all variables were determ ined as the mean values during a 3 seconds period 
and compared to  pre-experim ent baseline values. All changes were described separately fo r the 
righ t and le ft hemisphere o f the brain. Therefore AcHbD is expressed as AcHbDright and AcHbDleft, 
w h ile ActHb is expressed as ActHbright and ActHbleft. Maximal changes during IVA and 2 m inutes 
after the end o f IVA were compared to  the baseline values by using Student-t tests. We compared 
changes between the righ t and le ft cerebral hemisphere w ith  the Independent-Sam ples-t test. 
p-Values < 0.05 were considered to be statistically significant. Values are expressed as mean ± SD. 
Because o f the presumed effect o f transfused erythrocytes on near infrared ligh t absorption the 
results are described separately fo r erythrocytes as well as throm bocytes and NaCl 0.9%.
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Results
In the 2 year study period, 10 neonates treated w ith  va-ECMO at the Radboud University N ijm e­
gen Medical Centre were studied. In tota l, the effect o f 51 IVAs were observed: 26 adm inistrations 
o f NaCl 0.9%, 10 transfusions w ith  throm bocytes and 15 transfusions w ith  erythrocytes. The pa­
tients mean gestational age was 38 weeks and 6 days (range 34 weeks and 5 days to  41 weeks 
and 5 days). The mean b irth  w e igh t was 3168 g (range 2540 to  4190 g). Six newborns were diag­
nosed w ith  congenita l d iaphragm atic hernia, tw o  patients had m econium aspiration syndrome, 
one pa tien t had m ultip le  pneum othoraces and one patien t suffered from  id iopath ic  persistent 
pu lm onary hypertension. The study popu lation consisted o f 7 boys and 3 girls, the mean age at 
the in itia tion  o f ECMO was 2 days (range 0 to 9 days). The mean volum e o f the IVAs was 42 ± 11 
ml, corresponding to  13 ± 4 m l.kg-1. IVA was adm inistered to  the patients w ith  a mean ve loc ity  of 
0.41 ± 0.25 ml.s-1. Figure 1 shows the typica l pattern o f cHbD, ctHb, MABP and HR during IVA until 
2 m inutes after the end o f IVA in one patient.
Baseline values, calculated over a 15 seconds period before IVA showed a baseline variab ility  for 
cHbD (mean ± SD) o f 0.04 ± 0.03 |jm oM 00g-1 and fo r ctHb 0.02 ± 0.01 ml-100g-1 respectively in the 
righ t hemisphere and for cHbD o f 0.06 ± 0.05 ^m ol-100g-1 and fo r ctHb o f 0.03 ± 0.02 ml-100g-1 
respectively in the le ft hemisphere. Baseline values o f the measured variables, maximal changes 
and changes at 2 m inutes afte r the end o f IVA as compared to  the baseline values are presented 
in table 1. Changes o f variables were not d iffe rent between the righ t and the le ft hemisphere. 
During IVAs saO2 remained between the desired values. During adm in istra tion o f NaCl 0.9% and 
throm bocytes, cHbD, MABP and ctHb increased to maximum values tha t were statistically sig­
nificant higher than the baseline values. A fte r 2 m inutes cHbD and MABP were still h igher than 
the baseline values before IVA. The HR decreased during the adm in istra tion o f NaCl 0.9% and 
throm bocytes. The lowest value was statistically significant d iffe rent from  the baseline values. 
The HR was still lower than the baseline value 2 m inutes after the end o f IVA. Adm in istra tion of 
erythrocytes resulted in an increase o f cHbD, ctHb and MABP. Its m aximum value was statistically 
significant higher than the baseline value. A fte r 2 m inutes, values were still higher than baseline 
values. The HR decreased during the erythrocytes adm in istra tion w ith  a m inim um  value tha t was 
statistically d iffe rent from  the baseline value. The HR at 2 m inutes after the end o f IVA was still 
lower than its baseline value.
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F igu re  1. Typical pattern o f cHbD, ctHb, MABP and HR during IVA until 2 m inutes after the end 
o f intravascular volum e adm in istra tion w ith  erythrocytes and w ith  normal saline/throm bocytes 
during trea tm ent w ith  veno-arterial extracorporeal membrane oxygenation.
erythrocytes:
saline/thrombcytes:
In which cHbD = oxygenation index, ctHb = to ta l concentration o f hemoglobin, MABP = mean arte­
ria l blood pressure, HR = heart rate and A represents a change in parameters.
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Table 1. Baseline values and maximal changes o f cHbD, ctHb, MABP, HR and saO2 during and 
tw o  m inutes after intravascular volum e adm inistrations in newborns treated w ith  veno-arterial 
extracorporeal membrane oxygenation.
Baseline Max 2 min










48 ± 12 
139 ± 25
0.20 ± 0.18 * 
0.26 ± 0.28 * 
0.12 ± 0.13 * 
0.22 ± 0.42 ** 
12 ± 7 * 
-17 ± 12 *
0.04 ± 0.18 NS 
0.08 ± 0.22 *** 
-0.08 ± 0.18 *** 
0.04 ± 0.36 NS 
10 ± 7 *
-11 ± 13 *










48 ± 11 
153 ± 31
0.64 ± 0.86 *** 
0.84 ± 0.93 ** 
0.27 ± 0.32 *** 
0.46 ± 0.51 ** 
15 ± 7 *
-27 ± 16 *
0.55 ± 0.86 *** 
0.73 ± 0.93 *** 
0.15 ± 0.38 NS 
0.38 ± 0.52 *** 
14 ± 8 *
-20 ± 16 *
cHbD = hemoglobin oxygenation index, ctHb = concentration tota l hemoglobin, HR = heart rate, 
MABP = mean arterial blood pressure, IVA = intravascular volume administration, Sal = norm al saline, 
Ery = erythrocytes, Thr = thrombocytes, Max = m axim al change during IVA and 2 m in = change 2 m in­
utes a fter the end o f IVA. n.a = no t available. A ll changes are compared to baseline values. *: p=0.000; 
**:p<0.005; ***:p<0.05; NS=not significant. Values are mean ± SD.
Discussion
This is the firs t study concerning the effects o f IVA on cerebral oxygenation and hem odynam ­
ics in human newborns treated w ith  va-ECMO. We dem onstrated tha t IVA leads to  a significant 
increase o f cHbD and ctHb reflecting an increase in CBF and CBV. The consequence o f these 
changes in oxygenation and hem odynamics in ECMO patients is unknown. However, it  can be 
speculated tha t increase o f CBF and CBV in com bination w ith  vulnerable capillary endothelium  
due to  pro longed hypoxemia before ECMO can easily result in capillary rupture. In com bination 
w ith  heparinization during ECMO this may result in increased risk for developm ent o f ICH, an 
im portan t com plication during ECMO.
Recently we dem onstrated a statistically significant relationship between the to ta l num ber and 
volum e o f IVAs and the developm ent o f ICH during trea tm ent w ith  va-ECMO (7). In a consecutive 
study we showed tha t in te rrup tion  o f ECMO flow  due to  bladderbox alarms results in a significant 
decrease in cHbD and ctHb reflecting decreased CBF and CBV (8). Since bladderbox alarms are 
often resolved w ith  the use o f IVA, the successive events o f bladderbox alarms, in te rrup tion  of 
the ECMO flow, IVA and restoration o f the ECMO flow  can lead to substantial fluctuations in CBF
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and CBV. All studies were perform ed in an ECMO system includ ing a ro llerpum p and bladderbox. 
It is im aginable tha t the fluctuations o f CBF and CBV caused by these successive events are a risk 
factor fo r the occurrence o f cerebrovascular lesions.
Several authors reported tha t the m ajority  o f cases o f ICH occurred w ith in  72 h after the start of 
ECMO (20-22). This fits w ith  our findings, as the m ajority o f bladderbox alarms occur in the first days 
o f ECMO treatm ent, when a relatively high ECMO flow  rate is required to maintain adequate saO2. 
In order to  reduce the risk o f ICH we speculate tha t it m igh t be be tte r to adm in ister flu id volumes 
as slow as possible. In our study, which reflects the daily clinical situation, the infusion velocity 
was dependent on the attend ing physician and nurse. In case o f bladderbox alarms resulting in 
acute in te rrup tion  o f the ECMO pump, saline as a bolus was usually adm inistered more quickly 
in order to  restore the ECMO flow  as soon as possible. Throm bocytes or erythrocytes were in ­
fused more slowly, because it was usually adm inistered electively fo r reasons o f low  values in the 
patient. Nevertheless, this practice o f throm bocytes or erythrocytes transfusion does not seem 
to  prevent significant fluctuations in CBF and CBV. Bedside continuous m on ito ring  o f cerebral 
hem odynamics in infants m igh t be helpfu l to determ ine the optim al infusion ve loc ity  fo r the 
indiv idual pa tien t bu t such device is not yet available fo r the clinical setting.
A hypothetical explanation fo r the observed effects m ight be found in the disturbance o f cere­
bral au toregula tion (AR). In normal, healthy infants AR maintains the cerebral b lood flow  over 
a w ide range o f cerebral perfusion pressures. It has been shown however, tha t AR is disturbed 
in severely ill term  infants (23-25). Add itional studies in newborn lambs on ECMO showed that 
pro longed hypoxia and/or the ECMO treatm ent itse lf s ignificantly d isturb AR (26-28). However 
from  our data it is d ifficu lt to  distinguish w hether AR is disturbed, or w hether the AR mechanism 
needs more tim e to  regulate, since it  takes abou t 2 seconds fo r a contra regulation response of 
CBF to  occur a fter sudden changes in b lood pressure (23,29). During the IVAs in our study the 
MABP continuously increased and then decreased, lacking a steady state period o f 2 seconds for 
contra-regulation.
Some authors describe predom inance o f cerebral lesions in especially the righ t hemisphere of 
the brain, possibly related to ligation o f the righ t carotid artery and righ t internal jugu la r vein, 
w h ile in o ther studies this predom inance could not be confirm ed (30-36). To study possible d if­
ferences between both hemispheres we used tw o  receiving NIRS optodes. However, changes in 
cHbD and ctHb were no t d iffe rent between the righ t and le ft hemisphere o f the brain.
We established this clinical observational study tha t did no t in terfere w ith  the indiv idual clinical 
practice in our ECMO patients. An im portan t lim ita tion  o f our study tha t reflects daily practice 
instead o f a h igh ly contro lled laboratory setting is the difference in volum e and infusion velocity 
o f the studied IVAs. Nevertheless we were able to  clearly dem onstrate the effects o f IVA on cHbD, 
ctHb and MABP.
A nother im portan t lim ita tion  is the lack o f clin ically relevant reference values fo r NIRS vari­
ables. It thus remains d ifficu lt to  estimate the exact im portance o f the increased values o f cHbD 
and ctHb fo r the indiv idual patient. Baseline variab ility  o f cHbD has been described to  range
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from  -0.12 to  +0.13 |jm ol.100g-1 (37). In the same study a decrease in cHbD o f > 0.3 |jm ol.100g-1 
reflects the effect o f reducing saO2 by approxim ately 12%. Compared to  these values, mean 
changes in cHbD o f 0.2 to 0.84 |jm ol.100g-1 and changes fo r indiv idual neonates in cHbD up to 
3.48 |jm ol.100g-1 could be physio logically im portan t. Additionally, NIRS can only measure relative 
changes o f cHbD and ctHb, bu t we are not in form ed abou t the absolute quantita tive baseline 
values o f these variables. To in te rp re t w hether changes o f cHbD or ctHb are pathological, it is 
necessary to  get the in fo rm ation abou t the quantita tive baseline values.
When in te rpre ting  the value o f our results, one should also take in to  account the d ifferent 
effects on hem oconcentration o f adding erythrocytes versus the effect on hem od ilu tion  of 
adding saline and throm bocytes. Our results possibly overestimate the true increase o f ctHb 
during adm in istra tion o f erythrocytes, because the increase in ctHb is partly caused by the 
increase in intravascular hem oglob in concentration as a result o f adding erythrocytes to the 
circulation. On the o ther hand we possibly underestim ate the true increase o f ctHb during 
adm in istra tion o f NaCl 0.9% and throm bocytes, both o f which w ill e lic it some degree of 
hem odilu tion . Besides the m agnitude we stress tha t changes in cHbD and ctHb occur rapidly, 
which m igh t be a risk factor fo r cerebrovascular in jury. When treating a newborn w ith  va-ECMO 
one should be aware o f that. In order to reduce the risk for ICH during va-ECMO treatm ent it 
m igh t be indicated to  be cautious w ith  IVA. In conclusion, IVA on the first day during va-ECMO 
results in fluctuation o f cerebral oxygenation and hemodynamics. Further investigation is needed 
to  search for trea tm ent strategies during ECMO in which these fluctuations can be reduced.
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General discussion
W ith its more routine use from  the early 80's neonatal ECMO has become an accepted m odality 
fo r the trea tm ent o f severe respiratory insufficiency and pulm onary hypertension in neonates. 
Till today, neonatal ECMO has always been considered to  be a "rescue therapy", used after failure 
o f o ther therapies. This m igh t be explained by several reasons. First o f all, ECMO is an intensive 
and invasive therapy and a lthough there are nowadays more and more outcom e data support­
ing its effectiveness, there is on ly one randomized tria l (1). Furthermore, ECMO is no t available in 
all hospitals. Finally the risk o f ECMO related com plications, especially intracranial hemorrhage 
and ischemia, the main causes o f death and m orb id ity  among patients treated w ith  ECMO, m ight 
explain the current status o f ECMO as a rescue therapy.
As a result o f the "rescue" status o f ECMO in the newborn o ther new techniques in the treatm ent 
o f severe respiratory insufficiency and pulm onary hypertension o f the newborn are generally 
applied before the in itia tion  o f ECMO. When these techniques fail, it  m ight result in a delay in the 
in itia tion  o f ECMO, a pro longed ECMO runtim e, com plications related to  the therapy applied and 
a selection o f more severely ill neonates once ECMO is started. One o f these new, conservative, 
therapies is the use o f iNO. Currently there is clear evidence tha t iNO is effective in reducing the 
num ber o f ECMO treatm ents, bu t does not reduce m orta lity  in (near) term  infants w ith  hypoxic 
respiratory failure who do no t have a congenital d iaphragm atic hernia (1,3). It is known tha t the 
use o f iNO by itse lf does not result in im proved nor worsened neurodevelopm ental outcome 
in term  and near-term neonates w ith  severe respiratory insufficiency (4,5). However one study 
dem onstrated a relation between the response to  iNO and neurodevelopm ental outcom e (6). It 
is no t known, w hether neurodevelopm ental outcom e is im proved in those neonates kept from 
ECMO by the use o f iNO (and other trea tm ent modalities) and a pro longed conservative treat­
m ent, compared to those treated w ith  ECMO after prior iNO use. Based on the results o f the 
randomized tria l o f the UK collaborative ECMO group, tha t was discussed earlier, this m igh t at 
least be questionable (2,7,8). The benefit o f ECMO in comparison to  conservative trea tm ent is 
fu rthe r confirm ed in a Cochrane review from  2008 (9). However, it has to  be adm itted tha t the UK 
tria l m entioned before is by far the strongest study in this fou r trials counting Cochrane review. 
Study objectives in (near) term  infants w ith  severe respiratory insufficiency should not on ly be 
to  reduce the num ber o f ECMO treatm ents, bu t should aim on how to  im prove the combined 
param eter o f m orta lity  and neurodevelopm ental im pairm ent. From this po in t o f view, iNO treat­
m ent m igh t no t on ly be beneficial. Based on pathophysiological mechanisms (prolonged) use of 
iNO m ight play a role in the activation o f the coagulation system (10-17). However, the use o f iNO 
has also been related to  increased risk for bleeding com plications (18-23). Finally we stress that 
w a iting  fo r a response to  iNO trea tm ent m ight result in a delayed in itia tion  o f ECMO, especially 
in those neonates tha t do no t or partly respond to  iNO, occurring in up to  30% o f cases (24). In 
this thesis a later in itia tion  o f ECMO was related to  a longer ECMO runtim e, bu t there was no 
significant difference in the postnatal age at the start o f ECMO and duration o f ECMO treatm ent
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between neonates treated w ith  iNO before ECMO and those w ho were not treated w ith  iNO. We 
did not find any significant difference in hem orrhagic com plications, includ ing ICH, between 
the tw o  groups. We did, however, find a remarkable statistically significant relationship between 
c lo tting  com plications and/or DIC and iNO use prior to  ECMO treatm ent. Major clo t form ation 
in the circu it can be detected by c ircu it inspection, bu t small, undetected, clots can escape into 
the circulation o f the patien t and cause (small) cerebral infarctions. Disturbance in o ther organ 
functions can also be involved in DIC. We are aware o f the lim ita tions o f retrospective studies like 
ours, bu t because o f ethical and practical argum ents a prospective randomized tria l is hard to 
perform  and studies like ours do have a function  in the search fo r possible risk factors. Not all 
accepted therapies, like iNO, should autom atica lly be regarded to be beneficial, ju s t because they 
reduce the num ber o f ECMO treatm ents. Once iNO is in itia ted an unnecessary delay in the start 
o f ECMO needs to be avoided as this is related to  a pro longed ECMO runtim e. For this reason in ­
clusion criteria fo r ECMO m ight have to  be changed and adapted in those neonates treated w ith  
iNO (25). Because more and more o ther new therapies for the trea tm ent o f persistent pulm onary 
hypertension are arising (e.g. sildenafil), it  seems to be rational, tha t a lim ita tion  should be estab­
lished in the pre-ECMO phase o f conservative treatm ent, e ither for the duration or fo r the extent 
o f the clinical im provem ent. Once this lim ita tion  has been exceeded, ECMO should be started 
w ith o u t delay. Preferably, determ ination o f such lim ita tion  should be supported by m ulticenter 
randomized trials.
The e tio logy o f cerebral lesions in ECMO patients is considered to  be m ultifactoria l, as is de­
scribed earlier in this thesis. It is often impossible to iden tify  a specific cause in a given patient. 
Certain (technical) aspects o f ECMO m ight form  risk factors (26,27). One o f these aspects is the 
active use o f the va-bridge, a safety connection between the venous and arterial cannula o f the 
ECMO system. For many years it has been com m on use to  open the va-bridge in te rm itten tly , 
fo r example every 15 minutes, to  prevent the developm ent o f th rom b i due to  blood stasis in 
the bridge. In earlier studies o f our ECMO group Liem et al. and van Heijst et al. showed sign ifi­
cant changes in cerebral oxygenation and hem odynamics related to  the use o f the va-bridge in 
an animal model and a clinical study by using near infrared spectrophotom etry (28,29). Once 
opening the va-bridge, blood is shunting from  the arterial cannula towards the venous cannula. 
This results in an acute decrease in MABP and cerebral perfusion pressure, as the ECMO flow  is, 
especially at high flow  rates, responsible fo r a large part o f the systemic arterial blood flow  in 
va-ECMO. In this thesis an additional clinical study using Doppler ultrasound in the pericallosal 
artery has also shown acute and statistically significant changes in CBFV related to the use of 
the va-bridge. These changes can be avoided if the va-bridge is filled w ith  normal saline w ith  
stop-cocks on both sides. However, as surveyed at in ternational m eetings (e.g. the annual ELSO 
m eeting, Keystone, 2010), this is not common use yet. Up to 50% o f ECMO centers still perform ed 
in te rm itte n t opening o f the va-bridge. In daily practice, this means tha t in our patien t group this 
phenom enon w ould occur over 600 times per pa tien t based on a mean ECMO run-tim e o f 152
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hours. A lthough a d irect positive relation between the active in te rm itte n t use o f the va-bridge 
and the occurrence o f ICH and cerebral ischemia is not proven, fluctuations in CBFV due to  open­
ing o f the bridge can easily be avoided. Based on our studies we would advocate fu rthe r com ­
mon use o f the va-bridge filled w ith  normal saline and w ith  stopcocks located at the junc tion  
where the bridge connects to the venous and arterial tub ing.
A nother technical aspect o f the ECMO system using a ro llerpum p is the so-called "bladderbox", 
which is situated between the venous cannula and the pump. The bladderbox controls venous 
drainage from  the righ t atrium  o f the patient. In case o f insuffic ient venous drainage, the blad­
derbox w ill give an alarm, slow down the pum p and fina lly cause an acute in te rrup tion  o f the 
ro llerpum p resulting in in te rrup tion  o f arterial b lood flow  to the patient. If o ther causes o f blad­
derbox alarms are excluded, intravascular volum e adm in istra tion is often given to  restore the 
circulation through the ECMO system and the patient. We hypothesized tha t the sequelae of 
b ladderbox alarms and consecutive intravascular volum e adm in istra tion results in significant 
fluctuations in cerebral oxygenation and hemodynamics. These fluctuations w ill occur in a brain 
possibly suffering from  increased vascular vu lne rab ility  and disturbed cerebral autoregulation 
(AR). In normal, healthy infants, the brain is protected from  fluctuations in CBF by the cerebral 
AR, which acts w ith  a delay o f 2 s a fter sudden changes in b lood pressure. However, it has been 
shown tha t AR is d isturbed in severely ill term  infants (30-33). A dd itional studies in newborn 
lambs showed tha t pro longed hypoxia and/or ECMO treatm ent itse lf s ignificantly disturbs AR 
(34-37). Several authors reported tha t the m ajority o f cases o f ICH occur w ith in  the first 72 h after 
the start o f ECMO (38-40). In this episode, when most bladderbox alarms occur, the brain m ight 
be most vulnerable fo r intracranial hem orrhage and ischemia because o f the d isturbed AR.
In this thesis we first showed tha t the num ber and to ta l volum e o f intravascular volum e adm in­
istration in the first 8 to  24 hours o f va-ECMO treatm ent are statistically significant related to  the 
developm ent o f ICH. These results were the basis fo r tw o  fo llow ing  studies. In h igh ly contro lled 
laboratory settings bladderbox alarms were simulated in healthy lambs treated w ith  va-ECMO. 
We found acute and significant changes in cerebral oxygenation and hem odynamics during and 
after b ladderbox alarms. These changes were especially larger if b ladderbox alarms were re­
solved by intravascular volum e adm in istra tion. A consecutive study in human newborns showed 
tha t even an intravascular volum e adm in istra tion w ith  normal saline as well as w ith  erythrocytes 
and throm bocytes w ith o u t preceding bladderbox alarms, resulted in statistically significant fluc­
tuations in cerebral oxygenation and hem odynamics tha t m igh t be o f clinical and physiological 
im portance. Com bining the results o f the studies above, it can be speculated tha t a more subtle 
approach o f bladderbox alarms and consecutive intravascular volum e adm inistrations m igh t re­
sult in reduced risk o f cerebral lesions. It m igh t be tha t lower saO2 and paO2 values should be 
accepted during the firs t days o f va-ECMO. Using this strategy, high ECMO flow  rates can be 
avoided, resulting in less bladderbox alarms. If b ladderbox alarms do occur, it m igh t be interest­
ing to  study w hether slower infusion rates result in less fluctuation  o f cerebral oxygenation and
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hem odynamics in the vulnerable brain. Another possible op tion  w ould be to  use an ECMO sys­
tem w ith  a centrifugal pum p (w ithou t a bladderbox) instead o f a ro llerpum p. However, possible 
effects on the brain have to  be studied fo r these kinds o f pumps as well.
Future perspectives
The fu ture  perspectives o f research in the fie ld o f ECMO should be focused in reducing m orta lity  
and m orb id ity  o f ECMO treatm ent. Follow ing points should be considered.
a. As long as ICH and cerebral ischemia are still the m ost com m on im portan t complications, 
fu ture  research should be focused on gaining a be tte r understanding o f pa thophysio log­
ical and technical aspects related to  these cerebral com plications. One o f these aspects is 
the im proved understanding o f factors tha t are causally related to d isturbed autoregula­
tion.
b. Future research should also be aimed at the place o f ECMO in the trea tm ent cascade of 
severe neonatal respiratory insufficiency and pulm onary hypertension. New less aggres­
sive therapies like sildenafil should no t au tom atica lly be placed ahead o f ECMO w ith  un­
lim ited duration. Even the current com m only applied conservative trea tm ent should be 
critica lly evaluated, w hether its use w ill result in a delay o f ECMO in itia tion . Unnecessary 
delay in the in itia tion  o f ECMO m igh t result in longer ECMO treatm ents and an increased 
num ber o f com plications. Outcome parameters in studies considering the less aggressive 
therapies should not on ly focus on the avoidance o f ECMO, bu t concentrate on m orta lity  
and long-term  neurodevelopm ental outcome.
c. A possible po in t in fu ture  research is the developm ent o f more individualized ECMO cri­
teria based on factors like underlying disease and response to other treatm ents. It m ight 
be useful to  investigate w hether some underlying diseases w ill benefit from  lower, more 
relaxed, criteria than o ther prim ary diseases fo r the in itia tion  o f ECMO. This is in contrast 
w ith  the current practice, where the same criteria are used fo r all underlying diseases.
d. A nother po in t o f in terest is the fact tha t vv-ECMO is considered to  be more gentle for 
the brain, bu t tha t there is still a lack o f evidence tha t vv-ECMO does really result in less 
com plications and im proved long term  outcome. It is still unknown w hether vv-ECMO 
has resulted in high incidence o f posterior fossa hemorrhages due to more venous con­
gestion. Till today we have missed the op p o rtu n ity  to  perform  a m ulti center trial in which 
patients are randomized and treated by va- or vv-ECMO.
e. Besides iden tifica tion  o f and dealing w ith  factors tha t are related to  cerebral com plica­
tions, it  is im portan t tha t fu ture research should consider possible brain protective strate­
gies like (head) cooling and neuroprotective drugs during ECMO treatm ent. From this 
po in t o f view, results o f a current randomized contro lled tria l by Field et al seem to be 
very in teresting (41).
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Summary
Neonatal extracorporeal m embrane oxygenation (ECMO) is a rescue therapy for (nearly) term 
newborns suffering from  severe, bu t po tentia lly  reversible, respiratory insufficiency, o ften com ­
plicated by pu lm onary hypertension. Next to  this ECMO can be used as a bridge to  diagnosis in 
cases o f severe respiratory failure o f unknown origin. Finally ECMO can be useful, as a tem porary 
support fo r reversible cardiac failure, like after cardiac surgery. There are tw o  forms o f ECMO, 
veno-venous ECMO (vv-ECMO) and veno-arterial ECMO (va-ECMO). When va-ECMO is used, like 
in all studies o f this thesis, blood drained from  the righ t atrium  passes an artific ia l lung, the m em ­
brane oxygenator, where it is oxygenated. Oxygenated blood is returned to  the aorta o f the 
patient. Neonatal ECMO is an effective therapy, bu t un fortuna te ly  it has its disadvantages as well. 
M ost im portan t disadvantage is the occurrence o f cerebral lesions.
In this thesis we study risk factors for intracranial hem orrhage (ICH) and cerebral ischemia, tw o 
o f the most devastating com plications o f ECMO leading to m orta lity  or (long term) m orb id ity.
C hapte r 1 gives a general in troduction  in ECMO. It especially stresses the ECMO technique and 
w hat is known from  literature abou t factors related to the developm ent o f cerebral lesions. These 
factors can be divided in pre-ECMO, patien t related factors, like hypoxia due to  severe respiratory 
failure and factors related to  the use o f ECMO, like anticoagulation. A t the end o f chapter 1 a short 
in troduc tion  in near infrared spectrophotom etry (NIRS) is given. This technique, in which near 
infrared ligh t is used to measure oxygenated and non-oxygenated hem oglob in in the brain to 
determ ine fluctuations in cerebral oxygenation and hemodynamics, is used in tw o  o f the studies 
o f this thesis and m igh t be less known by the readers.
C hapte r 2  presents the results o f tw o  studies concerning the possible effect o f inhaled nitric 
oxide (iNO) used in patients before the in itia tion  o f ECMO on com plications during the ECMO 
treatm ent. Since ECMO was in troduced as a rescue therapy fo r newborns suffering from  severe 
respiratory failure, o ften com plicated by pulm onary hypertension, o ther less invasive techniques 
were developed to  treat these children. One o f these techniques is the use o f iNO to  trea t pu l­
m onary hypertension. A lthough used fo r its specific ity as a pu lm onary vasodilatator, iNO has 
systemic effects as well. We studied w hether these systemic effects, or a delay in the in itia tion  
o f ECMO because o f the use o f iNO, m ight lead to  an increased risk for com plications o f ECMO 
itself. From literature it  is known, tha t iNO effective ly reduces the num ber o f ECMO treatments, 
bu t does no t reduce m orta lity  in term  infants w ith  hypoxic respiratory failure. In both studies 
the possible effects o f iNO on hemostasis and coagulation are described. A lthough fu rthe r re­
search is absolute ly needed to  iden tify  possib le-underlying mechanisms, d iffusion o f NO into 
the systemic circulation m ight result in an increased risk for c lo tting  com plications as well as 
hem orrhagic com plications. We were the firs t to study its relation to these com plications when 
used before ECMO, a trea tm ent fo r which the often severely ill pa tien t w ill be heparinized and 
hem orrhage as well as c lo tting  com plications or disseminated intravascular coagulation (DIC) 
frequently  occur. In the firs t study we found a positive relationship between c lo tting  com plica­
tions and/or DIC and iNO use prio r to  ECMO treatm ent. A prospective randomized contro l study 
seems to be indicated, bu t w ill be hard to perform  because o f medical as well as ethical consid­
erations, as iNO has been accepted as standard therapy fo r newborns w ith  severe respiratory 
insufficiency w ith  pu lm onary hypertension. In the second study we found tha t the use o f iNO 
does not necessarily have to  result in a significant delay ne ither in the in itia tion  o f ECMO nor in an 
increase in duration o f the ECMO treatm ent. Next to this we found no statistically s ignificant rela-
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tion  between the use o f iNO prior to  ECMO and the occurrence o f hem orrhagic complications. 
C h a p te r3  describes the effects o f clam ping and unclam ping o f the veno-arterial bypass bridge 
(va-bridge) on cerebral b lood flow  ve loc ity  (CBFV) as measured by Doppler ultrasound in human 
newborns. Part o f the ECMO system is a va-bridge, which connects the arterial and venous can­
nula when va-ECMO is used. In the event o f emergencies the arterial and venous cannula can 
be clamped and the va-bridge opened to  a llow  continuation o f circulation th rough the ECMO 
system, w h ile the patien t is taken o ff from  ECMO. Under normal conditions the va-bridge is 
clamped. H istorically the va-bridge was filled w ith  blood. To prevent c lo tting  in the va-bridge 
because o f blood stasis, it has been recommended to  release the clamp on the va-bridge every 
15 to  60 m inutes during the course o f ECMO. There is, however, a lim ited num ber o f studies con­
cerning the im pact o f this in te rm itte n t opening procedure o f the blood stained bridge. In our 
study in 22 human newborns, Doppler ultrasound o f the pericallosal artery, a term inal branch 
o f the anterio r cerebral artery, during opening o f the va-bridge showed a strong and very acute 
decrease o f the peak systolic blood flow  ve loc ity  (PSV), end diastolic blood flow  ve loc ity  (EDV) 
and tim e average mean blood flow  ve loc ity  (TAM). Al changes were statistically significant. In 
several cases even a backward flow, negative EDV, was found. Once the va-bridge was clamped, 
there was an acute recovery o f all values. Changes persisted during the consecutive days o f the 
ECMO treatm ent. In add ition  we studied the relationship between the m agnitude o f changes in 
CBFV during opening o f the bridge and the ECMO flow  rate. The statistically significant overall 
corre lation between the changes in PSV, EDV and TAM and the ECMO flow  rate found in our 
study is mainly caused by flow  dependent fluctuations in CBFV at lower ECMO flows, up to 100 
m l/m in /kg . In addition to  some studies m entioned before, our find ings suggest tha t repetitive 
po tentia lly  harm ful fluctuations in CBVF should be avoided. Using a va-bridge, which is filled w ith  
normal saline and has stopcocks on both sides, can easily do this. Thereby in te rm itte n t opening 
o f the bridge is no longer necessary.
C hapte r 4  presents the find ings o f three studies, all concerning the possible harmful relation 
between bladderbox alarms, intravascular volum e adm in istra tion and cerebral lesions. Part of 
the va-ECMO system is a bladderbox, which is situated between the venous cannula and the ro ll­
erpum p o f the extracorporeal system. The bladderbox controls venous drainage o f blood from 
the righ t atrium  o f the patient. If the venous drainage becomes inadequate to  maintain the es­
tablished flow  o f the ECMO system, the bladderbox w ill give an alarm, slow down the pump, and 
fina lly cause an acute in te rrup tion  o f the ro llerpum p resulting in in te rrup tion  o f blood flow  to 
the patient. If o ther causes o f inadequate venous drainage from  the righ t atrium  and consecutive 
bladderbox alarms, like d isturbed position o f the cannula, are ruled out, intravascular volume 
adm in istra tion is often given to restore the circulation th rough the ECMO system and the patient. 
In the first study o f chapter 4 the relation between the frequency and am ount o f intravascular 
volum e adm in istra tion and the occurrence o f ICH was retrospectively studied in a matched case- 
contro l study w ith  25 newborns tha t developed an ICH and 40 contro l patients. We found a sta­
tistically significant relationship between the to ta l num ber and volum e o f intravascular volume 
suppletions and the developm ent o f ICH during the trea tm ent w ith  va-ECMO. Neonates, receiv­
ing >8 infusions or >300 ml o f volum e infusion during the firs t 8 hours or >10 infusions during the 
first 24 hours o f va-ECMO were statistically significant more at risk to  develop an ICH. A lthough 
no t necessarily causal, we hypothesized, tha t either the bladderbox alarms or the intravascular 
volum e adm in istra tion m ight cause po tentia lly  harm ful fluctuations in cerebral oxygenation and 
hemodynamics. This m ight be especially true, as cerebral au toregula tion seems to be disturbed 
in patients treated w ith  va-ECMO.
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In a second, consecutive prospective study, we analyzed the effect o f bladderbox alarms on ce­
rebral oxygenation and hem odynamics in lambs cannulated fo r va-ECMO. In a contro lled labora­
to ry  setting bladderboxalarms were simulated by e ither increasing the flow  o f the ro llerpum p 
o f the ECMO system or by partia lly  clam ping o f the venous cannula. Decreasing the flow  o f the 
ro llerpum p, intravascular volum e adm in istra tion or unclam ping o f the venous cannula resolved 
bladderbox alarms. Using NIRS, we found a statistically significant decrease in cerebral oxygen­
ation and hemodynamics as expressed by changes in hem oglobin oxygenation index (AHbD) 
and cerebral blood volum e (ACBV) once bladderbox alarms were simulated. These changes oc­
curred very acute. Once bladderbox alarms were resolved a recovery o f cerebral oxygenation 
and hem odynamics was seen w ith  an overshoot to values above baseline values before the ex­
periments. This overshoot was much larger if  intravascular volum e adm in istra tion was used to 
resolve b ladderbox alarms. These acute fluctuations in cerebral oxygenation and hem odynam ­
ics m igh t con tribu te  to the risk fo r intracranial lesions. Adaptations o f the ECMO circu it and/or 
changes in the ECMO treatm ent strategies m igh t result in less bladderbox alarms and by this less 
intravascular volum e adm inistration.
Principle aim o f the th ird  and final study o f chapter 4 is to fu rthe r determ ine the relation between 
the d iffe rent kinds o f IVA and changes in cerebral oxygenation and hem odynamics in daily prac­
tice in human newborns. M ost bladderbox alarms and consecutive intravascular volum e adm in­
istrations occur in the first three days o f ECMO treatm ent. This is also the period in which the 
m ajority  o f ICH is found. Following the find ings o f the second study o f this chapter we hypo th ­
esized tha t intravascular volum e adm in istra tion in human newborns causes changes in cerebral 
oxygenation and hemodynamics tha t m igh t con tribu te  to  the risk fo r intracranial lesions. Intra­
vascular volum e adm in istra tion can be given as normal saline, throm bocytes or erythrocytes. In 
to ta l 51 mom ents o f intravascular volum e adm in istra tion were observed in 10 neonates. NIRS 
was used to measure changes in cerebral oxygenation and hemodynamics. Changes in to ta l Hb 
(ctHb) and hem oglob in oxygenation index (HbD) were calculated. These parameters represent 
cerebral blood volum e and cerebral blood flow  respectively. We dem onstrated tha t intravascular 
volum e adm in istra tion w ith  normal saline and throm bocytes as well as w ith  erythrocytes result­
ed in rapid and statistically significant changes in ctHb and HbD. Results were equal fo r the right 
and le ft hemisphere o f the brain. These changes, m ight con tribu te  to  the occurrence o f cerebral 
lesions. D ifferent ECMO equ ipm ent or strategies m ight result in less mom ents o f intravascular 
volum e adm in istra tion. And if  necessary, it m igh t be w o rthy  to  consider lower adm inistration 
velocity.
Finally c h a p te r5  offers the general discussion o f this thesis. Main find ings o f the d iffe rent stud­
ies are discussed in a larger context. We conclude tha t new therapies, in troduced for the treat­
m ent o f pu lm onary hypertension in the newborn have to  be carefully evaluated and should not 
au tom atica lly be placed ahead o f ECMO treatm ent. Next to t this ECMO treatm ent itse lf should 
be discussed fo r its place in the cascade o f trea tm ent in neonates w ith  severe respiratory failure, 
o ften com plicated by pu lm onary hypertension. Indications fo r ECMO could be applied based 
on diagnosis and indiv idual criteria. In the second part o f this thesis it  became clear tha t in ter­
ventions and trea tm ent strategies during ECMO do cause changes in cerebral oxygenation and 
hem odynamics tha t m ight con tribu te  to cerebral lesions. More fine -tun ing o f the effective ECMO 
treatm ent or changes in equipm ent could reduce these possible risk factors fo r the brain.
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Samenvatting
Extracorporele membraan oxygenatie (ECMO) is een reddingsbehandeling voor (bijna) vo ldra­
gen pasgeborenen, m et ernstige maar po tentieel reversibele respiratoire insufficiëntie, vaak ge­
com pliceerd door pulm onale hypertensie. Daarnaast kan ECMO gebru ik t worden ter overbrug­
ging to t een diagnose gesteld kan worden bij pasgeborenen m et ernstig respiratoir falen waarbij 
de oorzaak ondu ide lijk  is. Tenslotte kan ECMO behulpzaam zijn als tijde lijke  ondersteuning na 
hartoperaties o f bij kinderen m et reversibel hartfalen. Er zijn tw ee vorm en van ECMO, veno-ve- 
neuze ECMO (vv-ECMO) en veno-arteriële ECMO (va-ECMO). Wanneer va-ECMO w o rd t gebruikt, 
zoals in alle studies van d it proefschrift, passeert bloed, afkom stig u it de rechter boezem van het 
hart, een kunstlong en w o rd t daarna terug geleid door een naar de grote lichaamsslagader van 
de patiënt. D it proefschrift is een zoektocht naar m ogelijke risico factoren voor hersenbloeding 
(ICH) en hersenischemie, twee van de belangrijkste complicaties van ECMO behandeling, lei­
dend to t m o rta lite it en (lange term ijn) m orb id ite it.
H o o fds tuk  1 is een algemene in troductie  over ECMO. Speciale nadruk w o rd t gelegd op w at be­
kend is u it de lite ratuur over factoren die verband houden m et het on tw ikkelen van schade aan 
de hersenen. Deze factoren kunnen worden opgedeeld in factoren die in principe vóór de ECMO 
behandeling liggen, zoals een relatief zuurstof teko rt door ernstig respiratoir falen van de pa ti­
ent en factoren die gerelateerd zijn aan de ECMO behandeling zelf, zoals de antisto lling die moet 
worden gegeven. Aan het eind van hoofdstuk vo lg t een korte in troductie  over near infrared 
spectrophotom etry (NIRS), om dat deze techniek m ogelijk  m inder bekend is bij de lezers. Hierbij 
worden frequenties van het bijna in frarode licht gebru ik t om veranderingen in geoxygeneerd 
en niet geoxygeneerd hem oglob ine te meten. Aan de hand hiervan kunnen fluctuaties in de 
zuurstof- en b loedvoorziening van het brein worden berekend.
H o o fd s tu k 2  beschrijft de resultaten van twee studies naar het m ogelijke effect van behande­
ling m et geïnhaleerd stiksto f oxide (iNO) van patiënten, voordat ECMO w ord t gestart, op het 
optreden van complicaties tijdens de ECMO behandeling. Sinds de in troductie  van ECMO als 
reddingsbehandeling van pasgeborenen m et ernstig respiratoir falen, vaak gecom pliceerd door 
pulm onale hypertensie, zijn andere, m inder invasieve, technieken ontw ikke ld om deze kinderen 
te behandelen. Eén van deze technieken is het gebru ik van iNO om pulm onale hypertensie te 
behandelen. Hoewel prim air gebru ik t als specifieke verw ijder van het pulm onale vaatbed, heeft 
iNO ook systemische effecten. W ij bestudeerden o f deze systemische effecten, o f een vertraging 
in het starten m et ECMO vanwege het gebru ik van iNO, zouden kunnen leiden to t een verhoogd 
risico op complicaties van de ECMO behandeling zelf. Vanuit de lite ratuur is bekend dat iNO het 
aantal behandelingen m et ECMO effectie f reduceert, maar dat de m o rta lite it van op tijd  geboren 
kinderen m et hypoxisch respiratoir falen niet afneemt. In beide studies w o rd t het m ogelijke ef­
fec t van NO op hemostase en sto lling beschreven. Hoewel verder onderzoek naar onderliggende 
mechanismen absoluut geïndiceerd is, is het m ogelijk  dat NO, dat naar de lichaamscirculatie d if­
fundeert, een verhoogd risico geeft op zowel sto lling- als bloedingcom plicaties. W ij hebben als 
eerste de d it risico onderzocht, wanneer iNO gebru ik t werd voor ECMO, een behandeling waar­
voor het meestal ernstig zieke kind "on ts to ld " w o rd t m et heparine en zowel b loeding als stol- 
lingscom plicaties en diffuse intravasale stolling (DIC) frequent optreden.
In de eerste studie vonden w ij een positieve relatie tussen stollingscom plicaties en /o f DIC en het 
gebru ik van iNO voor de ECMO behandeling. Een prospectieve gerandomiseerde en gecon tro­
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leerde studie lijk t te zijn geïndiceerd, maar zal vanwege klinische en ethische redenen m oeilijk 
haalbaar zijn, mede om dat iNO algemeen geaccepteerd is als therapie voor de behandeling van 
pasgeborenen m et ernstige pulm onale hypertensie. In de tweede studie vonden w ij dat het ge­
bru ik van iNO niet noodzakelijk hoeft te leiden to t een significante vertrag ing in het starten van 
ECMO, noch hoeft te leiden to t een verlengde behandelingsduur m et ECMO. Daarnaast vonden 
w ij geen statistisch significante relatie tussen het gebru ik  van iNO voor ECMO en het optreden 
van bloedingcom plicaties.
H o o fd s tu k3  beschrijft het effect van openen en sluiten van de veno-arteriële brug (va-bridge) op 
de cerebrale bloedstroom snelheid (CBFV), gemeten m et Echo Doppler bij pasgeboren kinderen. 
Een onderdeel van het ECMO systeem is de va-bridge, die de arteriële en veneuze canule m et el­
kaar verb indt wanneer va-ECMO w ord t toegepast. In het geval van een noodsituatie kunnen de 
arteriële en veneuze canule afgeklemd en de va-bridge geopend worden. Hierdoor kan circulatie 
door het ECMO systeem blijven plaatsvinden, terw ijl de patiënt op dat m om ent niet meer met 
ECMO w ordt behandeld. Onder normale condities is de va-bridge gesloten. Om stolselvorming in 
de va-bridge ten gevolge van stilstaand bloed te voorkomen w ord t aanbevolen om de va-bridge 
iedere 15 to t 60 m inuten kortdurend te openen gedurende de gehele ECMO behandeling. Er zijn 
echter enkele studies die de m ogelijk schadelijke gevolgen hiervan hebben onderzocht. In onze 
studie werd bij 22 kinderen, tijdens va-ECMO behandeling, echo Doppler onderzoek verricht van 
de arteria pericallosa, een eindtak van de arteria cerebi anterior. Tijdens het openen van de va- 
bridge vonden w ij een sterke en zeer acute daling aan van de piek systolische bloedstroom snel­
heid (PSV), eind diastolische bloedstroom snelheid (EDV) en tijd  gem iddelde bloedstroom snel­
heid (TAM). Alle veranderingen waren statistisch significant. In enkele gevallen vonden w ij zelfs een 
omgekeerde, negatieve EDV. Wanneer de va-bridge weer werd gesloten vond een snel herstel van 
alle waardes plaats. Veranderingen bleven zich voordoen gedurende de opeenvolgende dagen 
van de ECMO behandeling. Ook bestudeerden w ij de relatie tussen de mate van veranderingen 
in CBFV gedurende opening van de va-bridge en de pompsnelheid van het ECMO systeem. De 
statistisch significante correlatie tussen veranderingen in PSV, EDV en TAM en de pompsnelheid 
van het ECMO systeem w ord t vooral veroorzaakt door pompsnelheid afhankelijke veranderingen 
in CBFV bij lagere pompsnelheden to t 100 m l/m in/kg. Onze studie suggereert, in aanvulling op 
enkele genoemde studies, dat bij herhaling optredende, potentieel schadelijke, schommelingen 
in CBFV dienen te worden voorkomen. Dit kan eenvoudig bereikt worden door een va-bridge te 
gebruiken die gevuld is m et NaCl 0,9% en aan beide kanten voorzien is van een driewegkraan.
H o o fd s tu k 4 beschrijft de bevindingen van drie studies, die allemaal betrekking hebben op de 
m ogelijk  schadelijke relatie tussen bladderbox alarmen, intravasculaire volum e suppletie en het 
optreden van cerebrale laesies. Onderdeel van het ECMO systeem is de zogenoem de "b ladder­
box". Deze bev indt zich tussen de veneuze canule en de ro llerpom p van het extracorporele sys­
teem. De bladderbox con tro leert de mate van veneuze drainage u it het rechter atrium  van de pa­
tiën t. Wanneer de veneuze drainage tekortsch ie t om de ingestelde pom psnelheid van het ECMO 
systeem te waarborgen, zal de bladderbox alarmeren, de ro llerpom p langzamer laten draaien 
en tenslo tte  de ro llerpom p acuut to t stilstand brengen. Hierbij treed t een in te rrup tie  op van de 
b loedstroom  naar de patiënt. W anneer andere oorzaken van inadequate veneuze drainage van­
u it het rechter atrium  en de daarop volgende bladderbox alarmen, zoals een verkeerde positie 
van de veneuze canule, uitgesloten zijn, w o rd t vaak intravasculaire volum e suppletie gegeven 
om de circulatie door het ECMO system en de pa tiën t te herstellen.
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In de eerste studie u it hoofdstuk 4 werd de relatie tussen de frequentie en hoeveelheid van in ­
travasculaire volum e suppletie en het optreden van ICH onderzocht in een retrospectieve mat­
ched case-control studie onder 25 pasgeborenen die gedurende ECMO een ICH ontw ikkelden 
en 40 contro le patiënten. W ij vonden een statistisch significante relatie tussen het totaal aantal 
keren dat intravasculaire volum e suppletie werd toegepast en het to ta le  volum e aan suppletie 
enerzijds en het on tw ikkelen van ICH gedurende va-ECMO anderzijds. Pasgeborenen, die meer 
dan 8 keer, o f meer dan 300 ml volum e, suppletie kregen in de eerste 8 uur, o f meer dan 10 
keer gedurende de eerste 24 uur van de ECMO behandeling hadden een statistisch significant 
hogere kans om een ICH te ontw ikke len. Hoewel deze relatie n iet noodzakelijkerw ijs op een 
oorzakelijk verband hoeft te w ijzen, stelden w ij de hypothese dat de bladderbox alarmen en/of 
de intravasculaire volum e suppletie zouden kunnen leiden to t po tentieel schadelijke fluctuaties 
in cerebrale oxygenatie en hem odynam iek. Deze hypothese zou ondersteund kunnen worden 
door het fe it dat de cerebrale autoregulatie verstoord lijk t te zijn bij kinderen, die behandeld 
worden m et ECMO.
In een volgende prospectieve studie werd het effect van bladderbox alarmen op de cerebrale 
oxygenatie en hem odynam iek onderzocht in lammeren. Deze lammeren werden allemaal be­
handeld m et va-ECMO. In de gecontro leerde om geving van het d ierenlaboratorium  werden 
bladderbox alarmen gesimuleerd door het ophogen van de pom psnelheid van het ECMO sys­
teem o f door het partieel afklem m en van de veneuze canule. De bladderbox alarmen werden 
opgeheven door de snelheid van de ro llerpum p weer te verlagen, intravasculaire volum e supple­
tie te geven o f de klem van de veneuze canule af te halen. Door gebru ik te maken van NIRS von­
den w ij een significante afname van de cerebrale oxygenatie en hem odynam iek op het m om ent 
dat bladderbox alarmen werden gesimuleerd. Veranderingen werden u itged rukt in veranderin­
gen in de hem oglobine oxygenatie index (AHbD) en cerebraal bloed volum e (ACBV). Deze ver­
anderingen traden zeer acuut op. Wanneer bladderbox alarmen opgeheven werden vond een 
herstel plaats van de cerebrale oxygenatie en hem odynam iek, m et een "overshoot" to t  waardes 
boven de uitgangswaardes voor het experim ent. Deze "overshoot" was veel meer uitgesproken 
wanneer intravaculaire volum e suppletie werd gebru ik t om de bladderbox alarmen op te heffen. 
Deze acute fluctuaties in cerebrale oxygenatie en hem odynam iek zouden kunnen bijdragen aan 
het risico op schade aan de hersenen. Aanpassingen van het ECMO systeem o f veranderingen in 
het beleid rondom  ECMO zouden kunnen leiden to t m inder bladderbox alarmen en daardoor to t 
m inder m om enten van intravasculaire volum e suppletie.
Belangrijkste doel van de derde en laatste studie van hoofdstuk 4 is om de relatie tussen de 
verschillende soorten intravasculaire volum e suppletie en veranderingen in cerebrale oxygena­
tie en hem odynam iek verder te beschrijven. D it werd gedaan bij pasgeborenen behandeld met 
ECMO en in de dagelijkse praktijk. De meeste bladderbox alarmen en daarop volgende intravas­
culaire volum e suppleties v inden plaats in de eerste drie dagen van de ECMO behandeling. D it is 
ook de periode waarin de meeste hersenbloedingen worden gevonden. N.a.v. de resultaten van 
de tweede studie van d it hoofdstuk kwamen w ij to t de hypothese dat intravasculaire volume 
suppletie bij kinderen behandeld m et ECMO, le id t to t verandering in cerebrale oxygenatie en 
hem odynam iek, die zouden kunnen bijdragen aan het risico op schade aan de hersenen. Intra­
vasculaire volum e suppletie kan worden toeged iend in de vorm van fysiologisch zout, th rom bo- 
cyten transfusie o f e rythrocyten transfusie. In totaal werden 51 m om enten van intravasculaire 
volum e suppletie gemeten bij 10 pasgeborenen. NIRS werd gebru ik t om veranderingen in cere-
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brale oxygenatie en hem odynam iek te meten. Veranderingen in totaal Hb (ctHB) en hem og lo­
bine oxygenatie index (HbD) werden berekend. Deze parameters representeren respectievelijk 
cerebraal bloed volum e en cerebrale bloed stroom. Wij toonden aan dat intravasculaire volume 
suppletie m et zowel fysiologisch zout als m et th rom bocyten en erythrocyten le id t to t snelle 
en statistisch significante veranderingen in ctHB en HbD. Er was hierbij geen verschil tussen de 
rechter in linker kant van de hersenen. Deze veranderingen zouden het risico op schade aan de 
hersenen kunnen verhogen. Opnieuw concluderen w ij dat aanpassingen aan het ECMO systeem 
en /o f het beleid rondom  ECMO zouden kunnen leiden to t m inder m om enten van intravasculaire 
volum e suppletie. Het zou ook waardevol kunnen zijn om een lagere toedieningsnelheid van 
extra volum e te bestuderen.
H o o fds tuk  5  vo rm t de algemene discussie van d it proefschrift. De belangrijkste bevindingen 
van de verschillende studies worden bediscussieerd en in een grotere context geplaatst. Wij 
concluderen dat nieuwe therapieën voor de behandeling van pulm onale hypertensie van de 
pasgeborene zorgvuld ig moeten worden geëvalueerd en niet autom atisch vóór ECMO behande­
ling geplaatst dienen te worden. Daarnaast m oet er discussie plaats vinden over de plaats van 
ECMO in de behandeling van neonaten m et ernstig respiratoir falen, vaak gecom pliceerd door 
pulm onale hypertensie. De indicatie voor ECMO zou meer op basis van diagnose en indiv iduele 
criteria gesteld kunnen worden i.p.v. universele criteria voor alle kinderen. Voorts pleiten onze 
studies voor meer fine -tun ing van de op zich effectieve ECMO behandeling door aanpassingen 
aan het ECMO systeem en aanpassingen in het beleid rondom  ECMO. H ierdoor zou het risico op 
schade aan de hersenen gereduceerd kunnen worden.
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Dankwoord
Het to t  stand komen van een proefschrift kan misschien het best vergeleken worden m et het 
beklim m en van de Alpe d'Huez. Je aarzelt even, maar dan pak je  je  kans en begint aan een lange 
klim , die veel energie kost. Op lastige m om enten loop t het stijg ingspercentage op en soms heb 
je  even het gevoel alsof je  benen stil staan op de pedalen. Maar net als je  zomaar om zou kunnen 
vallen naar links o f rechts staat daar iemand om je  voo ru it te helpen. U ite indelijk  kom t het einde 
in zicht. Nog een laatste versnelling door de scherpe haarspeldbocht naar rechts en dan, na een 
flauwe bocht naar links, lig t daar een w itte  lijn, de finish. Opeens is alle m oeheid weg, opeens 
trek je nog even je  shirtje recht. Je verded ig t je  proefschrift en kom t ju ichend over de streep. Het 
begin van een feestelijke dag. Een feestelijke dag, die er zonder die "iem anden" langs de klim 
n iet zou zijn geweest. Die "iem anden" verdienen dus zeker een pluim  en een dankwoord!
A llereerst w il ik m ijn prom otor, Prof. R. de Groot en m ijn coprom otoren, Dr. K.D. Liem en Dr. A.F.J. 
van Heijst bedanken. Zij hebben altijd  hun enthousiasme getoond om iets dat begon als één 
losse studie in het kader van m ijn fe llowship neonatologie u it te laten groeien to t een prom o­
tieproject.
Prof. de Groot, beste Ronald, dank voor jo u w  positivism e en optim ism e. Ook als n iet ECMO des­
kundige w ist je  jo u w  w etenschappelijke enthousiasme altijd  over te brengen en in drukke tijden 
w ilde je  vo lop meedenken. Alles w at ik je  gaf voor publicatie had ik b innen een paar dagen terug 
m et a ltijd  weer een aantal goede opm erkingen en adviezen. Ik waardeer het b ijzonder dat je de 
taak van prom otor op je  hebt w illen nemen.
Dr. Liem, beste Djien, het was erg leuk om wetenschappelijk m et je  samen te werken, van onder­
zoeksaanvragen to t het begeleiden van een student tijdens de wetenschappelijke stage. Ook 
als anderen dat wat m inder deden, bewaarde j i j  op bewonderenswaardige manier de rust en 
kalmte. Behalve een lopende encyclopedie op het gebied van NIRS heb je me ook a ltijd  erg 
geholpen m et het systematisch opbouwen van publicaties. We kunnen er best trots op zijn dat 
onze eerste studie over iNO voor ECMO behandeling uitgegroeid is to t d it proefschrift. Zonder 
jo u  was dat n iet gelukt. Je hebt daar ook altijd  vertrouwen ingehouden, ook nadat ik n iet meer 
in Nijmegen kon blijven werken.
Dr. van Heijst, beste Arno, op de tweede dag dat ik voor de sollicitaties naar Nijmegen kwam 
schudde ik de hand van een man in b lauw w it geb lokt overhemd en dacht "daar kan ik het wel 
mee vinden" en dat klopte! Je hebt je  liefde en enthousiasme voor onderzoek aan me overgedra­
gen en samen m et Djien ben je essentieel geweest voor het to t  stand komen van d it proefschrift. 
En o f het nou gaat om Beppe's recepy, de hapfer o f de vele wetenschappelijke discussies, onze 
avonturen op grote hoogte in Keystone zal ik a ltijd  blijven koesteren. Shakespeare!!
Er zijn velen, die op de klim naar de top  een kleinere o f grotere duw  in de rug hebben gegeven. 
Beste Luella, dank voor je  bijdrage als student en later als arts tijdens de prom otie. Ik ben er van 
overtu igd dat ook jo u w  inzet zal resulteren in een mooi proefschrift. Beste Jeroen en Jan, ju llie  
inbreng vanuit de fysio log ie en de techniek vorm de een onmisbare schakel. Jullie kunnen met 
apparatuur en getallen dingen die waar ik alleen maar van kan drom en. Daarnaast waren ju llie  
kritische opm erkingen van grote waarde om scherp te blijven.
Een dankwoord ook voor alle neonatologen in Nijmegen, Theo als nurse practitioner voor de 
ECMO, de verp leging en na tuurlijk  de diverse fellows, Ethel, Tim, Rene M en Marije. Beste Rob, 
gaaf dat je  creatief mee w ilde  denken over de vorm geving van d it boekje, volgens mij is het
136 | Chapter 6
nu niet alleen inhoude lijk , maar ook van buiten, een m ooi stukje werk geworden. Zij die niet 
bij name genoem d worden maar wel langs de klim  hebben gestaan mogen zich n iet vergeten 
voelen.
Dan m ijn paranim fen, Rene en Hans, wat een mazzel, o f meer dan dat, dat ik  ju llie  tegen ben ge­
komen in m ijn geneeskunde carriere. Als je dat van te voren zou weten, waren ju llie  twee goede 
redenen om oo it geneeskunde te gaan studeren.
Beste Rene, je  was een collega fellow , maar nog veel meer kam ergenoot en vriend vanaf de eer­
ste dag. Je bent gewoon een gouden gozer, m et a ltijd  een luisterend oor en een eigen mening. 
Onze vriendschap en het jaarlijks congres, w aarbij we opn ieuw  de kamer en veel verhalen delen 
zijn mij erg dierbaar. Ook je  vrouw, Esther, en de kinderen w il ik bedanken, om dat ik a ltijd  w e l­
kom was en ben bij ju llie .
Beste Hans, ik zou een pagina vol kunnen schrijven over jou , onze vriendschap en w at die voor 
m ij betekent. Gelukkig hoeft dat niet, w ant als ik alleen zeg "bedankt voor alles", w eet j i j  ook 
genoeg. Het is geweldig als je  een vriend hebt, die a ltijd , en dan ook a ltijd , naast je w il staan. Het 
was dan ook ondenkbaar dat ik je  n iet zou vragen dat vandaag weer te doen.
Lieve ouders, zonder ju llie  had ik hier vandaag niet gestaan. Door opvoeding, vrijheid in keuzes, 
maar ook het stim uleren van m ogelijkheden en capaciteiten ben ik u ite inde lijk  arts geworden. 
Pa, w a t onge loo flijk  jam m er, dat j i j  hier vandaag niet kan zijn. Hoewel...., op jo u w  begrafenis heb 
ik je gedicht gelezen "n ie t alleen". Wat een ander daar ook van mag denken, volgens mij ben je  er 
vandaag wel dege lijk  bij. Ma, bedankt voor je  liefde en in het b ijzonder voor de noo it aflatende 
steun de afgelopen jaren.
Beste schoonouders, jam m er dat Jelle ook zijn grootvader veels te vroeg kw ijt raakte, maar ik 
w eet zeker dat ook ju llie  er beiden zijn en het is fijn  dat ju llie  in de vreugde w illen delen.
Lieve, lieve Henny Hessel en Jelle, ju llie  zijn een mooie reden om voor te leven. Heerlijk om een 
gezin te hebben, waar je  a ltijd  thuis kunt komen. Henny Hessel, je  bent een geweldige steun en 
toeverlaat en een heerlijke vrouw. We kunnen gerust zeggen dat we samen al heel w a t bergen 
hebben beklom men. Het geweldige van een berg is dat er na een klim ook altijd  weer een super 
gave afdaling volgt. Dank voor alles en het voo ru itz ich t om nog lang samen te mogen fietsen. 
Lieve Jelle, je  bent super! Alleen al jo u w  energie, enthousiasme en verw ondering maken dat je 
bewuster gaat leven. Wat een heerlijke u itdaging om je  van je  zijw ie ltjes af te helpen. "...Je hart 
z it heel diep in mij..".
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Van januari 1998 to t januari 1999 was hij werkzaam als AGNIO kindergeneeskunde in het Groene 
Hart Ziekenhuis te Gouda. Hierna bekleedde hij van januari 1999 to t novem ber 1999 een zelfde 
functie  in het St. Franciscus Gasthuis te Rotterdam. Na aansluitend te zijn aangesteld als AGNIO 
kindergeneeskunde in het AZL werd in ju li 2000 begonnen m et de specia listenopleiding k in­
dergeneeskunde (Opleider Prof. Dr. J.M. Wit). Het n iet academisch gedeelte van de op le id ing 
vond van 1 mei 2001 to t 1 mei 2003 plaats in het Juliana Kinderziekenhuis te den Haag. Hij kon 
toen nog niet verm oeden dat een opm erking van de opleidster, Dr. A. Derksen-Lubsen, later een 
stimulans zou vorm en to t het schrijven van een proefschrift. Na het succesvol afronden van de 
specialisatie to t kinderarts, in het inm iddels Leids Universitair Medisch Centrum, werd op 1 ok to ­
ber 2004 begonnen m et de deelspecialisatie neonatologie in het Universitair Medisch Centrum 
St Radboud te N ijmegen (Opleider Dr. K.D. Liem). Tijdens deze verdere specialisatie begon hij 
m et het verrichten van wetenschappelijk onderzoek. Na het afronden van de deelspecialisatie 
neonatologie in april 2007 werd hij staflid neonatologie in het A lbert Schweitzer Ziekenhuis te 
Dordrecht, alwaar hij nog steeds werkzaam is. Tevens bleef hij echter verbonden aan de afde­
ling neonatologie van het Universitair Medisch Centrum St Radboud om het gestarte onderzoek 
voo rt te zetten en af te ronden middels het hier voor u liggende proefschrift.
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